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ABSTRACT 
This overall aim of this thesis was to develop and optimise the synthesis of 
superparamagnetic iron oxide nanoparticles (IONPs) as potential magnetic resonance 
imaging (MRI) contrast agents. Indeed, these nanoparticles offer the possibility of 
multimodality, surface biofunctionalisation, and can offer better MRI sensitivity than 
conventional molecular-based contrast agents as long as their magnetic properties are 
adequate and that they are administered in a sufficient and safe dose.  
In the initial phases of this project, IONPs were synthesised by the polyol method in various 
experimental conditions: under inert atmosphere using a Schlenk line, using a microwave 
reactor and in high pressure high temperature conditions. The impact of these synthetic 
methods and the reaction variables on the physical and chemical properties of 
nanoparticles were studied. Iron oxide nanoparticles with low polydispersity were obtained 
through the polyol synthesis in high pressure high temperature conditions. Iron oxide NPs 
with a diameter of ca. 8 nm could be obtained in a reproducible manner and with good 
crystallinity as evidenced by X-ray diffraction analysis and high saturation magnetisation 
value (84.5 emu/g). However, poor results were obtained for their stability in aqueous 
solution.  
To overcome this, alternative surface functionalisation was investigated, using a variety of 
ligands in order to improve their stability. The surface of the IONPs could be modified post 
synthesis with the ligand 3,4-dihydroxyhydrocinnamic acid (DHCA) which provided 
functionality and long term stability in water and phosphate buffer saline (PBS). Their 
potential as MRI contrast agents was confirmed as they had an improved r2/r1 ratio by a 
factor of more than 3 in comparison to FDA-approved nanoparticles for MRI  Resovist® and 
Endorem®, with relaxivity values of r1 = 7.95 mM
-1 s-1 and r2 = 185.58 mM
-1 s-1 measured at 
1.4 T. To assess their biocompatibility, multiparametric high-content imaging analysis was 
carried out with human mesenchymal stem cells (hMSCs) to evaluate cell viability, 
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formation of reactive oxygen species, mitochondrial health, as well as cell morphology. 
Results demonstrated that hMSCs were minimally affected after labelling with IONP-DHCA. 
Their cellular uptake was confirmed by transmission electron microscope (TEM) and iron 
specific Prussian Blue staining and quantified using a colourimetric method. In vivo, IONPs 
were detected as hypointense regions in the liver by 9.4 T MRI up to two weeks after 
intravenous administration into six Swiss female mice.  
These results demonstrate the successful development of novel iron oxide nanoparticles, 
their biocompatibility with hMSCs, and their potential as MRI contrast agents.  
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Chapter 1 INTRODUCTION 
 SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES  1.1
Magnetic IONPs  have been the subject of great interest in recent years due to their various 
potential biomedical applications such as magnetic hyperthermia,2 MRI,3-5 drug delivery, or 
cell tracking for example.6-9 Their unique physical and chemical properties which make 
them valuable are due to their size, biocompatibility, non-toxicity and non-immunogenicity 
in biological systems. Furthermore, Feridex© or Resovist© are example of IONPs which have 
been approved for clinical applications by the federal drug administration (FDA) in the 
1980s and have since then been discontinued.10, 11 These were developed as contrast 
agents for MRI of malignant diseases in organs associated with the reticuloendothelial 
system (e.g., liver, spleen)12-14 and lymph nodes.15  
Despite all these advantages, the in vitro and in vivo use of IONPs still faces some 
challenges. The lack of reproducibility in the synthesis methods that yield water-dispersible 
nanoparticles is a major setback that this project aims to address. The wide size 
distribution of nanoparticles synthesised and the lack of control of their aggregation are 
also current limitations to their use for biomedical applications. Indeed, while the co-
precipitation of Fe(II) and Fe(III) ions in a basic solution is a widespread method in 
literature due to the high yields obtained,16, 17 the reproducibility of this synthesis remains 
a limitation.18 On the other hand, the main synthetic pathways which allow for better 
control of the size and shape of nanoparticles obtained involve the use of organic solvents. 
The nature of these solvents means post synthesis steps to render the nanoparticles 
hydrophilic and biocompatible are necessary, but these are difficult to monitor and control 
precisely in a quantitative manner.  
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 Magnetite and maghemite  1.1.1
This thesis focused on the development of superparamagnetic IONPs as these have been 
previously FDA approved for clinical MRI. The most studied IONP materials for this 
biomedical application are magnetite (Fe3O4) and its oxidised form maghemite (γ-Fe2O3). 
This is because they possess ferrimagnetic properties, and are less toxic and less 
susceptible to oxidation than other magnetic nanoparticles (MNPs).  
Ferrites are described by the structural formula MIIFe2O4 where M represents a divalent 
metal ion such as FeII, CoII or NiII for example, or a mixture of two metals. They are 
characterised by a spinel cubic crystal structure in the Fd3m space group. The crystal 
structure will be described as spinel or inverse spinel depending on whether the metallic 
divalent ions M2+ occupy the tetrahedral or octahedral sites of the face-centred cubic 
formed by the oxygen atoms.   
Magnetite Fe3O4 is a black ferrimagnetic material containing both Fe
2+ and Fe3+. It has 
an inverse spinel structure which can be written as B(AB)O4 with 32 oxygen anions O
2- 
forming a face-centred cubic crystal system, where B describes the tetrahedral sites and 
(AB) describes the octahedral sites.19 As shown in Figure 1-1, all tetrahedral sites are 
 
Figure 1-1 Scheme representing the inverse spinel structure of magnetite. Reproduced from Mornet S., 
Doctoral dissertation, 2002.  
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occupied by Fe3+ and octahedral sites are occupied by both Fe3+ and Fe2+ in equal 
amounts.20 Magnetite exhibits the strongest magnetism in comparison to the other 
transition metal oxides,21 this is mainly due to the occupancy of octahedral sites with Fe2+ 
ions.  
Maghemite is a red brown ferrimagnetic material isostructural to magnetite but with 
cation deficient sites. It is characterised by all of the iron present being in the trivalent state 
(Fe3+) and by the existence of cation vacancies in the octahedral sites. Spontaneous or 
provoked oxidation of magnetite to maghemite may occur through aerial oxidation, or 
under specific pH conditions in solution, or specific pressure and temperature conditions. 
For example, under acidic and anaerobic conditions, surface Fe2+ may be desorbed; under 
basic conditions, oxidation may occur at the surface of the NP. This explains the formation 
of vacancies in octahedral positions due to the oxidation of Fe2+ to Fe3+. The oxidation 
model is based on the assumption that free oxygen at the surface of the crystal is adsorbed 
and ionized by Fe2+ atoms, according to the reaction: Fe2+ + ½zO ---> zFe3+ + (1-z)Fe2+ + 
½z02-, where the degree of oxidation z is the ratio between the number per f.u. of oxidised 
Fe2+ ions and the initial number,Fe0
2+ (0 ≤ z ≤ 1).22, 23 This is always accompanied by a 
migration of cations through the lattice, which creates vacancies, in order to maintain the 
charge balance.24 These vacancies can be random, ordered or partially random and will 
lead to symmetry lowering. The degree of ordering in the distribution of the vacancies 
affects the magnetic properties, implying that magnetic moments in the interior of the 
particles can be significantly influenced by canting effects and may lead to lower saturation 
magnetisation in comparison to magnetite. Infrared spectroscopy and x-ray diffraction 
(XRD) studies have shown that vacancies are ordered in IONPs exceeding 5 nm in 
diameter.25  
 Magnetite and maghemite are often chosen for the development of magnetic IONPs for 
biomedical applications as they have the desired magnetic properties for these applications 
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and fulfil the requirements of non-toxicity and non-immunogenicity essential for pre-
clinical and clinical use. 
 Magnetic properties 1.1.2
The change in size of certain materials from their bulk state to the nanoscale modifies their 
magnetic properties which may be interesting for different applications of these 
nanomaterials. A number of ferrite-based nanoparticles are studied for various applications 
such as their use as semiconductors, electrochemistry, or energy storage applications for 
example.26 The choice of nanomaterial will depend on the desired application. In the case 
of biomedical applications, IONPs composed of magnetite and/or its oxidised form 
maghemite, are some of the most frequently investigated as they possess the desired 
magnetic properties, they have been previously FDA approved for clinical MRI and are 
deemed some of the safest in terms of cytotoxicity. For example, the use of hematite (α-
Fe2O3) nanoparticles, a canted anti-ferromagnetic material would not be ideal when a high 
magnetic moment is needed as this is the case in MRI.  
Magnetism originates from the magnetic moment of electrons. As illustrated in Figure 1-2, 
these charged particles experience a movement, which can be described by two 
components: an orbital angular momentum and a spin momentum. The electrons are 
magnetised by spinning on their own axis at a constant rate which causes the spin 
 
Figure 1-2 Scheme of different components of the magnetic moment of electrons in atoms.  
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magnetic moment; as well as by orbiting around the nucleus which is called the orbital 
magnetic moment. 
Diamagnetism is a form of atomic magnetic effect which occurs in all materials as it is 
inherently due to the presence of paired electrons. If other magnetic effects are present, it 
may be ‘masked’ by stronger magnetic effects such as paramagnetism or ferromagnetism 
for example. Diamagnetic materials will contain paired opposing electron spins which 
cancel each other out, thus leading to a weak repulsion of the magnetic field. In the 
absence of an external magnetic field, these materials will not possess a magnetic moment.  
Paramagnetism is another atomic magnetic effect. Unlike diamagnetism, this effect occurs 
when the atomic orbitals contain unpaired electrons. The Pauli exclusion principle infers 
that two electrons in an orbital spin must have opposite spins and thus cancel each other 
out. However, when dealing with unpaired electrons, these may have a random 
orientation. When an external magnetic field is applied, some of the unpaired spins may 
occupy a lower energy level and align with the applied field, thus leading to positive 
magnetisation and positive magnetic susceptibility. However, paramagnets will not retain 
magnetisation once the field is removed as thermal energy will dominate and electron 
spins will regain a random orientation.  
In the case of paramagnets, the magnetic susceptibility is temperature dependent and 
follows the Curie-Weiss law (Equation 1-1):  
   
 
    
       (Equation 1-1) 
where χm is the susceptibility, C is the Curie constant, T is the temperature and θ is the 
Weiss constant in units of temperature. θ is a measure of the interaction of atomic 
magnetic moments. If there are no interactions, then θ is negative and the moments are 
opposing the applied field.  
  
 
43 
Additional interactions between atoms can be extrapolated to the whole lattice by the 
following Hamiltonian (H) in Equation 1-2, initially described for the interaction between 
two atoms by Heisenberg:  
       ∑                 (Equation 1-2) 
where i and j represent the position of the atoms within the crystal lattice and J is the 
exchange constant. The strength and nature of intermolecular interactions will be 
dependent upon the crystalline structure.  
Ferromagnetic materials will have paramagnetic domains aligned parallel, thus J will be 
positive. Ferromagnetism appears below the Curie temperature, the latter being material 
dependent. Above the Curie temperature, the moments are randomly oriented resulting in 
no net magnetisation and the material behaves as a paramagnet. On the contrary, if J is 
negative, the spins are coupled in an anti-parallel manner. This is the case in ferrimagnets 
or anti-ferromagnets. Anti-ferromagnetic materials will have dipoles with equal moment 
but in opposing directions, thus resulting in the absence of magnetisation as they cancel 
each other out. Ferrimagnets will also have dipoles of opposing directions but these do not 
cancel each other out, thus resulting in a magnetic moment. All these magnetic behaviours 
are illustrated in Figure 1-3 below. 
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As explained in the previous paragraph, some paramagnetic materials undergo a transition 
upon cooling to an ordered state in which there is local alignment of atomic moments. A 
critical temperature, named the Curie temperature for ferrimagnets and Néel temperature 
 
Figure 1-3 Scheme illustrating the arrangements of magnetic dipoles in one dimension for different 
types of magnetic materials in the absence or presence of an applied external magnetic field H. 
Reproduced from Jeong et al., Advanced Materials, 2006 with permission from John Wiley and Sons.  
 
Figure 1-4 Magnetic behaviours derived from the scale reduction in magnetic materials. Reproduced 
from Ortega D., Chapter 1 in Magnetic Nanoparticles: From Fabrication to Clinical Applications, 2012, 
CRC Press.  
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for anti-ferromagnets, is the temperature above which thermal energy fluctuations will 
dominate and the magnetisation will drop to zero.  
The internal structure of a bulk magnetic material is made of magnetic domains which have 
coupled magnetic moments, and which are separated by domain walls. These walls 
constitute a transition area between two magnetic domains where a gradual reorientation 
of the moments occurs, and where defects are usually found. Domain walls may be 
displaced gradually with the application of an external magnetic field. When magnetic 
materials, such as magnetite for example, are reduced in size there is a critical size below 
which it is more energetically favourable to split the magnetic domains into a single 
domain (Figure 1-4), and where the formation of a domain wall is energetically too costly.  
  
This critical size Rc is also known as the “Weiss domain”, which is when there is only a 
single domain and its magnetic moment is blocked at room temperature (RT). This critical 
size is determined by the following equation: 
    
     
    
 
 
        (Equation 1-3) 
where RC is the critical domain size, A is the exchange stiffness (measure of the critical 
temperature for which this material is magnetically ordered), K is the magnetic anisotropy 
of the particle, μ0 is the permeability of free space and Ms is the saturation magnetisation.  
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The critical size will be material dependent (90-100 nm for maghemite and 80-90 nm for 
magnetite),27, 28 but generally is a particle containing 1012 to 1018 atoms approximately.  
As seen in Figure 1-4, for simplification purposes, a single domain will be represented as a 
single vector. In the absence of an external field, the latter will show a certain preference 
for an axis along which its magnetisation will align, this is referred to as the easy 
magnetisation axis or anisotropy axis. An energy barrier imposed by the anisotropy energy 
of the system will separate and limit the possible orientation states of the magnetisation. 
This energy will be dependent upon the angle between the magnetisation vector and the 
easy axis, and will also depend on the crystal structure of the material. This is described by 
the Stoner-Wohlfarth model (Figure 1-5)29 and by the following equation: 
                   (Equation 1-4) 
where K is the anisotropy constant, V is the volume of the sample and θ the angle formed 
between the easy axis and the magnetic moment.  
Both orientations of the magnetisation with minimum energy (θ = 0 or θ = π) are equally 
probable and are separated by the anisotropy energy barrier Ea = KV. When applying an 
external magnetic field H along the easy axis, the energy barrier is reduced, thus facilitating 
 
Figure 1-5  Switching of the magnetisation of a particle across the anisotropy barrier under a) no 
external magnetic field; b) external magnetic field pointing downwards; and c) external magnetic field 
pointing upwards. Reproduced from Nguyen, V.T.A., Doctoral dissertation, 2015.  
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the change of direction of the magnetisation from an energetically unfavourable state 
(opposed to H) to an energetically favourable state (same direction as H).  
When the size of a particle is further reduced, there is a size below which the thermal 
energy will overcome the anisotropy energy barrier and the magnetisation will be able to 
flip easily between the two states. This is known as the superparamagnetic regime and 
starts at r < 17.5 nm for maghemite and r < 12.2 nm for magnetite.30, 31  
Superparamagnetic NPs will demagnetise spontaneously after saturation magnetisation is 
reached. This is important for biomedical applications in order to minimise the risk of 
IONPs retaining any magnetic moment in vivo once an external field is removed.32 Under 
the effect of thermal energy, NPs with uniaxial anisotropy can randomly flip the direction 
of their magnetisation. The average time to perform a flip is defined as the relaxation time 
τ, also known as Néel relaxation time which is defined in Equation 1-5:  
        
  
           (Equation 1-5) 
where τ0 is a length of time characteristic of the material (typical values for τ0 are between 
10−9 and 10−10 sec), ∆E is the energy barrier the magnetisation flip has to overcome by 
thermal energy, kB is the Boltzmann constant and T is the temperature.  
When characterising superparamagnetic IONPs, the measurement time τM is an essential 
parameter to consider. If τM > τ, then it will appear that the magnetisation will flip several 
times during the measurement, and so the magnetisation will average to zero. The NP is 
said to exhibit superparamagnetic behaviour. However if τM < τ, it will appear that the 
magnetisation has not flipped and is that of the NP at the beginning of the measurement. 
The NP is said to be “blocked”. The transition between both states can occur when τM = τ, 
and this is generally done by keeping the measurement time constant and varying the 
temperature. The temperature at which the transition occurs is called the blocking 
temperature. The blocking temperature is routinely reported in scientific publications and 
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used to approximate the NP size and to gain information on the behaviour of a NP in a 
specific set of conditions (magnetic field applied field and temperature). However, this 
remains approximate as it assumes all NPs in the sample are perfectly spherical, and is 
defined by the measurement time which depends on the measurement tool used.  
Unless an applied external magnetic field is applied, the superparamagnetic NPs will have 
paramagnetic behaviour: no net magnetisation is present. However, when applying a 
magnetic field the spins will align along the line of easy axis to provide a net magnetisation. 
The response of a magnetic material to an applied field is described by: 
          (Equation 1-6) 
where M is the magnetisation, χ the susceptibility and H the applied field. The susceptibility 
will depend on the temperature and the magnetic field applied H. This can be observed 
when considering the sigmoidal shape of M-H plots as illustrated in Figure 1-6.  
The initial curve, also known as the virgin curve, is characterised by an increase in the 
sample magnetisation following the application of an external magnetic field. This curve 
cannot be obtained twice with the same sample, as it is only obtained from a 
demagnetised sample which has not been previously exposed to a magnetic field. After all 
magnetic moments in the material are aligned with H, the maximum value of M obtained is 
defined as the saturation magnetisation (Ms) and is often used to characterise materials. 
When decreasing the applied field, the material will retain a certain amount of 
magnetisation, which is defined as the remanent magnetisation Mr when H = 0. In order to 
completely demagnetise the sample, the field to apply is defined as the coercive field Hc or 
coercivity.  
In ferromagnetic materials, the plot will be characterised by hysteresis, a loop opening 
which is caused by magnetic pinning sites due to impurities, grain boundaries or 
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movements of domain walls, and which will vary with the size of the NPs. This hysteresis 
behaviour was first described by Pierre Weiss in 1907 with the assumption that 
ferromagnetic materials are made of magnetic domains.33 The presence of pinning sites 
means a larger field will be necessary to displace domain walls, and this is why the M-H 
plot can be characterised by a hysteresis loop and remanence. Superparamagnetic NPs are 
characterised by the absence of coercivity and remanence. Due to an increased surface to 
volume ratio at the nanoscale, the presence of surface canted spins which are not aligned 
with the spins of the NP core, will lead to a decrease in the Ms in comparison to the bulk 
material (92 emu/g for Fe3O4 and 78 emu/g for γ-Fe2O3).
34-36  
 
 
 
Figure 1-6 Hysteresis cycle of a multidomain magnetic material and domain wall displacements in such a 
material (squares symbolise multidomain material, with magnetisation of each domain; arrows on the 
cycle indicate the way the cycle is described when increasing or decreasing the field amplitude). 
Reproduced from S.Mornet et al., Journal of Materials Chemistry, 2004 with permission from the Centre 
National de la Recherche Scientifique (CNRS) and the Royal Society of Chemistry.  
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 Synthesis methods 1.1.3
Iron oxide nanoparticles used for MRI have been routinely synthesised by the alkaline co-
precipitation of ferric Fe3+ and ferrous Fe2+ iron in ratio 2:1 in an aqueous solution37, 38 and 
coated with hydrophilic molecules such as dextran,39, 40 citrate,7 chitosan,41 heparin,42, 43 
and albumin.44 More recently, the use of phosphonate ligands has been of interest45-47 as 
they create dense and stable Fe-O-P bonds which have a pH dependent conformation and 
could enhance the magnetic properties of IONPs through the absence of surface spin 
canting, unlike carboxylate groups (Figure 1-7).48, 49 Co-precipitation is a widespread 
method in literature due to the low reaction temperature, short reaction time and high 
yields obtained,16 but does not generate nanoparticles in a reproducible manner.18  
Different factors such as the pH, Fe(II)/Fe(III) ratio or ionic strength of the reaction medium 
will influence the growth of the IONPs.10, 50, 51 For example, the use of a strong base such as 
ammonia will induce severe localised pH changes which lead to multiple bursts of 
nucleation and thus have an impact on the IONP size distribution.52 The pH will affect the 
protonation and deprotonation process of surface hydroxyl groups which in turn will 
impact the electrostatic surface charge. To obtain monodisperse NPs, a short burst 
 
Figure 1-7 The most likely conformations of the 6-phosphonohexanoic acid (PHA) molecule at the NP 
surface. Reproduced from Thomas et al., Dalton Transactions, 2016 with permission from with 
permission from the Centre National de la Recherche Scientifique (CNRS) and the Royal Society of 
Chemistry. 
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nucleation and slow controlled growth is required.   
On the other hand, methods involving the use of organic solvents allow better control of 
the morphology of the IONPs and improved crystallinity. The synthesis of monodisperse 
crystalline NPs is essential to obtain a high magnetic moment and saturation 
magnetisation, and so a high relaxivity value for MRI. These methods involve the 
decomposition of organometallic complexes in organic solvents at high temperatures with 
the use of surfactants to tailor the nanoparticle’s surface.  
Sun et al. synthesised IONPs through the decomposition of iron (III) acetylacetonate in 
phenyl ether or benzyl ether with the addition of 1,2 hexadecylamine, oleic acid and 
oleylamine.53 The particle size was tuned from 4 – 20 nm by first growing smaller seed 
particles and then adding more reagents. TEM images of the obtained NPs are reported in 
Figure 1-8. This method of synthesis yielded NPs of narrow size distribution and highly 
uniform shape. 
 
Figure 1-8 TEM images of a) 6-, b) 7-, c) 8-, d) 9-, e) 10-, f) 11-, g) 12-, and h) 13-nm-sized air-oxidised 
iron oxide nanoparticles showing the one nanometer level increments in diameter. Scale bar 20 nm. 
Reproduced from Park J. et al., Angewandte Chemie International Edition, 2005, with permission from 
John Wiley and Sons. 
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A similar technique was used by Park et al.54 to produce monodisperse IONPs using iron (III) 
chloride and sodium oleate, which are both inexpensive and non-toxic, to generate an iron 
oleate complex. The latter was then decomposed at high temperatures (240 – 320 °C) in 
different solvents to produce IONPs with diameters in the range of 5 – 22 nm depending on 
the temperature and aging period. The same group produced monodisperse iron NPs by 
the sequential decomposition of iron pentacarbonyl Fe(CO)5 and the iron oleate complex at 
different temperatures.55 The reaction is similar to a seed mediated growth process and 
allows very fine control over the particle size.  
However, when considering NPs for biomedical applications, the main drawback of this 
synthesis method lies in the hydrophobic nature of the particles obtained. MNPs must be 
rendered water dispersible through a post synthesis step: phase transfer or ligand 
exchange, so that the NPs are coated with an alternative hydrophilic ligand. The new ligand 
should present a higher affinity for the NP than the hydrophobic one, and should confer 
the desired properties to the NP. Otherwise this may lead to a mixed organic shell (mixture 
of the hydrophobic and hydrophilic ligands) which could have an impact on the colloidal 
stability of NPs.56 In most cases, an excess of the new ligand allows for the complete 
replacement of the original ligand. Another drawback is that the yield of the ligand 
exchange reaction will depend on the experimental conditions (i.e. pH, temperature, 
stirring/agitation, time, etc.) in which they are done.57, 58 However, even though the ligand 
exchange process is frequently reported in publications reporting the synthesis and 
biomedical applications of NPs synthesised in research laboratories, this step often lacks 
characterisation. This is the main drawback as not only is aggregation of the NPs during the 
ligand exchange step possible, but the new organic shell is not defined in terms of 
composition and quantity of ligands present. To date, attempts to characterise this 
reaction have been scarce as IONP characterisation methods present technical limitations. 
The robustness and reproducibility of the analytical techniques chosen must initially be 
proven before addressing how this process affects the properties of the NPs. In 2014, Davis 
and colleagues were able to qualitatively and quantitatively assess the ligand exchange 
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reaction of IONPs in which radiolabeled oleic acid was replaced by poly (ethyleneglycol) 
with various terminal groups.59 This research confirmed hierarchal binding of functional 
groups on the surface of magnetite NPs with catechol derived groups and phosphonate 
groups having higher binding affinity than amine and carboxylate derived PEG ligands. As 
Figure 1-9 illustrates, even with high affinity ligands such as catechol derived groups, oleic 
acid still remained on the surface of the NPs after ligand exchange.  
 
In a more recent study by the same team, the higher affinity of catechol derived ligands for 
IONPs in comparison to other functional groups was demonstrated.60 Bifunctional ligands 
were found to coat the NPs in a more efficient manner the monofunctional ligands.  
 
Figure 1-9 Chains of oleic acid remaining on the surface of the nanoparticles before and after ligand 
exchange determined by liquid scintillation counting (LSC). The data for the PEG-coated nanoparticles 
represent the amount of oleic acid remaining after dialysis. Reprinted from Davis et al., Langmuir, 
Copyright 2014 American Chemical Society.  
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More recently, hydrothermal synthesis of IONPs has been studied more intensely. This 
method is based on the crystallisation of a substance in a high temperature aqueous 
solution (130 to 250 °C) in a sealed container. The synthesis uses the dehydration and 
hydrolysing power of supercritical water to make metal oxides from their salts. The main 
advantages of this method lie in the use of non-organic solvents and the high crystallinity 
of the NPs obtained which should lead to a high Ms. While this method allows for good 
control of the shape and size of NPs obtained,61-63 it is inconvenient because of the 
extremely high temperatures and pressures needed. For example, in terms of safety and 
scalability, this can be difficult to set up in an industrial or university research environment.  
This project focused on the polyol method as it is a simple one-pot synthesis, which leads 
to water dispersible IONPs. One or more metal salts are dissolved in an alkaline polyalcohol 
and heated to obtain MNPs. The composition, size, and crystallinity of the particles are 
determined by the reaction rate of the polyol process.64 The reaction rate in turn is a 
function of many experimental parameters such as polyol reduction potential, metal salt 
concentration, pH and reaction temperature. The synthesis of magnetite occurs by the 
decomposition of the iron precursor, iron (III) acetylacetonate Fe(acac)3, at high 
temperature (180 - 190 °C). The polyol will act as a solvent as well as a reducing agent and 
surfactant to avoid the aggregation and control the growth of NPs. IONPs smaller than 10 
nm have been obtained through the decomposition of Fe(acac)3 in diethylene glycol 
(DEG).65, 66 Other groups have also proven that the type of polyol and its length may 
influence the reaction conditions and shape of NPs obtained.67, 68 The thermal 
decomposition of Fe(acac)3 is initiated around 180 °C but is optimum at temperatures 
above 200 °C and manifests by a decrease in the iron metal – acetlyacetonate π 
interactions with the progressive removal of iron acetylacetonate groups. From the metal 
acetylacetonate/polyol mixture, several gaseous compounds will be eliminated during the 
thermal decomposition process such as acetaldehyde, carbon dioxide and carbon 
monoxide.69-71 The formation of NPs by the polyol process has been recently studied and 
exact nature of the iron complexes formed has not been determined experimentally, 
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several studies suggest that the polyol is coordinated to the iron centre.69, 72, 73 This has led 
to the identification of the following phases which are represented in Figure 1-10: the 
heating of Fe(acac)3 in a polyol solvent leads to the formation of an intermediate alkoxy-
acetylacetonate-Fe3+ with the ferric iron being coordinated with both the polyol and the 
acetylacetonate ions. In turn, these complexes would assemble and form larger complexes 
with the polyol acting as a ligand.  
The hydrophilic nature of the polyols on the surface of the NPs implies there is no need for 
a post synthesis ligand exchange process as they are water dispersible.74  
During this project, water-dispersible magnetite NPs were synthesised as described by Cai 
and Wan with some modifications of the experimental conditions used detailed in chapter 
3.65, 75 Some reactions were initially carried out inside a microwave vessel and later on 
these reactions were conducted in an autoclave to meet high temperature and high 
Figure 1-10 Illustration of the proposed reactions between Fe(acac)3 and triethylene glycol (TEG) 
molecules. Reprinted with permission from Miguel-Sancho et al., Industrial & Engineering Chemistry 
Research, Copyright 2012 American Chemical Society. 
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pressure conditions. The increased temperature led to increased solubility and reactivity of 
the metal precursor Fe(acac)3 as well as a significant decrease in the viscosity of the 
solvent.69  The latter has an essential role in determining the size of the NPs obtained. 
Indeed, the low viscosity of polyol at their boiling point, in conjunction with the increased 
diffusion coefficient, means a large number of iron species in solution may diffuse rapidly 
and lead to crystal growth by their addition onto previously formed crystals at lower 
temperatures. Furthermore, the high concentration of Fe(acac)3 in the initial solution leads 
to a gradual release of iron species, which will be added onto growing crystals in solution. 
Cheng et al. demonstrated the important of the reduction potential of the polyol solvent 
on the size and morphology of NPs obtained by polyol synthesis carried out in an 
autoclave.76 Propylene glycol, which has a higher reduction potential than ethylene glycol, 
leads to a quicker formation and growth of NPs. The latter therefore do not have time to 
align correctly to minimise their surface energy and will instead form a cluster of 
misaligned crystals. During the second phase of the synthesis, the NPs continue to grow 
and since their surface energy is high, they disaggregate and the monomers attach onto 
the surface of larger NPs. With the solvent of lower redox potential, such as ethylene 
glycol, NPs aligned along the same crystal orientation and formed flower-like shaped 
clusters, which were maintained through the growth of the NPs because of low surface 
energy.  
However, the coating of IONPs by polyol ligands may lead to a lack of biological 
compatibility and stability. In a recent study, triethylene glycol (TREG) was shown to have 
short-term stability on the surface of NPs and to degrade with time.77 Ligand exchange of 
TREG with dimercaptosuccinic acid (DMSA) was necessary in order to provide better 
stability of the NPs both in water and PBS. The next section (1.1.4) will explain the 
importance of the surface ligands for interactions of IONPs with biological systems.  
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 Surface functionalisation of IONPs 1.1.4
IONPs are more reactive when their size decreases due to a large surface area to volume 
ratio. For example, smaller NPs will be more rapidly degraded and excreted from the body 
once exposed to biological systems. IONPs with sizes smaller than 10 nm are essentially 
eliminated by renal clearance, whereas IONPs larger than 200 nm are taken up by 
phagocytic cells of the body such as macrophages, especially in the spleen and liver.78, 79 
IONPs within the size range of 10 to 100 nm are considered to be optimal for biomedical 
applications, as they allow for longer circulation times by avoiding rapid elimination by the 
reticuloendothelial system (RES).  
The interaction of NPs with biological systems occurs in 2 phases. The first one is their 
recognition by circulating plasma proteins, opsonins, which will adsorb to their surface. The 
latter then initiate the second phase as they recognise cells of the RES (blood monocytes, 
macrophages and bone marrow progenitor cells), which will interact with the NPs through 
endocytosis or phagocytosis. The NPs can then be eliminated in organs of the RES, mostly 
in the liver, kidneys, spleen and lymph nodes. It has been reported in several studies that 
coating NPs with polysaccharides or polymers improves the adhesion of NPs to cell 
membranes.80 Furthermore, the surface charge strongly impacts the biodistribution of NPs 
within cells and living organisms.81 Positively charged NPs, with amino functions on their 
surface for example, will have a higher cellular uptake than those negatively charged, but 
this can be non-specific. This can be explained by an affinity between positively charged 
NPs and negatively charged cellular membranes.82 This has been observed with most cell 
lines excluding certain macrophages and stem cells (SCs).83, 84 Cationic particles interact 
with cells by penetrating the cell membrane, which may contribute to their cytotoxicity. On 
the other hand, phagocytic cells and SCs have been shown to preferentially internalise 
negatively charged particles. In phagocytic cells, this phenomenon has been suggested to 
be due to their inherent function: the uptake of bacteria, which is negatively charged.85 The 
internalisation of negatively charged MNPs is believed to occur through nonspecific binding 
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and clustering of the NPs on the few positively charged sites on the plasma membrane 
followed by endocytosis.86 In more recent studies, thiolated NPs had a higher level of 
tumour accumulation than non-thiolated NPs.87 Also, they accumulated more significantly 
in the spleen. This could be due to aggregation of NPs by disulfide bond formation or 
reaction with thiolated proteins in the bloodstream.  
The surface functionalisation of IONPs is a critical parameter when considering their 
interactions with cells or other biological systems. The isoelectric point of bare magnetite 
NPs is around pH 7, and can vary with the temperature or presence of ions in solution.88 It 
is therefore necessary to modify the surface of the NPs to avoid their sedimentation or 
precipitation at physiological pH 7.4. Furthermore, they must be able to withstand 
environments of different pH. For example, tumour tissues are nearly neutral (pH 6 – 8) 
whereas certain intracellular organelles such as lysosomes are characterised by very acidic 
conditions (pH 4 - 5). There are two strategies for the stabilisation of NPs:  
 - Electrostatic stabilisation, which will depend on the surface charge of the colloid, the 
ionic strength and pH of the solution in which it is dispersed. It relies on the repulsion of 
overlapping double layers of NPs with the same charge. The attractive van der Waals forces 
are counterbalanced by repulsive Coulomb forces. This strategy will however be pH 
sensitive, and there is a risk of aggregation when the pH is close to the isoelectric point of 
the NPs in solution. 
 - Steric stabilisation, which uses sterically bulky molecules on the surface of NPs and which 
will depend on the grafting density of the coating and its molecular weight. This relies on 
molecules of polymer adsorbed to the surface of NPs in order to create a repulsive force 
between them.  
It has been shown however, that magnetite requires both steric and electrostatic stability 
to prevent aggregation or precipitation across a wide range of pH.89 
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 Coatings of IONPs frequently used are lipids, dendrimers,90 carboxylic acids,91 
phosphonates,45-47 carbohydrates or starch,92 proteins or peptides,29  various polymers 
such as polyethylene glycol (PEG) or poly(acrylic acid) (PAA).93 PEG is commonly used to 
render IONPs stealth for biomedical applications as it provides steric hindrance and 
reduces protein adsorption.94  Functionalised PEG may also provide free functional groups, 
which can be used for further functionalisation with various biomolecules.95, 96 Coating the 
NPs with an inert silica shell is also another way of minimising interactions with biological 
environments and also adding functional groups on the surface for further 
biofunctionalisation for example. Most of the clinically approved IONPs for MRI are 
functionalised with dextran or its derivatives as it has proven to have a high affinity for iron 
oxide and they have also been efficiently used as plasma extenders.97, 98  
 MAGNETIC NANOPARTICLES AS CONTRAST AGENTS FOR MRI  1.2
The clinical potential of NPs has been the subject of a number of scientific studies, 
particularly for their use as MRI contrast agents.11, 99 The use of NPs in a clinical setting 
requires specific properties which will be determined by their synthetic pathway as well as 
the application for which they are designed. For instance, the challenge remains of 
developing tools to specifically monitor and/or deliver drugs to cancer cells as well as to 
monitor the biodistribution and viability of SCs for tissue engineering applications. While 
there is an array of medical imaging techniques available in the clinic (see Table 1-1), 
choosing one for a specific application requires consideration of various factors such as: 
sensitivity, resolution, specificity and exposure of patients to secondary effects.5 In this 
project the main focus was on the use of IONPs for MRI as it presents the following 
advantages:  
 MRI is readily accessible in a clinical setting 
 It is a non-invasive imaging modality  
 The use of non ionising radiation  
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 With the exception of the use of NPs in microbubbles used as intravenous 
ultrasound enhancing agents, MRI is the only clinically available imaging 
technique for which IONPs have been FDA approved.  
IONPs approved by the FDA for MRI, Feridex® or Resovist® for example, have now been 
discontinued by manufacturers. To overcome the unmet need of IONPs as MRI contrast 
agents in a clinical setting, more and more studies rely on the use of Ferumoxytol 
(Feraheme®) which is an FDA-approved iron replacement therapy for iron anaemia caused 
by chronic kidney disease.100 Indeed, the majority of the clinical trials in which it is used 
focus on imaging of cancer or other pathologies (22 for imaging vs 6 for anaemia 
treatment).11 
 Magnetic Resonance Imaging 1.2.1
MRI is a powerful diagnostics tool which is based on the nuclear magnetic resonance 
(NMR) phenomena initially described by F.Bloch and E.Purcell in 1946.101-103 The first MR 
image was published in 1973,104 while the first MRI scan on a human was done in 1977.105, 
106 It has been developed over the past decades as a non-invasive method to obtain high 
resolution anatomical images.  
 T1 and T2 relaxation 1.2.2
MRI detects the signal emitted by the protons present, which will respond to a magnetic 
field in an environment-dependant manner (i.e. different tissues). Hydrogen protons are 
the predominant source of the MRI signal because of their high magnetic moment and high 
abundance in tissues such as water and fat. In the presence of an external magnetic field B0 
along the z axis, the nuclear spins will align with the applied field. The latter also causes a 
precession of the spins around the axis B0 at a frequency ω, known as the Larmor 
frequency. When radiofrequency (RF) pulses are applied at the Larmor frequency, the 
nuclei become excited and transit between low and high energy levels. 
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Table 1-1 Comparison of several imaging modalities. Reproduced from Hachani R. et al., Nanoscale, 2013, 
Published by The Royal Society of Chemistry. 
 Source of 
imaging 
Spatial 
resolution 
Tissue 
penetrating 
depth 
Sensitivity Types of  
probe 
MRI radiowave 25−100 μm no limit mM to μM 
(low) 
para- (Gd
3+
) or 
superparamagnetic 
(Fe3O4) materials 
Positron 
emission 
tomography 
(PET) 
γ-ray 1−2 mm no limit pM (high) radionuclides 
(
18
F,
11
C, 
13
N, 
15
O, 
124
I,
64
Cu) 
Computed 
tomography 
(CT) 
X-ray 50−200 μm no limit not well 
characterised 
high atomic number 
atoms (iodine, barium 
sulphate) 
Optical 
fluorescence 
imaging 
visible or 
near-infrared 
light 
in vivo, 2−3 
mm; in vitro, 
sub-μm 
< 1 cm nM to pM 
(medium) 
fluorescent dyes, 
quantum dots 
When switching off the RF pulse, the protons return to a state of equilibrium in alignment 
with B0 through a phenomenon known as relaxation.
32, 107 Two different relaxation signals 
are generated:108  
i) The T1 relaxation (longitudinal, or spin-lattice relaxation) involves the release of the 
adsorbed energy to the surrounding lattice or dispersant; it is described by the decay 
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constant Mz (the parallel component of the nuclear spin vector M). The longitudinal 
relaxation time T1 is the time it takes to recover 63% of the original magnetisation.  
 
ii) The T2 relaxation (transverse, or spin-spin relaxation) involves the exchange of 
energy between proton spins. This dephasing of spins is due to inhomogeneities in 
the magnetic field; it is described by the decay constant Mxy (the perpendicular 
component of the nuclear spin vector M). The transverse relaxation time T2 is 
defined as the time required after excitation for the magnetisation to be reduced to 
37% of the equilibrium magnetisation. When the magnetic field B0 is not 
homogenous, there may be dephasing of the magnetisation of individual protons, 
thus leading to a more rapid loss of transverse relaxation and this is referred to as 
T2
*. This T2
* decay is what a coil receiver will actually detect immediately after 
application of the pulse and is of much greater magnitude than T2 in tissues due to 
the inhomogeneities of the magnetic field. If the latter were perfectly uniform and 
the materials or tissue being visualised did not lead to any susceptibility effects, the 
T2 and T2
* would be equal. Although this was not used during our project, certain 
sequences described as “T2
* weighted” can be used to accentuate local magnetic 
inhomogeneities in order to detect calcifications or haemorrhage for example.  
These two relaxation phenomena are described by the following equations: 
             (   
 
 
  )     (Equation 1-7)  
                   
  
       (Equation 1-8)  
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 MRI contrast agents (molecular-based and magnetic nanoparticles) 1.2.3
 
Magnetic resonance imaging, without the use of contrast agents (CAs), allows one to 
distinguish between various tissues or anatomical structures. However, these can 
sometimes be difficult to discern and identify, and the use of CAs then helps increase the 
spatial resolution of the images obtained as well as to identify the nature of certain tissues 
such as tumours for example. CAs will act by influencing the relaxation times of the 
protons, T1 or T2, and will consequently be categorised as T1 (positive) or T2 (negative) CAs. 
They are commonly described and compared by their relaxivity values r1 and r2 (Figure 
1-11). While a large r1 is important for a T1-weighted contrast agent, this criteria is not 
exclusive and it is also the ratio r2/r1 which determines the properties of a CA: the ratio 
 
Figure 1-11 Representative T1 and T2 relaxation mechanism (top) and a representative Z-spectrum are 
illustrated (bottom). Adapted from C. Khemtong, et al., Chemical Communications, 2009, with 
permission from the Royal Society of Chemistry. 
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r2/r1 is generally between 1 and 3 for a T1 CA, whereas T2 CAs will generally have a ratio 
r2/r1 >10.  
The properties of CAs approved for clinical applications can be found in Table 1-2. The 
increase in r1 with increasing diameter is attributed to the decrease in rotation correlation 
time as the molecular weight or diameter increases.109 Amongst the potential candidates 
for cellular paramagnetic labelling, gadolinium-based CAs offer efficient intracellular 
labelling, and certain Gd chelates present the advantage of having clinical FDA approval 
(Magnevist® or Omniscan® for example).109, 110  The structures of the three most commonly 
used gadolinium-based CAs are shown in Figure 1-12. However, precaution must be taken 
when using CAs containing gadolinium because of the risk of development of nephrogenic 
systemic fibrosis (NSF) in patients with renal failure as this occurred following the 
administration of Omniscan®.111 Indeed, free Gd3+ ions are able to bind to Ca2+ binding 
enzymes and voltage-gated Ca2+ channels, which can lead to adverse biological 
effects.88 Therefore, as a preventive measure, Gd3+ cations are administered in a chelated 
form. Complexes of Gd3+ are now routinely used in MRI and can be conjugated with NPs to 
render the latter suitable for T1 weighted MRI.
112  
The complexes which chelate Gd3+: DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid) and DTPA (diethylenetriaminepentaacetic dianhydride), are stable and 
soluble in physiological medium. Their chelation to Gd3+ can be seen in Figure 1-12 with the 
structures of these clinically approved CAs. They have a low osmotic potential and are 
rapidly eliminated from the body by renal excretion, so this confers the minimal biological 
impact desired. Although Gd-DTPA (Magnevist®) was the first chelate to be commercially 
available in 1988,30 Gd-DOTA (Dotarem®) is preferentially used as it is more advantageous 
in terms of high relaxivity, blood clearance rate in vivo, higher binding coefficient to Gd3+ 
(more stable in vivo in terms of thermodynamics and kinetics) and for the same image 
quality a smaller dose is required than the DTPA chelate.113 All these characteristics make it 
safer and more efficient in comparison to Gd-DTPA. The main drawback of using this CA is 
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that it must be administered in high concentrations to produce an effective contrast. This is 
because of diffusion, low relaxivity (the change in relaxation rate) per gadolinium ion and 
dilution phenomena in vivo after injection.  
In comparison to molecular-based CAs, NPs allow a higher concentration of CA to be 
administered with fewer risks, through binding of multiple complexes of Gd per NP. They 
can also potentially lead to improved targeting as it is the case in tumours with passive 
targeting by the enhanced permeability and retention (EPR) effect.114-116 Indeed, tumour 
sites have a dense vasculature but lack lymphatic drainage, which allows the retention of 
molecules or NPs by the EPR effect. 
Unlike molecular-based positive CAs, to this day, only superparamagnetic IONPs have been 
used as T2 negative contrast agents. They are frequently used when investigating tumours 
or other abnormalities affecting the liver, spleen, lymph nodes and bone marrow as they 
are internalised non-specifically by the macrophages of the RES.117, 118 IONPs clinically 
approved for such applications include ferumoxides Feridex® in the USA, Endorem® in 
Europe) functionalised with dextran; and Ferucarbotran (Resovist®), which is functionalised 
with carboxydextran. The main characteristics of these IONP based CAs are listed in Table 
 
Figure 1-12 Structures of the Gd(III) based MRI contrast agents currently used in the clinical practice. 
Adapted from Zhou et al., Wiley Interdisciplinary Reviews: Nanomedicine and Nanotechnology, 2012 
with permission. 
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1-2. They are both comprised of a magnetite core 10-20 nm in size with a biocompatible 
polymer leading to a hydrodynamic diameter of approximately 60-250 nm. In the case of 
liver imaging, they usually undergo phagocytosis by macrophages of the RES. However, in 
the case of lesions lacking hepatocyte Kupffer cells this process does not occur.15, 119-121 
FDA-approved IONPs such as Ferumoxides and Ferucarbotran were discontinued in 2008 
and 2009. Since then, the only formulation remaining on the market is Ferumoxytol 
(Feraheme®), an ultrasmall IONP used in the treatment of iron deficiency anaemia, which 
has been investigated more recently in cellular labelling applications.122, 123 
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Table 1-2 Characteristics of clinically approved IONP colloids as MRI contrast agents, adapted from Anselmo et. al, Bioengineering and 
Translational Medicine, 2016,1, 10-29. 
Name Company Coating agent Hydrodynamic 
size (nm) 
Relaxivity at 
1.5 T  
(mM
-1
 s
-1
) 
Applications Status 
Ferumoxides (Feridex 
IV®, Endorem®) 
Feridex IV® by Berlex Laboratories, 
Endorem® by AMAG Pharmaceuticals 
Dextran 120 - 180 nm r1 = 4.7 
r2 = 41 
Liver lesions 
imaging 
FDA approved in 1996, 
discontinued in 2008 
Ferucarbotran  
(Resovist®)  
Ferucarbotran by Meito Sango, 
Resovist® by Schering  
Carboxydextran 40 - 60 nm r1 = 8.7 
r2 = 61 
Liver lesions 
imaging 
EMA approved in 2001, 
discontinued in 2009 
Lumirem®, 
Gastromark
TM
 
AMAG Pharmaceuticals Silicone 50 nm r1 = 10.7 
r2 = 38 
Bowel imaging FDA approved in 1996, 
discontinued in 2012 
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When using MNPs as CAs, size is an important factor because the domain size and magnetic 
state (superparamagnetism or ferromagnetism) will determine the magnetic property.124 
Generally, smaller particles will have a smaller relaxivity r2 due to a smaller magnetic 
moment. This has been observed in magnetite Fe3O4 NPs where the decrease in size from 12 
nm to 4 nm was accompanied by a decrease in the saturation magnetisation from 102 to 25 
emu/g as well as the r2 relaxivity value.
125 In another recent study, the r2 value of IONPs 
synthesised in organic solvents increased from 84 to 317 mM-1 s-1 as the particle size 
increased from 4 nm to 9 nm.126 It has been frequently demonstrated that larger IONPs have 
higher r2 relaxivity values due to higher saturation magnetisation values.
127, 128 With larger 
NPs, the interactions between NPs are very strong within aggregates formed in suspensions 
solidified by agar gel. These strong inter crystal interactions produce a high magnetic field 
gradient which leads to an enhanced r2 effect by accelerating the loss of phase coherence of 
the spins contributing to the MR signal. This study also highlighted the importance of the 
crystallinity of the NPs synthesised as well as the effect of their aggregation on an increased 
r2 relaxivity. This strategy has been used to encapsulate several IONPs in order to enhance 
their sensitivity for T2-weighted MRI.
129, 130 Furthermore, it has been shown that when 
IONPs are small enough or coated with the right polymer, they may be used as T1 contrast 
agents.131, 132 This may be useful depending on the anatomical structures to be observed 
and to avoid potential long term toxicity in comparison to gadolinium-based CAs. Indeed, 
when decreasing the size of IONPs (5 nm diameter and below), the magnetic moment of the 
IONPs will also decrease due to the reduction in the volume magnetic anisotropy and spin 
disorders on the surface of the IONPs.133, 134 The small IONPs can therefore potentially be 
used as T1 CAs as their large surface area with 5 unpaired electrons enhances the T1 
relaxation process, and their small magnetic moment decreases the T2 effect, thus leading 
to an overall increase in the r1/r2 ratio.
135  
 
Another factor to consider is the surface chemistry of the NPs used in MRI as this will impact 
the NP’s environment and its interactions with it. For example, in the case of ultrasmall 
 69 
 
Gd2O3 NPs, polyvinyl pyrrolidone (PVP) coated Gd2O3 NPs showed an enhanced longitudinal 
r1 relaxivity in comparison to oleic acid and cetyl trimethylammonium bromide (CTAB) co-
coated Gd2O3 NPs of identical size. The authors hypothesised that this phenomenon was 
due to better interaction of the NPs with surrounding water molecules.136 
 Advantages and limits of MRI  1.2.4
The use of contrast agents to monitor cells is recent, with the first studies taking place in 
2000.90, 137 More recently, labelling and monitoring of SCs by MRI for cellular therapy has 
been investigated more intensely.138 However, a number of variables such as the cellular 
localisation of NPs for example, can influence the signal obtained. The cellular 
compartmentalisation into lysosomes strongly decreases the longitudinal relaxivity of Gd-
based CAs, this is probably due to the limited accessibility of water protons to the surface of 
the spatially confined CAs.139 140 This leads to a T2 weighted MRI of labelled cells due to an 
increased r2/r1 ratio in a dose-dependent manner. Also, some technical constraints such as 
the inherent absence of signal in certain anatomical regions can make it difficult to interpret 
the negative contrast obtained with IONPs by T2 weighted images. To overcome this, 
different MRI sequences have been developed which allow us to generate positive MRI 
signal from IONPs and to quantify the labelled cells.141 As little as 120 000 cells could be 
visualised in a rat using a modified sequence with a conventional clinical MRI scanner 
operating at 1.5 T.99 
Clinical MRI (1.5 T scanner with radiofrequency coils) is not ideal for imaging of single cells 
after systemic administration. The spatial resolution needed would require long scanning 
times, which is not realistic in clinical settings. They are however still adequate for 
visualising magnetically labelled cells administered locally (for example, in the case of an 
implanted scaffold). This requires a compromise between the minimum number of cells 
detectable and the concentration of NPs to ensure there is no effect on cell viability or 
proliferation. Schäfer et al. determined that at least 1000 IONP-labelled mesenchymal stem 
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cells (MSCs) could be visualised by MRI in vitro after exposition to a magnetic field.142  
Another recent study showed that a relatively high incubation concentration (10 µg 
ultrasmall IONPs per 105 cells) and a long incubation time (21 h) were needed to detect a 
minimum of 250 000 MSCs in vivo.143  In comparison, the in vitro detection threshold of cells 
after incubation with gadolinium oxide NPs at a Gd concentration of 0.2 g per 5 x 105 cells 
for 2 h was estimated to be about 10 000 cells.144 Yang et al. were able to compare the 
efficiency of MSC labelling with IONPs and paramagnetic chelates.145 IONP labelling had a 
detection threshold of 12 500 cells in vitro, while gadolinium chelate labelling could be 
detected for at least 50 000 cells.145  
New strategies have been explored to overcome the limits of clinical MRI when studying the 
biodistribution of a single cell. These include the use of high field MRI scanners (for example 
9.4 T, 17.6 T),146 cryogenic probes,147  or high temperature superconducting coils148  that can 
be mounted on clinical 1.5 T devices and which allow the resolution at a single cell level 
even after systemic administration. For example, a cryo cooled high temperature 
superconducting coil can increase the signal-to-noise ratio by decreasing the noise 
generated by the detection coil, thus allowing for the detection of 1.3 pg Fe/cell in vitro with 
lymphocytes.148  
MRI is an imaging technique which produces anatomical images with good resolution (25–
50 µm), but is limited by its low sensitivity. Current research focuses on its combination with 
other higher sensitivity-low resolution techniques such as Positron Emission Tomography 
(PET), Single Photon Emission Computed Tomography (SPECT) or Near Infrared Fluorescence 
(NIRF) imaging. Indeed, multimodal NPs incorporating several imaging probes on a single 
platform are being developed to overcome the limitations of a single modality by 
complementing it with another one.149  
Biomedical applications of IONPs will require an efficient and sufficient uptake in cells.  In 
terms of cell labelling, the main limitations of MRI are currently the loss of signal with time 
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and the lack of specificity. NPs can be internalised by non-specific cells in vivo after 
implanted SCs undergo apoptosis or degradation, or their exocytosis can occur under stress 
conditions.6, 150-152  To overcome these limits, chitosan coated NPs have been studied as they 
allow an enhanced uptake and long term tracking of adult neural SCs through limited endo-
lysosomal trafficking and exocytosis.153 Recently, hydrophilic IONPs coated with 
glucosaminic acid  were shown to selectively enhance cellular uptake of NPs in cancer cells 
but not in macrophages or fibroblast cells after 40 h of cell culture.154 Furthermore, once 
SCs divide or differentiate the concentration of NPs decreases rapidly hence the MRI signal 
is lost with time. Encapsulation of IONPs in polymeric microparticles has been a strategy 
explored to help maintain a strong MRI signal and reduce exocytosis in order to enable the 
longitudinal tracking of SCs.155 
Although this was not investigated during our project, it is worth mentioning that IONPs 
may potentially be used for dual purpose in MRI: not only as a contrast agent to visualise 
the cells, but also to label cells that can be then magnetically targeted by MRI. This has been 
recently demonstrated within clinical grade MRI scanners and MSCs.156-158 
 NANOPARTICLE-CELL INTERACTIONS  1.3
 Mechanisms of cellular uptake of nanoparticles  1.3.1
As explained in section 1.2.4, a prerequisite in the use of IONPs for MRI is that a sufficient 
amount of NPs enter the cells. This will be dependent upon the cell type, cell culture 
conditions and some of the NPS properties such as their shape, size, coating, and surface 
charge. To label cells with NPs, the most simple and common method used is to label them 
in vitro.  The NPs may enter cells by endocytosis through different pathways as illustrated in 
Figure 1-13.159 Endocytosis is the process by which cells take in foreign materials by 
engulfing and fusing them with their plasma membrane. It will be dependent upon the NP’s 
size, degree of aggregation and surface chemistry. It is reported in most scientific 
publications that NPs used in biomedical applications (< 100 nm) will be internalised by 
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endocytosis (clathrin or caveolae mediated), whereas larger particles (> 0.5 µm) will be 
internalised by phagocytosis or macropinocytosis.160, 161 NP internalisation by receptor-
mediated endocytosis may be visualised and characterised as small vesicles made of the NPs 
by TEM.162  
A strategy commonly used to increase the labelling efficiency of cells by NPs is to 
functionalise the latter with transfection agents or cell penetrating peptides to enhance 
their endocytosis.163, 164 These peptides are mostly cationic and include poly (l-lysine) 
(PLL),165 lipofectamine,166 and protamine sulphate.167  
They will enhance the uptake of NPs through electrostatic interactions with negatively 
charged phospholipids of the cellular membrane. Another strategy is to use HIV derived Tat 
(Arginine rich) peptides, which avoid the endosomal endocytosis pathway and allow the 
uptake of NPs to the cytoplasm or nucleus.137, 168 A lower number of labelled cells can then 
be visualised by MRI in vivo or labelled cells may be magnetically sorted after in vivo 
migration for further analysis.137 However, these peptides may present a risk of toxicity if 
 
Figure 1-13 Pathways of entry into the cell. Reproduced from L. Y. T. Chou et al., Chem. Soc. Rev., 2011 
with permission from The Royal Society of Chemistry. 
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their ratio is not controlled and if used on their own without NPs.163, 169 
A new strategy has been recently investigated to label cells more efficiently with minimum 
invasiveness: in vivo labelling. Khurana et. al used the phagocytic capacity of MSCs to label 
them in vivo after intravenous injection. In comparison to the equivalent ex vivo labelling, 
the iron uptake was found to be significantly higher with fluorescence intensity of NPs being 
3.2 times higher in the case of cells labelled in vivo. The labelled MSCs were then implanted 
into the knees of rats with an induced osteochondral defect, and could be visualised up to 4 
weeks after transplantation by T2 weighted MRI.
170 This strategy could only be implemented 
for cells that are phagocytic in nature such as MSCs, and there will always be the inherent 
inability to distinguish live from dead cells, or to know whether the labelling agent has been 
taken up specifically by MSCs or macrophages. However, this technique is clinically relevant 
to track the cells immediately post transplantation to monitor the cell engraftment in real 
time. Labelling in vivo aims to eliminate the risks of contamination and biologic alteration of 
SCs which may occur with ex vivo or in vitro methods.171 
 Cell – iron oxide nanoparticle interactions 1.3.2
One of the main reasons IONPs are considered advantageous in comparison to other 
nanomaterials is that in acidic conditions in the human body, iron oxide can be degraded 
into iron ions. Briefly, after cellular endocytosis, IONPs may be degraded in lysosomes into 
Fe2+ ions. These can potentially cross the nuclear or mitochondrial membrane, and if so, can 
react with hydrogen peroxide and oxygen produced by the mitochondria to produce highly 
reactive hydroxyl radicals and ferric ions (Fe3+) via the Fenton reaction.172 The Fe3+ ions 
resulting from this process may then be part of the biologically available iron storage which 
is approximately 3 to 5 g: approximately 2.5 g in haemoglobin and the rest in ferritin (bone 
marrow, liver and spleen).27, 173 Considering that most applications will require a dose 
administered in the range of 0.5 – 5 mg of IONPs per kg of body weight, the resulting iron 
produced will be negligible.15 Iron is considered safe as long as it is bound to a protein or 
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chelated, as this is the case in heme for the transport of O2 in the blood. Otherwise, free 
iron can catalyse the conversion of H2O2 into free radicals such as: H2O2 + Fe
2+  Fe3+ + OH° 
+ OH-. More recently, safety concerns have risen regarding the use of IONPs as iron overload 
occurred in a cirrhosis model. Accumulation of iron in the liver over the course of several 
weeks induced oxidative stress and an increase in lipid peroxidation.174 The impact of the 
nanomaterials on biological systems is an important factor to take into account when 
considering their biomedical applications. For example, copper-based NPs are inert in their 
bulk state, but numerous studies have demonstrated that they exhibit toxicity through DNA 
damage and oxidative stress at the nanoscale.93, 175-177  
When administering NPs in vivo, one must avoid aggregation and adsorption of proteins or 
other macromolecules to their surface. To render them stealth, various polymers or surface 
functionalisation strategies can be investigated in order to ensure plasma proteins, such as 
opsonins, will not adsorb on the NP surface which would lead to their uptake by 
macrophages, monocytes and dendritic cells, thereby leading to their clearance from 
circulation. PEG is currently the most widespread polymer used to render the surface of the 
NPs stealth. It induces steric hindrance between NPs thus avoiding their agglomeration,178 
as well as decreasing the surface charge which could in turn decrease the cellular uptake in 
a dose and cell-type dependent manner.179 Proteins exhibit less attractive van der Waals 
forces towards it due to its low refractive index, thus minimising interaction.180 Briefly, the 
first approach to van der Waals interactions between two colloidal particles developed by 
Hamaker was called pair-wise addition. However, in the case of NPs, the alternative Lifshitz 
theory should be applied as this takes into account the many-body effect: the dipole field of 
one particle is influenced by its neighbouring particles. This theory considers each particle as 
a dielectric continuum characterised by a frequency/wavelength dependent refractive 
index.181 As modelled by Jeon et al., the interaction between the protein and a polymer 
surface across water is van der Waals interaction.180 The latter has been modelled and 
calculated by Jeon and colleagues. When increasing the surface density of the polymer, the 
volume fraction of the polymer increases, in turn leading to a higher refractive index while 
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the static dielectric constant decreases, thus resulting in an increase in the van der Waals 
free energy. Furthermore, the water molecules arranged around PEG minimise the 
interaction of the polymer chains with proteins in the local environment. However, whereas 
many  publications have found PEG to be a non-toxic organic coating for NPs; a recent study 
has shown cytotoxicity of PEG-coated gold NPs through production of reactive oxygen 
species in comparison to a same intracellular concentration of polymer coated gold NPs.179 
Conflicting results regarding the interaction of IONPs with cells in vitro or in vivo have been 
published in recent years. It is clear that parameters such as the size or coating will play a 
major role in determining the fate of the NPs.182 It was found for example that 12 nm 
magnetite NPs coated with PEG circulated twice as long in the bloodstream as 2,3-
dimercaptosuccinic acid coated NPs of the same size and material.183 Also, studies have 
consistently demonstrated that smaller IONPs will tend to accumulate in the liver rather 
than the spleen.95  
The interaction of NPs with living organisms poses several questions such as their 
internalisation pathway, biodistribution or their toxicity. The latter has been the subject of 
over 10 000 papers in the past 30 years however there is still a fundamental lack of 
standardisation for answers to this question.184 Indeed, a recent review175 found that most 
of these publications did not characterise their nanomaterials (no study was done to see 
whether there was any contamination of the engineered nanomaterials for example), or no 
reference or control samples were used. To date however, the scientific community regards 
iron oxides as being the safest material to investigate for biomedical applications. In 
comparison to gadolinium for example, IONPs have shown limited toxic effects and are 
considered safer as confirmed by their previous FDA approval for clinical MRI.  
 
For in vivo applications, the administration mode must also be considered in regards to the 
potential toxicity of the nanomaterials. For example, IONPs injected systemically may lead 
to significant toxicity in a dose and size dependent manner.185 The impact of the IONPs 
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developed during this project will be investigated in vitro and in vivo and detailed in a later 
chapter.  
 THESIS OUTLINE 1.4
This thesis reports the synthesis of superparamagnetic IONPs for MRI applications. The 
objective was to develop and optimise a novel and reproducible synthesis method from 
which could be obtained IONPs with finely controlled properties and with MRI relaxivity 
values as good as previously FDA approved IONPs. To fulfil these requirements, the thesis 
will address each one in the following chapters:  
 The different materials and methods used during this project are reported in 
chapter 2.  
 In order to obtain IONPs with desired sizes and shapes for MRI applications, chapter 
3 investigates the optimisation of the polyol synthesis method using different 
experimental conditions. The impact of reaction parameters such as the reaction 
time or temperature is reported and optimised.  
 After optimising the synthesis conditions, the polyol coating of the IONPs is found to 
be unstable and lead to aggregation of the nanoparticles in aqueous solution. If 
these IONPs are to be considered for any biomedical application, they must remain 
stable and disperse homogenously in biological media. To achieve this, their 
functionalisation and stabilisation with different ligands is investigated in chapter 4.  
 Finally, once colloidal stability was achieved with a selected ligand, their 
biocompatibility with human mesenchymal stem cells and their potential as MRI 
contrast agents is investigated in chapter 5.  
 The main conclusions which can be drawn from this thesis are reported in chapter 6, 
as well as suggestions for further work. 
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Chapter 2 MATERIALS AND METHODS 
 MATERIALS 2.1
 Chemicals for the synthesis of IONPs 2.1.1
Iron(III) acetylacetonate (Fe(acac)3, 99.9%), triethylene glycol (TREG, 99%), diethylene glycol 
(DEG, 99%), and tetraethylene glycol (TEG, 99%) were purchased from Sigma-Aldrich, UK. 
Acetone was purchased from VWR International, UK. All chemicals were used as received 
without further purification. 
 Chemicals for the functionalisation of IONPs 2.1.2
L-Tartaric acid (≥ 99.5%), 3,4-dihydroxyhydrocinnamic acid (3,4-DHCA, 98%), citric acid 
monohydrate (≥ 99%), 3-mercaptopropionic acid (3-MPA, ≥ 99%), folic acid (≥ 97%), oxalic 
acid (98%), succinic acid (≥ 99%), PEG 200 (United States Pharmacopeia Reference 
Standard), PEG 300, PEG 2000, PEG 6000, PEG diacid 600, L-glutamic acid (≥ 99%),  Tiopronin 
(99%),  terephtalic acid (98%) were purchased from Sigma-Aldrich, UK. 2-mercaptopropionic 
acid (2-MPA, 97%) was purchased from Alfa Aesar, Thermo Fisher Ltd GmbH, Germany. 
Meso-2,3-dimercaptosuccinic acid (DMSA, 98%), L-cysteine (L-Cys, > 99%), and azelaic acid 
(98%) were purchased from Acros Organics, Thermo Fisher Scientific Ltd, UK. Oxamic acid 
(98%) was purchased from VWR International Ltd, UK. Slide-a-Lyzer dialysis cassettes with a 
10 kDa molecular weight cut off (MWCO) were purchased from Thermo Fisher Scientific Ltd, 
UK.  All chemicals were used as received without further purification. 
 Human mesenchymal stem cells (hMSCs) 2.1.3
Bone marrow derived mesenchymal stem cells (MSCs) were obtained from Professor Mark 
Lowdell (Department of Haematology, University College London) at the UCL/Royal Free 
Biobank and from Thermo Fisher Scientific, UK. Progenitor cells or hMSCs were 
cryopreserved after samples were collected from patients of various clinical trials.  
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 MSC culture  2.1.4
Nuclear fast red solution (0.1% in 5% aluminium sulfate), hydrochloric acid (HCl 36.5-38.0%), 
dimethyl sulfoxide (DMSO, sterile-filtered, ≥ 99.9%), paraformaldehyde (PFA), and Trypan 
blue solution (0.4%, sterile-filtered) were obtained from Sigma-Aldrich, UK.  Trypsin of 
fungal origin (TrypLE™ Select Enzyme (1X) without phenol red), foetal bovine serum (FBS), 
minimum essential medium alpha (MEMα) with GlutaMAXTM supplement and without 
nucleosides, Hank's balanced salt solution (HBSS) without calcium or magnesium were 
obtained from Life Sciences Technologies Ltd, UK. All reagents were used as purchased 
without any further modification. The complete media (cMEM) is defined as MEMα 
complemented with 10% FBS.  
 In vitro studies of cell-nanoparticle interactions 2.1.5
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT, BioReagent, ≥ 97.5%), potassium 
hexacyanoferrate(II) trihydrate (≥ 99.95%, trace metals basis), agarose (BioReagent, low 
electroendosmosis) and Triton™ X-100 were obtained from Sigma-Aldrich, UK.  CellTiter 96® 
Aqueous Non-Radioactive Cell Proliferation Assay (MTS) was purchased from Promega 
Corporation, Madison WI, USA. Annexin V apoptosis detection kits were purchased from BD 
Biosciences, Oxfordshire, UK. DRAQ7 was obtained from BioStatus Limited, Leicestershire, 
UK. CM-H2DCFDA was purchased from Molecular Probes, Invitrogen, Belgium. MitoTracker 
Red CMXRos and Hoechst 33342 were obtained from Thermo Fisher Scientific, Belgium. 
Acti-stain 488 was purchased from Tebu-Bio, Belgium. Cell scrapers were purchased from 
VWR, United Kingdom. 
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 METHODS 2.2
 Conventional polyol synthesis using a Schlenk line 2.2.1
Iron (III) acetylacetonate (from 0.35 g to 0.7 g) was dissolved in 20 - 30 ml of polyol solvent 
previously degassed by the freeze-thaw method. The reaction mixture was then transferred 
into a round bottom flask under a nitrogen atmosphere, purged with nitrogen three times 
before being heated up to 250 – 280 °C and maintained at this temperature for 5 to 90 min, 
before being cooled back down to room temperature (RT). The black dispersion of 
nanoparticles obtained was washed with acetone by centrifugation (8500 rpm, 10 min, 3 
times) in a Heraeus Biofuge Stratos centrifuge, and then redispersed in dH2O before further 
characterisation. An aliquot (approximately 2 ml) was freeze-dried over 48 h (Lyolab 3000, 
Thermo Scientific Heto) for XRD and SQUID-VSM characterisation.  
 Microwave synthesis  2.2.2
IONPs were synthesised by the polyol method in a CEM SP-Discovery Microwave (CEM, 
USA). Iron (III) acetylacetonate (from 0.35 g to 1.4 g) was dissolved in 15 ml of polyol 
solvent, then transferred into a 35 ml vial and sealed with a pressure cap. The solution was 
heated to 250 – 280 °C (250 W, power max off) and maintained for 5 to 90 min at this 
temperature. Samples were automatically cooled down back to RT, before being washed by 
centrifugation with acetone (8500 rpm, 10 min, 3 times) and redispersed in dH2O for further 
characterisation. An aliquot (approximately 2 ml) was freeze-dried over 48 h (Lyolab 3000, 
Thermo Scientific Heto) for XRD and SQUID-VSM characterisation. 
 Polyol synthesis in high pressure high temperature conditions  2.2.3
Fe(acac)3 (0.35 g to 2.1 g) was mixed with the polyol solvent and sonicated for 30 to 60 min 
in order to homogenise the red dispersion. Shorter sonication times were found insufficient 
as traces of Fe(acac)3 could still be visualised at the bottom of the tube. The resulting 
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mixture was then transferred into a 45 ml capacity Teflon liner and this was assembled with 
the autoclave jacket and placed into an oven (Memmert, model UFP400). The autoclave 
vessels have a flat polytetrafluoroethylene (PTFE) gasket that is sealed with a screw cap. The 
screw caps and bodies of the vessel are made of alloy steel which allows experimental 
conditions of up to 300 °C and maximum working pressure of 1700 psi (115 bar). A pre-set 
program was run where the oven was heated up to 250 °C then maintained this 
temperature for 30 min to 24 h before ramping down to RT for 2 h. Samples were washed 
by centrifugation with acetone (8500 rpm, 10 min, 3 times) and redispersed in dH2O for 
further characterisation. An aliquot (approximately 2 ml) was freeze-dried over 48 h (Lyolab 
3000, Thermo Scientific Heto) for XRD and SQUID-VSM characterisation. 
 Ligand exchange with IONP powder and magnetic separation  2.2.4
For the ligand exchange process, IONPs in powder form were redispersed in water to 10 
mg/ml and sonicated in order to improve their dispersion. The ligands of choice were 
dissolved in 2 ml DMSO to a final concentration of 30 mg/ml. The resulting mixture was kept 
under continuous stirring overnight to achieve the total displacement of TREG on the 
nanoparticle surface. The next day, the IONPs were separated by magnetic separation and 
repeatedly washed with distilled water until a clear supernatant was obtained.  
 Ligand exchange with IONP powder and dialysis  2.2.5
Iron oxide nanoparticles were prepared as in section 2.2.4. The ligands of choice were 
dissolved in 2 ml distilled water to a final concentration of 30 mg/ml. The next day, the 
IONPs were separated by magnetic separation and further purified by dialysis against 
distilled water with a molecular weight cut-off (MWCO) of 10 kDa.  
 81 
 
 Ligand exchange with IONP solution and dialysis  2.2.6
A colloidal dispersion of IONPs in water (10 mg/ml) was added to the ligands of choice in 
water. Different ratios of IONPs to ligand (1:1 up to 1:50) were tested. The resulting mixture 
was stirred for 48 to 72 h at 300 rpm at RT. Then, the IONPs were purified by dialysis in a 5 l 
beaker against water with a membrane of MWCO 10 kDa. The volume of ultra-purified 
water used in the process is at least 100 times the volume of IONP solution. The dialysis was 
performed for 7 d and the water was changed daily, unless specified otherwise.  
 Cell culture of human mesenchymal stem cells (hMSCs) 2.2.7
hMSCs were supplemented with cMEM. An initial stock of 700 000 cells was cultured at 
37 °C in a 5% CO2 atmosphere. When 70 – 75% confluency was achieved, adherent 
fibroblast-shaped cells were trypsinised, passaged and returned to culture, unless cells were 
needed for experiments. If cultured, the seeding density chosen was in the range of 1000 to 
3000 cells/cm2.  
 Cell thawing after cryopreservation  2.2.8
Cells stored in liquid nitrogen at -80 °C were returned to cell culture by thawing the cryovial 
in a water bath at 37 °C until only a small pellet could be observed. The cells were then 
transferred into a larger vial and then 10 ml of warm medium was added drop wise while 
the sample was lightly agitated. An additional 10 ml of warm medium was then added, 
before counting the number of cells by Trypan Blue exclusion using a haemocytometer. Cells 
were then introduced into a tissue culture flask at a seeding density of 500 cells/cm2.  The 
medium was then changed every 2 to 3 d, until 70-75% confluency was reached.  
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 Trypsinisation of cells  2.2.9
Cell culture medium was aspirated from the tissue culture flask, and the cells were rinsed 
with HBSS 3 times. Then 10 ml of pre warmed TrypLE™ (trypsin of fungal origin) was added 
and the flask was returned to the incubator for 7 min. The flask was then gently tapped to 
ensure the detachment of the cells. cMEM (10 ml) was added to neutralise the action of 
TrypLE™. The cell suspension was centrifuged at 200 g for 10 min, after which the 
supernatant was discarded and the number of cells remaining in the pellet was determined 
by Trypan blue staining and a haemocytometer. The cells could then be cryopreserved in 
liquid nitrogen with 10% FBS in cMEM, or returned to culture, or used immediately for 
experiments.  
hMSCs may be detached with diluted Trypsin-EDTA (0.05%) for very brief exposure times (2 
to 3 min maximum). However, in this method, TrypLE is our reagent of choice as it is gentler 
and there is little risk of damaging cells. Furthermore, these hMSCs have been expanded by 
Professor Mark Lowdell and his team for the development of Advanced Therapy Medicinal 
Products (ATMP) which require animal-free products in cGMP grade cultures.186  
 Quantification of uptake of IONPs in hMSCs by a colourimetric method 2.2.10
This protocol was obtained from a method previously published.187, 188 hMSCs were seeded 
on a 24 well plate (20 000 cells/well) and returned to culture overnight. Cell loading with 
IONPs was carried out at concentrations 0, 10, 100 and 150 µg Fe per ml (V = 500 µl), over a 
period of 24 h. Cells were then rinsed 3 times with HBSS to remove any free iron oxide, 
cellular debris, and traces of FBS which contains protease inhibitors. A set of standards 
ranging from 0 to 100 μg Fe3+ per ml were also constructed. After rinsing with HBSS, HCl (9.6 
µl, 37%) and HNO3 (3.2 µl, 65%) were added to each well in order to ensure the oxidation of 
all Fe2+ to Fe3+, and the volume was adjusted with 2-[tris(hydroxymethyl)-methylamino]-
ethanesulfonic acid (TES) buffer (28.8 µl) pH 9.5-10. Solubilisation was enhanced by placing 
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the plate on a shaker at room temperature for 2 h. After shaking, distilled water (52 µl) was 
added to each well. Then, both the samples and standards were mixed with a 5:1 solution 
(96 µl) of Tiron (16 μl, 0.25 M) and KOH (80 μl, 4 M), followed immediately by the addition 
of PBS (160 µl, 0.2 M, pH 9.5). After 15 min, A480nm was measured. 
 Visualisation of cellular uptake of IONPs by Prussian Blue staining 2.2.11
hMSCs were seeded on a 96 well plate (1000 cells/ well) and returned to culture overnight. 
The visualisation of cellular uptake of IONPs by Prussian Blue staining being an image-based 
assay, we aimed for the cells to remain in a monolayer for efficient staining and 
visualisation. Cell loading with nanoparticles was carried out at a range of concentrations 
from 0 to 250 µg Fe per ml (V = 100 µl), over a period of 24 h. Cells were then rinsed 3 times 
with HBSS to remove any free IONPs, before fixing with 4% PFA for 15 min at room 
temperature. The fixative was removed, and then the hMSCs were incubated for 10 min 
with 2% potassium ferrocyanide and 6% HCl in a volume ratio 1:1, until the appearance of 
blue colour. The cells were then rinsed with distilled water 3 times leaving the water on the 
cells for 5 min for each wash. Finally, cells were rinsed twice with HBSS to get rid of any 
excess stain before being observed and captured using an Olympus BX51 light microscope.  
 Visualisation of IONP uptake in hMSCs by TEM imaging 2.2.12
For TEM imaging, cells were harvested by gentle trypsinisation and the cell number was 
determined with Trypan Blue staining and a haemocytometer. The cells were then seeded 
on 12 mm cover slips in 24 well plates and allowed to adhere overnight.  The next day, they 
were rinsed with sterile HBSS twice, before incubating them with IONPs at a concentration 
previously deemed safe (50 µg Fe/ml, V = 500 µl) (see chapter 5) and for different periods of 
time (1 h, 4 h or 24 h). The media was then removed and the cells were rinsed again with 
cold sterile HBSS before adding a fixative solution of 2% paraformaldehyde (PFA), 1.5% 
glutaraldehyde in 0.1 M PBS pH 7.3 for at least 24 h. The cells were then washed twice with 
0.1 M PBS buffer for 5 min, before being post-fixed in a solution of 1% osmium tetraoxide 
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and 1.5% potassium ferrocyanine (1 h, 4 °C). Cells were rinsed with 0.1 M PBS, 1% tannic 
acid in 0.05 M PBS for 5 min, 0.1 M PBS for 5 min and then with dH2O for 5 min. The cells 
were then dehydrated with increasing ethanol (25, 50, 70, 90 and 100%) each for 5 min. Cell 
layers were infiltrated with increasing embedding medium of epoxy resin (25, 50, 66%) in 
propylene oxide and transferred into polyethylene capsules. Fresh resin (100%) was added 
and allowed to harden at 60 °C for 24 h. The resin blocks obtained were sectioned and 
mounted onto copper TEM grids and examined under a JEOL 1010 TEM at 80 kV.   
 Colorimetric viability assays (MTT and MTS) 2.2.13
The MTS assay is based on the reduction of the tetrazolium salt MTS (3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) and an electron 
coupling reagent PES (phenyl ethosulfate) into a soluble formazan product (purple colour). 
This reaction takes place solely in metabolically active cells by the mitochondrial 
dehydrogenase enzyme. The formazan product, which is measured by absorbance at 490 
nm, is therefore directly proportional to the number of metabolically active cells.  
hMSCs were seeded on a 96 well plate (5000 cells/well) and returned to culture overnight. 
Cell loading with IONPs was carried out at concentrations of Fe from 0 to 1 mg/ml, over a 
period of 24 h. Sterile-filtered MTS solution (20 µl) was then added to each well. After 4 h of 
incubation, the absorbance was read at 492 nm using BMG FluoStar Galaxy Optima 
Microplate Reader (BMG LabTech GmbH).  
The MTT colorimetric assay reflects the ability of viable cells to convert the soluble MTT [3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium salt (yellow colour) into an insoluble 
formazan precipitate (purple colour). These reactions are the result of the succinate 
dehydrogenase enzyme’s activity, which is part of the mitochondrial electron transport 
system. The precipitate obtained is dissolved in organic solvents and its concentration can 
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be determined by absorbance at 570 nm. The amount of the formazan dye is therefore 
directly proportional to the number of metabolically active cells. 
hMSCs were seeded on a 96 well plate (5000 cells/well) and returned to culture overnight. 
Cell loading with IONPs was carried out at concentrations of Fe from 0 to 1 mg/ml, over a 
period of 24 h. Cells were then rinsed 3 times with HBSS to remove any free IONPs. MTT was 
dissolved at a concentration of 5 mg/ml in HBSS and sterile-filtered. To each well 190 µl of 
HBSS and 10 µl of the MTT solution were added. After 4 h, the MTT solution was removed, 
and then 200 µl of DMSO or acidic isopropanol (0.04 - 0.1 N HCl in absolute isopropanol) 
was added to each well. After shaking for 10 min, the absorbance was read at 570 nm and 
the background was read at 620 nm using BMG FluoStar Galaxy Optima Microplate Reader 
(BMG LabTech GmbH).  
 Apoptosis detection by flow cytometry using Annexin V 2.2.14
Cell viability was initially assessed by flow cytometry (MACSQuant Analyzer, Miltenyi 
Biotech, Bergisch Gladbach, Germany) with FITC (fluorescein isothiocyanate) - Annexin V 
and 7-AAD (7-aminoactinomycin D) - Annexin V apoptosis detection kits.189 Cells cultured 
and adherent to tissue culture flasks were trypsinised, counted by Trypan Blue staining, and 
resuspended in 1x binding buffer at 106 cells/ml. The 1x buffer is obtained from dilution in 
water of a 10x concentrate solution. The latter is composed of 0.2 µm sterile filtered 0.1 M 
HEPES (pH 7.4), 1.4 M NaCl, and 25 mM CaCl2 solution. The cell solution (100 µl, 10
5 cells) is 
transferred into a flow cytometry tube and 5 µl of Annexin V-FITC and 5 µl of propidium 
iodide (PI) or 7-AAD are added. The tube is gently mixed and incubated for 15 min at RT in 
the dark. 1x binding buffer (400 µl) is added to each tube and the cells are maintained on ice 
and analysed by flow cytometry within 1 h.  
Apoptosis is a physiological process, which occurs to maintain tissue homeostasis. One of 
the early stage signs of apoptosis is the translocation of a phospholipid , phosphatidylserine 
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(PS), from the inner to outer layer of the membrane, resulting in membrane asymmetry.190 
Annexin V is a protein, which will bind PS when it expressed on the outer cellular 
membrane. Annexin V is conjugated to fluorophores such as FITC, and thus allows us to 
determine by flow cytometry if cells are in the early stages of apoptosis. In addition, a 
viability dye such as PI or 7-AAD is used.191, 192 These will bind to DNA and emit fluorescence 
only when the cellular membrane is no longer intact and the cells are therefore no longer 
considered viable.  
 Apoptosis detection by flow cytometry using DRAQ7 2.2.15
To overcome the large number of false positives obtained with Annexin V viability assay by 
flow cytometry, an additional method was investigated to determine the viability of cells 
after incubation with different concentrations of IONPs.  
DRAQ7 is a far-red fluorescent dye, which binds to DNA and emits fluorescence only in dead 
cells when the cell membrane is no longer intact. In comparison to PI, the use of DRAQ7 is 
advantageous as it does not absorb in the UV range, and is non-toxic to cells so it may be 
used to study of viability of cells by live imaging or high content screening on a longer 
timescale. Indeed, UV excitation is not generally available on most common bench top flow 
cytometers. Furthermore, this avoids any double staining with Hoechst, a nuclear stain 
routinely used and which is excited in the 350 to 450 nm range.  
Cells from a tissue culture flask were trypsinised, counted by Trypan blue staining and 
haemocytometer, and resuspended in HBSS at 106 cells/ml. An aliquot of the cell solution is 
transferred into a flow cytometry tube and DRAQ7 is added to a final concentration of 3 µM 
(1 µl per 100 µl media). The tube is gently mixed and incubated for 10 min at RT in the dark. 
The cells are maintained on ice and analysed by flow cytometry within 1 h.  
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 High content imaging analysis 2.2.16
Cell viability, oxidative stress and mitochondrial health 
hMSCs were seeded in 96 well plates (1000 cells/well) and were allowed to adhere in a 
humidified atmosphere. The media was then removed and the cells were incubated with 
increasing concentrations of IONPs (0, 5, 10, 50, 100, 150, 200 and 250 μg Fe per ml) for 24 
h. After cell labelling, cells were washed three times with HBSS to remove any remaining 
free IONPs, after which the cells were incubated with 10 μM 5-(and-6)-chloromethyl-2',7'-
dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA) containing media for 30 
min at 37 °C. The dye was then removed and cells were washed with HBSS after which they 
were exposed to 200 nM MitoTracker Red CMXRos cell containing media and incubated for 
30 min at RT in the dark. Cells were then washed and incubated with cell media containing 3 
µM DRAQ7 for 10 min at RT in the dark. The cells were then fixed with 4% PFA for 15 min. 
The fixative was washed away, after which the cells were rinsed once with HBSS. The 
nucleus was then stained with Hoechst 33342 for 10 min at RT in the dark. The cells were 
then rinsed with HBSS and the plates were analysed with the InCell analyser 2000, where 
bright field and fluorescence-based images for the following channels were acquired: 
DAPI/DAPI (Hoechst nuclear counterstain), FITC/FITC (DCFDA ROS probe), DsRed/DsRed 
(MitoTracker Red CMXRos) and Cy5/Cy5 (DRAQ7) for a minimum of 500 cells per condition. 
Data analysis was performed on the InCell Developer software (GE Healthcare Life Sciences, 
Belgium) using in-house developed protocols. Cell numbers were first determined by 
counting the number of nuclei. Cell nuclei were segmented based on the DAPI/DAPI channel 
(Hoechst stain). The level of oxidative stress was based on the FITC/FITC channel. Cell 
cytoplasm were segmented based on the FITC/FITC channel (autofluorescence), using the 
DAPI/DAPI channel as seed images. Then, the average intensity of the FITC/FITC channel was 
measured for every individual cell and normalised to the intensity level of untreated control 
cells (100%). Mitochondrial health was evaluated similarly using the DsRed/DsRed channel, 
where the intensity of the MitoTracker Red CMXRos probe depends on the mitochondrial 
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membrane potential and thus is lost in non-functional mitochondria. All red spots localised 
within a single cytoplasm (based on the FITC/FITC channel) were counted and the average 
intensity of all mitochondria per cell was then measured. This value was then normalised to 
the intensity level of untreated control cells (100%). Viability was based on the Cy5/Cy5 
channel as DRAQ7 emits at wavelengths above 650 nm. Dead cells were defined as DRAQ7 
signal that had an intensity of 3-fold higher than background levels and that co-localised 
with cell nuclei of the DAPI/DAPI channel. The relative number of dead cells was then 
determined based on the number of red-stained cell nuclei over the total number of nuclei 
and normalised to the number of dead cells found for untreated control cells (100%). 
Cell morphology 
After cell exposure to the IONPs, cells were washed three times with HBSS and fixed for 15 
min at RT with 4% PFA. The fixative was removed, cells were washed with HBSS after which 
they were permeabilised with Triton X-100 (1%) for 10 min at RT. Cells were then blocked 
with 10% serum-containing HBSS for 30 min at RT followed by the addition of 200 µl (1/40 
dilution) Acti-Stain 488. Cells were incubated for 30 min at RT in the dark. The dye was 
removed, cells were washed with HBSS and the nucleus was stained with Hoechst 33342 for 
10 min at RT in the dark. The cells were then rinsed before 200 µl fresh HBSS was added to 
each well and plates were analysed on the InCell analyser 2000, where phase contrast and 
fluorescence-based images for the DAPI/DAPI and FITC/FITC channels were collected at 
minimum of 500 cells/condition. Data analysis was performed on the InCell Developer 
software (GE Healthcare Life Sciences, Belgium) using in-house developed protocols. First, 
cell nuclei were segmented based on the blue channel (Hoechst stain). Using the green 
channel, cells were then segmented, where any holes in the cells were filled up and included 
any cells on the border of the field of view were excluded from the analysis. The 
segmentation was based on the blue channel as seed channel for the nucleus. The total area 
of every individual cell was then determined. For determination of skewness (i.e. the shape 
of the cells, being the ratio of cell width over cell length), the same approach was used. 
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After segmentation, the “form factor” was calculated which provides the ratio of the cell 
width over cell length. This value will always be between 0 (straight line) and 1 (perfect 
circle).  
 IONP ANALYTICAL TECHNIQUES 2.3
 Magnetic measurements by SQUID-VSM magnetometry 2.3.1
Different methods can be used to characterise the magnetic properties of a sample such as 
Mossbauer spectroscopy, Hall effect magnetometry and superconducting quantum 
interference device (SQUID) magnetometry for example. In order to determine the 
magnetic properties of IONPs, a Quantum Design Magnetic Property Measurement System 
(MPMS) SQUID Vibrating sample magnetometer (VSM) was used (LOT Quantum Design, 
Germany). This is a device which can measure the magnetisation of IONPs with high 
sensitivity (≤ 10-8 emu). As represented in Figure 2-1, it is composed of two Josephson 
junctions in a loop. Each junction is made of 2 layers of semiconductors, which are 
separated by a thin insulator through which a tunnel current can flow.  The current 
generated will depend on the magnetic field. The measurement consists in moving the 
vibrating sample (ʋ = 14 Hz) through superconducting detection coils at a given temperature 
 
Figure 2-1 Scheme of principle of a SQUID magnetometer. Adapted from http://hyperphysics.phy-
astr.gsu.edu/hbase/solids/squid.html 
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and in a homogenous magnetic field. A change in the magnetic flux will induce a change in 
the current.  
 The SQUID is the most sensitive apparatus available for the measurement of induced 
current due to the magnetic sample and is an extremely sensitive current-to-voltage 
convertor. The induced voltage measured is proportional to the magnetic moment of the 
sample.193  
SQUID-VSM was routinely used to obtain hysteresis curves of the IONPs, by measuring the 
magnetisation against the applied magnetic field. These measurements are carried out at 
300 K or 5 K, and magnetic fields applied between -7 and 7 T. Prior to each measurement, 
samples were demagnetised to ensure there was no magnetic memory effect and that 
electron spins were randomly oriented. 
By varying the temperature, essential information was obtained such as the saturation 
magnetisation, coercivity, and remanence. These parameters will allow us to determine if 
the NPs are superparamagnetic behaviour (as described in section 1.1.2 of chapter 1). This is 
critical as MNPs with any remanent magnetisation cannot be considered for biological 
applications as this may lead to inter-particle magnetostatic interactions causing their 
agglomeration. As explained in section 1.2.3 of chapter 1, higher saturation magnetisation 
will be ideal for MRI as this will lead to higher relaxivity values.194, 195 
SQUID samples were mounted using soft gelatin capsules and plastic straws according to the 
manufacturer’s instructions. Approximately 5 mg of the IONP sample as powder was placed 
at the bottom of the capsule, so as to limit the height of the sample to 1 mm. Cotton wool 
was then added to the capsule in order to fill the remaining space and ensure the 
immobilisation of the sample in the capsule. The latter was then placed inside a plastic 
straw at 66 mm from the base of the sample rod, then immobilised by two additional straw 
supports on either side to prevent the capsule from moving during the measurement.  
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 Magnetic measurements by Mössbauer spectroscopy 2.3.2
This technique is based upon the Mössbauer effect. Briefly, upon the emission or absorption 
of a gamma ray, nuclei in atoms will undergo energy level transitions. The local magnetic 
and electronic environment can modify or split these energy levels. During emission or 
absorption of a ɣ-ray in a free nucleus, the latter will recoil due to conservation of 
momentum. Rudolf Mössbauer made the discovery that within a solid or matrix, if the ɣ 
energy is small enough, the recoil of the nucleus is too small to be transmitted as a phonon 
as this is the case of a free nucleus. Instead the whole system recoils, which means that 
when the absorbing and emitting nuclei are in the same matrix, the energy of absorbed and 
emitted ɣ-rays are the same and resonance occurs. Resonance will only occur when the 
transition energy of the emitting and absorbing nucleus match. The number of recoil-free 
events is dependent upon the ɣ-ray energy and so the Mössbauer effect is only observed 
with isotopes with very low lying excited states. The most used isotope for this technique 
is 57Fe as it has a very low energy ɣ-ray and long-lived excited state. 
The Doppler Effect is used to detect the minute energy level changes due to the hyperfine 
interactions of the nucleus with its environment. The radioactive ɣ-ray source will oscillate 
with a velocity of a few mm/s and the recorded spectrum will be expressed as a function of 
the source velocity. When the modulated ɣ-ray energy matches the energy of a nuclear 
transition in the absorber the ɣ-rays are resonantly absorbed and a peak is observed. There 
are three hyperfine interactions originating from the nucleus’ electron density: the isomer 
shift, quadrupole splitting and magnetic splitting. These will be explained briefly.  
The isomer shift is due to the electron density of the nucleus by the presence of the s-
electrons. A difference in the environment of the s-electrons will produce a shift in the 
resonance energy; as such the whole spectrum will be shifted positively or negatively 
relative to a known absorber, such as alpha-iron at RT. This shift provides information on 
valency or the bonding of ligands for example.  
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For nuclei with an angular momentum quantum number I> ½, as this is the case with the 
excited state of 57Fe, the charge distribution is non-spherical. The asymmetric electronic 
charge distribution will define the quadrupole moment Q of the nucleus. The latter will be 
able to interact with any asymmetric electric field from surrounding electrons. As a 
consequence of the asymmetric field, the nuclear energy levels will split and this will lead to 
a doublet instead of a single line. The magnitude of splitting, delta, will be related to the 
nuclear quadrupole moment Q.  
In the presence of a magnetic field, the nucleus spin moment will experience dipolar 
interaction with the latter; this is also known as Zeeman splitting. The ground state energy 
splits into 2 levels and the excited state splits up into 4 levels, leading to a sextet of lines. 
The line positions are related to the splitting of the energy levels, but the intensities are 
related to the angle between the ɣ-ray and the nuclear spin moment.  
57Fe Mössbauer spectra were collected from freeze-dried samples mixed with boron nitride 
and measured in transmission mode in a commercial spectrometer (SEE Co Inc, USA) 
working in constant acceleration mode, calibrated relative to metallic α-Fe at room 
temperature. 
 Determination of core size by Transmission Electron Microscopy 2.3.3
TEM is commonly used in the development of nanomaterials in order to observe their 
morphology (size and shape). Unlike optical microscopy, which relies on the use of photons, 
TEM will have a source which emits electrons, an electron gun, which may be 
a tungsten filament or a lanthanum hexaboride single crystal. The electrons will allow for an 
enhanced resolution in comparison to optical microscopy. The resolution in optical imaging 
is defined by the Rayleigh criterion Rc: two point sources are considered resolved when the 
principal diffraction maximum of one image coincides with the first minimum of the other. If 
the distance between the points is greater, they are well resolved and if it is smaller, they 
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are not resolved. When considering light passing through a circular aperture, Rc is defined 
by the following equation where λ is the wavelength of radiation, n is the refractive index of 
the imaging medium and sin θ is the sine of the aperture angle:  
     
     
     
       (Equation 2-1) 
    
 
 
         (Equation 2-2) 
On the other hand, when using electrons with a smaller wavelength, this resolution can be 
as low as 0.1 Å, which is ideal for nanomaterials with dimensions between 1 – 100 nm. The 
De Broglie equation (Equation 2-2) defines the wavelength of an electron as a wave-particle 
duality where λ is the wavelength, h is Planck’s constant and p is the electron momentum. 
High voltages used in TEM (up to 450 kV) accelerate electrons towards the speed of light. 
The electrons will be accelerated from an electron gun and focused using electromagnetic 
lenses; the image will then be formed upon a digital camera as shown in Figure 2-2. The 
electrons are accelerated at several hundred kV leading to much smaller wavelengths; 
however the resolution will be limited by aberrations in electromagnetic lenses (condenser 
and objective) to about 0.1 nm.  
The most common mode of use for a TEM is the bright field imaging mode: only the direct 
beam contributes to image formation. Thicker regions of the sample or regions with a 
higher atomic number will appear dark, whilst regions with no sample in the beam path will 
appear bright, hence the term "bright field". 
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Care must be taken when interpreting the images obtained by TEM, as sample preparation-
induced artefacts may for example lead to aggregation of NPs on the grid. During sample 
preparation, attractive inter-particle forces will dominate and lead to aggregation which is 
enhanced by drying as the NP concentration increases during the drying of the grid. This is 
known as surface dewetting or the ‘coffee-ring’ effect.196 Also, although some TEM staining 
techniques allow visualisation of the NP coating,197 the drying process causes it to collapse 
and it will vary with environmental conditions such as the temperature or solvent, the shell 
thickness can therefore not be determined accurately by this method.  
In our case, a JEOL 1200EX TEM was used at 120 kV for IONP dispersions. In the case of 
biological samples, a JEOL 1010 TEM was used at 80 kV. After their synthesis, 5 µl of the 
obtained IONP dispersion was diluted in approximately 1.5 ml of water, so that the diluted 
solution remained transparent. The TEM samples were prepared by dropping 5 µl of the 
diluted aqueous solution of the IONPs onto a carbon coated 200 mesh copper grid (EM 
 
Figure 2-2 Schematic view of a transmission electron microscope (TEM) with its lenses and the 
pathway of the electrons. Reproduced from A.  Mescher, Junqueira's Basic Histology: Text and Atlas, 
McGraw Hill Professional, 2009, 12th Edition.  
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Resist Ltd, United Kingdom) which was then air dried overnight. The preparation of 
biological samples is explained in section 2.2.12. 
 Determination of crystallite phase and size by X-ray diffraction (XRD)  2.3.4
To determine the crystallographic arrangement of atoms present in NPs, X-ray diffraction 
(XRD) is used. This method can be used to determine the lattice parameter of the 
nanomaterial synthesised, as well as the crystallite size.  As can be seen in Figure 2-3, X-rays 
are produced in an X-ray tube consisting of 2 metal electrodes in a vacuum chamber. 
Electrons are produced from a tungsten filament cathode and are accelerated towards the 
anode, from which the loss of energy of the electrons after impact is emitted as X-rays.198 
XRD relies on the physical phenomena of X-ray diffraction, which occurs when the X-rays 
interact with crystallographic lattice planes. Upon diffraction, constructive interference can 
occur with specific wavelengths and incident angles, which must be met by Bragg’s law: 
                   (Equation 2-2) 
        
Where n is an integer, λ is the wavelength of the incident X-ray, d is the spacing between 
the atomic planes and Ɵ is the incident X-ray angle.  
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Once the diffraction pattern is obtained, the position, width, intensity and shape of the 
peaks obtained can be compared to reference patterns in known databases. These peak 
parameters are characteristic of a material in a specific crystallographic arrangement and 
therefore help identify the crystalline structure of the NPs as well as the crystallite size. The 
Scherrer equation may be used to determine the approximate size of the crystallites by 
relating it to the broadening of a peak in a diffraction pattern:  
  
  
     
       (Equation 2-3)  
Where τ is the mean crystallite size, K is a dimensionless shape factor, λ is the wavelength of 
the incident X-ray, β is the line broadening at half the maximum intensity (FWHM) after 
subtraction of the background, and Ɵ is the incident angle of the X-ray.   
 
Figure 2-3 Scheme showing the components of a modern X-ray tube. Beryllium is used for the 
window because it is highly transparent to x-rays. Reproduced from Suryanarayana et al., X-ray 
diffraction: a practical approach, 2013, Springer Science & Business Media. 
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This should not be confused with the NP size, as the crystallite size is defined as the area or 
volume of the material where x-ray diffraction is coherent. This analysis was carried out 
with the PANalytical X’Pert Highscore Plus software. It is worth mentioning that only a few 
peaks distinguish Fe3O4 and ɣ-Fe2O3 and their low intensity is blurred by background noise or 
crystallite size effect (broadening due to instrumental effects and crystal strains).  
XRD patterns were obtained with a PanAlytical X-ray diﬀractometer, using CoKα radiation (λ 
= 1.789010 Å). The patterns were collected from 2θ degrees = 20° to 100°. Samples were 
prepared by pressing dried powders on a zero background silicon wafer. 
 Determination of surface functionalisation by Attenuated total reflectance – 2.3.5
Fourier transform infrared spectroscopy (ATR-FTIR) 
ATR-FTIR is a variant of FTIR spectroscopy, which allows identification of different surface 
functional groups of NPs. It relies on the absorption of infrared electromagnetic radiation 
(4000 – 400 cm-1) by different chemical bonds in various functional groups. This occurs 
when the radiation is at the resonance frequency of these chemical bonds; this corresponds 
to their transition energy. ATR-FTIR therefore allows us to obtain information on the nature 
of the chemical groups and the bonds by which they are linked.199 ATR-FTIR was used in 
chapter 4 to obtain information regarding changes in the functional groups before and after 
the ligand exchange reaction of IONPs. FTIR is routinely used in the mid-infrared region (400 
to 4000 cm-1) as this provides information on the rotational-vibrational structure of the 
surface of MNPs. For example, by determining the wavenumber difference between the 
asymmetric and symmetric stretching modes of the coordinated carboxylate group, 
information can be obtained as to whether or not the COOH group is linked by 
chemisorption to the NP.200, 201 The vibration for the asymmetric stretching of the COOH 
groups of citric acid will shift when binding to the surface of the NP occurs.202 Also, 
depending on whether ligands bind to the surface via a mono-dentate or bi-dentate form, a 
change in the spectrum may be noticeable.203, 204 
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The Fe-O band is also useful to evaluate the influence of the surface functionalisation 
reaction on the oxidation of IONPs.  Indeed, the core of magnetite will be surrounded by an 
oxidized layer due to the fact that surface Fe2+ is very sensitive to oxidation.205 Also, when 
studying IONPs, the Fe-O peak of magnetite is found around 570 cm−1, while maghemite will 
have several peaks between 400 to 800 cm-1, the number peaks increasing with the 
structural ordering of its vacancies.49, 206 
In ATR-FTIR, the infrared (IR) radiation passes through a crystal on top of which the sample 
is placed (Figure 2-4).207 The crystal must be made of an IR transparent material with high 
refractive index. The IR beam will enter the crystal and be reflected at the crystal-sample 
interface. Due to its wave properties, the IR will emit an evanescent wave that will interact 
with the sample and be attenuated in the regions where the sample absorbs the energy. 
Then IR radiation then exits the crystal and interacts with a detector. A spectrum will be 
obtained by measuring the interaction of the evanescent wave with the sample. If an 
absorbing material is placed in contact with crystal, the wave will be absorbed by the 
sample and its intensity is reduced in regions of the IR spectrum where the sample absorbs, 
thus, less intensity can be reflected (attenuated total reflection).208 
 
Figure 2-4 Schematic diagram of a horizontal ATR sampling accessory illustrating the important 
parameters. Reproduced from Atitar et al., The Relevance of ATR-FTIR Spectroscopy in Semiconductor 
Photocatalysis, Emerging Pollutants in the Environment - Current and Further Implications, 2015, 
InTech. 
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In the analysis of NPs, one characteristic phenomenon is the breaking of a large number of 
bonds of surface atoms, leading to electrons being rearranged on the surface.209 As a result, 
the surface bond force constant increases as Fe3O4 is reduced to the nanoscale dimension, 
so the absorption bands of IR spectra shift to higher wavenumbers. 
ATR-FTIR analysis was carried out using a Spectrum 100 spectrophotometer from Perkin 
Elmer. Spectra were acquired from 4000 to 650 cm-1 with a resolution of 2 cm-1 and 
averaging over 16 scans. The samples were used in powder form after freeze drying for 48 h 
minimum and did not need to undergo any further preparation. The powder was ground 
and placed on the crystal and a screw press was used to compress the sample. Data 
acquisition was monitored in real time to ensure sufficient signal to noise ratio by adjusting 
the pressure exerted on the sample.  
 Hydrodynamic diameter measurements by Dynamic Light Scattering (DLS) 2.3.6
DLS allows us to determine the hydrodynamic diameter of the IONPs in solution. The 
hydrodynamic diameter is defined as the diameter of a hard sphere that diffuses at the 
same speed as the NP being measured. This parameter will depend on the size, shape and 
speed of the NP in solution as well as the environment it is in such as the ionic strength of 
the solution. This measurement allows us to estimate the NP’s behaviour in solution and 
whether or not any aggregation can be expected in different conditions such as varying salt 
concentration of pH for example. Dynamic Light Scattering (DLS), also known as Photon 
Correlation Spectroscopy (PCS), is a non-destructive method, which determines the size of 
particles or molecules.   
In a solution, if the particles are small enough (Ø ≤ 250 nm) they undergo a random 
Brownian motion due to thermal energy. When a monochromatic He-Ne laser beam (λ = 
633 nm) interacts with particles in solution, the latter scatter the light in all directions in a 
uniform manner, this is known as Rayleigh scattering. This will depend on the particle’s size, 
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shape and the interactions with the surrounding solvent molecules in solution. A 
photomultiplier detector allows one to observe time-dependent fluctuations in the 
scattered intensity because of the Brownian movement. The intensity of the scattered light 
fluctuates at a rate that depends on the size of the particles, and is correlated to the 
diffusion coefficient. Using the following Stokes-Einstein formula, the latter leads us to the 
radius, hence the size of the NPs:  
  
   
    
       (Equation 2-4)   
Where D is the diffusion coefficient, k is the Boltzmann constant, T is the temperature, η is 
the viscosity of the solvent and a is the radius of the particle. The measurement will depend 
on the particles shape or the temperature. DLS allows us to obtain an average diameter of 
NPs dispersed in a solvent, but is unable to distinguish NPs with slight variance in their 
diameter or to resolve polydisperse samples. This is because it measures the intensity of the 
scattered light which is proportional to the sixth power of the particle diameter in the 
Rayleigh equation. Therefore, in the case of a polydisperse sample, the scattered light of 
larger particles will strongly overlay that of smaller particles.  
This measurement is carried out with the Zetasizer Nano S instrument distributed by 
Malvern Instruments Ltd, UK. For hydrodynamic diameter measurements, 20 µl of an 
aqueous solution of IONPs was pipetted into a disposable polystyrene cuvette. These 
cuvettes were purchased from Malvern Instrument Ltd, UK. The average diameter and 
polydispersity index were measured and presented as the average value of three 
measurements. The mean and standard deviation of size were calculated for each sample.  
 Determination of surface charge by zeta potential measurements 2.3.7
The apparatus used to determine the zeta potential (also ζ-potential or electrokinetic 
potential) is the same as previously described in section 2.3.6. For ζ-potential 
measurements, the NPs were diluted and adjusted to the desired pH (from 3 to 10). 
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Measurements were recorded at 25 °C within a disposable capillary cell (DTS1070) 
purchased from Malvern Instrument Ltd, UK. The ζ-potential was determined in the solvent 
of choice and presented as the average value of three measurements. The mean and 
standard deviation were calculated for each sample.  
The ζ-potential is correlated to the surface charge and provides an estimation of the charge 
interactions that the NP will have with its environment. It can also give qualitative 
information about surface functional groups. Indeed, the NPs in solution will acquire a 
surface charge by adsorption of solvent molecules or by ionisation of chemical groups on 
their surface.  Consequently, counter ions gather around the surface of the NP and assemble 
into a double layer: an inner concentrated layer (or stern layer) and an external more diffuse 
layer.210 Within the diffuse layer there is a boundary at which the ions and NPs form a stable 
entity. The potential at this boundary is the ζ-potential.211  
It is determined by applying an electric field upon which the NPs will move towards the 
oppositely charged electrode. Viscous forces will oppose this movement until equilibrium is 
reached and the NPs reach a final equilibrium velocity. This velocity can then be correlated 
to the ζ-potential by the Smoluchowski approximation of the Henry equation in aqueous 
solutions:  
    
        
  
       (Equation 2-5)  
Where UE is the electrophoretic mobility, ɛ the dielectric constant,   is the zeta potential, 
ʄ(Ka) is Henry’s function and Ƞ is the viscosity.212 The Smoluchowski approximation is used 
when measuring the ζ-potential in aqueous solutions of moderate electrolyte concentration 
and gives the value of 1.5 to Henry’s function. This is applied for systems fitting the 
Smoluchowski model, and is used for folded capillary cells with aqueous samples as this is 
the case in our project. Arbitrarily, a ζ-potential value of ± 30 mV indicates a stable 
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suspension of NPs by charge repulsion. Values smaller than this (-30 mV < ζ < 30 mV) 
indicate unstable NPs in solution. 
 
 Determination of the iron content of IONPs 2.3.8
2.3.8.1 Inductively coupled plasma – Atomic Emission spectroscopy  
This method (ICP-AES) was used to determine the total iron content of IONPs in solution. 
This was provided as a service by the National History Museum in London, and by PhD 
student Sarah Belderbos from the MoSAIC laboratory in KU Leuven, Belgium.  
In ICP-AES, the sample is introduced in the spectrophotometer and is atomised before being 
carried into a plasma with a stream of argon gas. The plasma is used to dissociate the 
sample whereby the atoms in the sample are excited to a higher energy state. When 
returning to their ground state, the energy is emitted from the atoms at characteristic 
 
Figure 2-5 Schematic representation of zeta potential: ionic concentration and potential differences as a 
function of distance from the charged surface of a particle suspended in a medium. Reproduced from A. 
Liese et al., Chem. Soc. Rev., 2013 with permission from The Royal Society of Chemistry. 
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wavelengths that provide qualitative multi-elemental analysis of the sample. It is also 
possible to determine the concentrations of the elements present by measuring the 
intensity of the emitted radiation. Strong acids must be used to ensure the entire 
dissolution of the sample and avoid clogging the nebuliser which is responsible for the initial 
atomisation of the sample into a mist.  
The sample preparation consisted in the aqueous solution of IONPs being mixed with aqua 
regia (very strong acid obtained from a mixture 1:3 of nitric acid and hydrochloric acid) to 
ensure their entire dissolution. The solution was then diluted with deionised water until 
reaching a final acid concentration of 5% and an estimated iron concentration of 2 mg/l. A 
colorimetric assay (2.3.8.2) was used to estimate the iron concentration in the samples.  
2.3.8.2 Colorimetric method  
A colorimetric method used to determine the iron content of our samples was based on the 
intrinsic enzyme mimetic activity of IONPs similar to that found in natural peroxidases which 
oxidise organic substrates and lead to the formation of a coloured product measured by 
absorbance at 510 nm.187, 188  
A calibration curve was initially plotted using serial dilutions of known concentrations of 
iron. Each dilution (1 ml) was mixed with 1 ml of 4 M HCl and heated to 90 °C for 30 min. 
Each aliquot (400 µl) was mixed with 900 µl of sodium acetate, 100 µl of hydroxylamine 
hydrochloride and 600 µl of 1,10-phenanthroline. A red colour developed and the 
absorbance of the solution was measured at 510 nm and plotted as concentration of iron vs 
absorbance. The determination of the iron content in IONP solutions was conducted using 
the same protocol, but using 1 ml of dilute IONP solution at the first step, instead of the 1 ml 
of iron standard dilution.  
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 Quantification of organic content by Thermogravimetric Analysis (TGA) 2.3.9
Some experiments were carried out by fellow PhD student Aziliz Hervault at the 
Japan Advanced Institute of Science and Technology (JAIST), Ishikawa, Japan and Georgios 
Kasparis at University College London (UCL), London, UK.  
In JAIST, thermogravimetric analysis (TGA) was performed using freeze-dried IONP powder 
samples with a TGA Seiko Exstar6000 TG/DTA6200 instrument. At UCL, a TA Instruments 
Discovery TGA was used to analyse powders. A nitrogen flow rate of 25 ml/min and a 
temperature ramp of 10 °C/min from 25 to 600 °C were used in both cases. As the sample is 
heated, the changes in mass of the sample are monitored. This method allows us to 
determine the quantity of organic coating or any impurities present on the IONPs. More 
precisely, TGA allows us to obtain the residual weight accounting for the mass of IONPs. This 
allows us to correct the magnetisation by taking into account the percentage of organic 
coating which does not contribute to the magnetic material weight used for the SQUID-VSM 
measurements for example. Also, the temperature at which organic ligands are burnt off, 
can give an indication as to whether they are bound to the IONPs or not.  
 CHARACTERISATION OF IONPS AS POTENTIAL MRI CONTRAST AGENTS  2.4
 MR relaxivity measurements of nanoparticles in solution  2.4.1
Relaxivity measurements at 1.47 T were performed in collaboration with Professor Sylvie-
Begin Colin and Dr Damien Mertz from the Department of Chemistry and Inorganic 
Materials in the University of Strasburg, France.  
All experiments were performed on a Bruker MQ60 NMR Analyzer, BrukerCanada, Milton, 
Ont. Canada, working at a Larmor frequency of 60 MHz (1.41 T) and at 37 °C.  The T1 and T2 
measurements were performed according to the procedure described in the literature.213 
Briefly, a series of IONP aqueous dispersions with different Fe concentrations (0.25, 0.5, 
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0.75 and 1 mM) determined by ICP-AES were prepared. A limited volume (300 µl) of each 
sample was transferred into a glass 5 mm nuclear magnetic resonance (NMR) spectroscopy 
tube with a level sufficient to fit the size of the coil. Using a temperature-controlled probe 
cavity with an external water bath, each sample was preheated to 37 °C as the relaxation 
rates are temperature dependent. Each measurement was repeated three times to measure 
variations within the readings. T1 values were obtained using the instrument’s inversion-
recovery pulse sequence with a recycle delay (repetition time) 2 sec, a delay sampling 
window 0.05 msec, and a sampling window 0.02 msec. A total of 15 data points were 
collected for fitting, starting at 10 msec and ending at one sec. T2 curves were obtained 
using the instrument’s Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence with a recycle 
delay of one sec and a of 0.5 msec. The first echo was not included for fitting and 250 data 
points were collected. T2 curves were fit to a monoexponential decay equation using 
CFTOOL in Matlab® 7.0. Relaxivities (mM–1 s–1) were calculated by taking the inverse of T1 
and T2 times (sec) and dividing these values by the iron concentration (mM) of each sample. 
Measurements were plotted as r1 and r2 values according to the linear relationship of 
longitudinal and transverse relaxation rates versus the magnetic metal concentrations of Fe.  
Relaxivity measurements at 7 T were performed by Cody Amir Gharagouzloo, a PhD student 
under the supervision of Professor Srinivas Sridhar from Northeastern University (Boston, 
MA, USA). The protocol used was the following:  
Six 2-ml vials containing the diluted solutions were arranged in a circular pattern around a 
blank vial of distilled water for the IONP formulation. Relaxivity r1 was measured with a 
variable TR spin-echo sequence and r2 was measured with a multi-echo spin-echo sequence 
with TR fixed. ParaVison 5.1 software was used to draw regions of interest (ROIs) and 
calculate relaxation rate values. Decay curves were fit with a mono-exponential decay 
equation to calculate T2,       
   
  
⁄
 and a mono-exponential growth saturation 
recovery equation to calculate T1,      (   
   
  
⁄ ), where A is the absolute bias 
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and C is the signal intensity. T2 of the samples was measured using the Bruker Multi-Slice 
Multi-Echo (MSME) pulse sequence with the following parameters: Effective TE: 4.25 ms, 
with 30 echoes ranging 4.25 - 127.5 ms, TR = 2500 ms, 40 x 40 mm2 x-y field of view (FOV), 
30 mm slice thickness, 200 × 200 matrix size providing 200 µm2 x-y resolution, number of 
averages = 2, total acquisition time = 11 m 55 s. 
T1 of the samples was measured using a Rapid Acquisition with Refocused Echoes variable 
TR (RARE VTR) pulse sequence with the following parameters: TE = 4.25 ms, Rare Factor: 1, 8 
TRs ranging from 100 – 2500 ms, 40 x 40 mm2 x-y FOV, 30 mm slice thickness, 200 × 200 
matrix size providing 200 µm2 x-y resolution, number of averages = 1, total acquisition time 
= 27 m 15 s. For DI-H20 T1 & T2, two separate scans were run with effective TE = 40 ms for T2 
and TRs ranging from 100 - 3500 for T1. 
 In vitro MR image acquisition of hMSCs labelled with IONPs 2.4.2
These experiments were performed by Willy Gsell, Dr Bella B. Manshian, Dr Stefaan J. 
Soenen and Professor Uwe Himmelreich from the MoSAIC laboratory in KU Leuven (Leuven, 
Belgium).  
hMSCs were seeded on a 24-well plate (10 000 cells/ well) and returned to culture 
overnight. Cell loading with IONPs was carried out at a range of concentrations from 0, 1, 2, 
5 and 100 µg Fe per ml of cMEM on cells, over a period of 24 h. Cells were then rinsed 3 
times with HBSS to remove any free IONPs, before fixing with 4% PFA for 15 min at RT. The 
fixative was removed, and then the hMSCs were stored at 4 °C until use.  
Cells were detached from the multiwall plate using cell scrapers and counted on a 
haemocytometer. 10 000 cells were retained for each sample, which were aliquoted into a 
0.25 ml Eppendorf microfuge tube containing 1.5% agar in PBS. Samples were mounted 
onto a phantom holder and stored at 4 oC until ready for MRI scanning. All images were 
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acquired with a 9.4 T Biospec small animal MR scanner (Bruker Biospin, Ettlingen, Germany, 
horizontal magnet) equipped with actively shielded gradients of 440 mT m-1 and using a 
transmit/receive 72 mm quadrature resonator (Rapid Biomedical, Rimpar, Germany). 
Phantom homogeneity and positioning was assessed using FLASH 3D sequence (TE/TR: 
15/200 ms, matrix: 512x512x128, FOV: 60x60x30 mm, resolution: 0,117x0,117x0,234 mm).  
For T1 measurements, data were extracted using a spin echo sequence with inversion 
preparation (TR: 10 000 ms, TE: 5,67 ms, TI: array of 12 Tis starting from 50 ms with regular 
increment of 500 ms, FOV: 60 x 60 mm, matrix: 256 x 256, 5 slices of 1 mm thickness and 1 
mm gap). Data were fitted to a mono-exponential recovery function and T1 extracted 
(processing performed in PV5,1 using image sequence analysis tool). 
For T2 measurements, data were using a multi Spin Echo sequence (TR: 5000 ms, TE: 20 TEs 
equally spaced by 11,35 ms, FOV: 60 x 60 mm, matrix: 512 x 512, 5 slices of 1 mm thickness 
and 1 mm gap). Data were fitted to a mono-exponential and T2 extracted (processing 
performed in ImageJ using the MRI processor plugin. T2 maps were generated for pixels for 
which the R2 of the fit was higher than 0,9 and capped at 1000 ms) 
 In vivo magnetic resonance imaging of IONPs 2.4.3
These experiments were performed in collaboration with Dr Willy Gsell, Dr Bella B. 
Manshian, Dr Stefaan J. Soenen and Professor Uwe Himmelreich from the MoSAIC 
laboratory in KU Leuven, Belgium.  
All MR images were acquired with the 9.4 T Biospec small animal MR scanner (Bruker 
Biospin, Ettlingen, Germany, horizontal magnet) described in section 2.4.2. Prior to 
scanning, mice were anaesthetised with 2% isoflurane for induction and 1.5% isoflurane for 
maintenance (carrier gas O2). Three female Swiss mice received PBS only (control), while 3 
others received IONPs through intravenous injection of 200 µl of 300 µg Fe/ml diluted in 
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PBS. Animals were scanned on the day of the injection, then once a week for the next 2 
weeks. The in vivo MR imaging protocol used for liver imaging consisted of 2DT2*-weighted 
fast low angle shot (FLASH) and a multi-slice-multi-echo (MSME) sequence. The FLASH 
sequence (TE = 2.3 ms, TR= 203 ms, flip angle = 30 degrees, FOV = 30 x 30 mm, matrix = 256 
x 256, 9 contiguous axial slices of 1 mm thickness acquired in an interleaved scheme, 
averages = 10) was used to determine the decrease in the signal intensity (SI) post injection. 
T2 values (maps) were determined from the MSME experiments and were used for a semi-
quantitative analysis. Parameters for the MSME sequences were TR of at least 3000 ms, 
echo spacing of 7 ms, with 234 mm² in plane resolution with six slices of thickness 1 mm 
each. In order to evaluate particle distribution post intravenous administration in other 
organs, mice were subjected to whole body scan with a Rapid Acquisition with Relaxation 
Enhancement (RARE) sequence (TE = 15.88 ms, TR = 6000 ms, spatial resolution of 200 
mm², slice thickness = 0.5 mm with 50 slices) was performed. Mice were monitored using a 
monitoring and gating model (type 1030) from Small Animal Instruments Inc. (SAII, Stony 
Brook, NY, USA) for controlling physiological parameters. Temperature and respiration were 
monitored throughout the experiment and maintained at 37 °C and 40 to 100 breaths min-1. 
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Chapter 3 POLYOL SYNTHESIS OF IRON OXIDE NANOPARTICLES 
 AIMS AND OBJECTIVES 3.1
A background on the use of IONPs in biomedical applications has been provided, in 
particular their use as contrast agents in MRI. The chemical and physical properties of these 
IONPs will depend on the synthesis method chosen. In order to obtain biocompatible NPs, 
the main objective is to produce monodisperse water dispersible NPs and the polyol 
synthesis has been chosen to achieve this. This is a simple and effective method to produce 
IONPs and will not require a post synthesis step of phase transfer from an organic solvent to 
water, unlike more conventional methods as described in chapter 2. The polyol acts as the 
solvent, a surfactant, as well as the reducing agent. The polyols are known to reduce the 
metal salts to metal nuclei which then nucleate to form metal particles.214 
This chapter will focus on the polyol synthesis of IONPs by different experimental set-ups: 
under inert atmosphere (N2) using a Schlenk line, using a microwave reactor, and in high 
pressure high temperature conditions. The influence of the latter on the NPs obtained will 
be studied, as well as the impact of the different reaction parameters such as the amount of 
iron precursor, temperature and reaction time on the formation of the IONPs. The 
objectives of the research described in this chapter were to optimise the synthesis method 
so as to obtain IONPs in the range of 5 – 10 nm suitable for biological applications, stable in 
aqueous solution, as monodisperse as possible, with relevant magnetic properties for 
potential MRI applications and in a reproducible manner.   
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 RESULTS AND DISCUSSION 3.2
 Conventional polyol synthesis of IONPs using a Schlenk line 3.2.1
3.2.1.1 Preliminary experiments 
These initial experiments were carried out to determine whether or not a reproducible 
method using the polyol synthesis could be found in current literature. IONPs were initially 
synthesised using a modified polyol synthesis described by F. Hu et. al and by both Cai and 
Wan.65, 66, 75, 215 This reaction was carried out with different conditions as reported in 
literature, listed in Table 3-1, to study the effect of the temperature, reaction steps and 
times on the IONPs obtained. Degassed diethylene glycol (DEG) (20 ml) was mixed with 2.4 
mmol Fe(acac)3 (0.85 g) and stirred for 45 min at 100 °C to ensure the complete dissolution 
of the iron precursor. The reaction mixture was heated up to 200 °C for 7 h, the colour of 
the solution changing from dark purple to black, before cooling down back to room 
temperature (RT). Samples were washed by centrifugation with 100 ml of ethanol/ether (v/v 
= 1:8) (8500 rpm, 10 min, 3 times) and redispersed in dH2O for further characterisation. An 
aliquot (approximately 2 ml) was freeze-dried for 48 h (Lyolab 3000, Thermo Scientific Heto) 
for XRD and SQUID-VSM characterisation.  
The reaction was initially carried out in a 2 step process according to the protocol described 
in literature (samples IONP-A and IONP-B). The purpose of the first step is the dissolution of 
the iron precursor in solution while the second step is to ensure the nucleation and growth 
of the particles. This step was carried out initially at 230 °C for 7 h as per reference 53, 
however the IONPs obtained had a broad size distribution as determined by TEM: dTEM = 
11.6 nm ± 2.1 nm (δ = 18%, n = 207) where δ is the dispersity of the mean diameter and n 
the number of particles counted. The TEM images of the IONPs obtained are shown in 
Figure 3-1. 
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Table 3-1 Synthesis of IONPs using a Schlenk line as reported in the literature along with their reaction 
conditions.  
Sample  DEG (ml)  Quantity of 
Iron 
precursor  
Fe(acac)3 
(mmol) 
Reaction step 
1  
Reaction step 
2  
Reference 
IONP-A  20 2  1 h at 140 °C  7 h at 230 °C  54 
IONP-B  20 2 1 h at 140 °C  4 h at 230 °C  54 
IONP-C 20 1 30 min at 
240 °C 
N/A 53 
IONP-D  30 1   30 min 180 °C  2 h 250 °C  53,54 
 
 
Figure 3-1 TEM images of samples obtained at 230 °C for 7 h. (A) magnification 50 k scale bar 20 nm, (B) 
magnification 100 k scale bar 10 nm. 
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In comparison to Hu et. al who obtained nanoparticles of 6 nm ± 0.6 nm, IONPs with a larger 
mean size distribution and which were not monodisperse were obtained. In literature, 
monodisperse IONPs have been defined as a population of particles with a dispersity of the 
mean diameter being less than 10%.66, 216 Throughout our project, this definition was used 
to characterise the size distribution and dispersity of the IONPs. This parameter is critical as 
the magnetic properties (in particular their saturation magnetisation) strongly depend on 
the size distribution of the IONPs, and this in turn will determine their relaxivity values and 
their potential as MRI contrast agents. As per suggested in the literature, in order to 
decrease the size distribution of the IONPs, the next strategy investigated was to shorten 
the second reaction time. For example, Hu et. al were able to decrease the size of the IONPs 
obtained from 6 nm to 3 nm by decreasing the reaction time from 8 h to 2 h. 
3.2.1.2 Influence of the reaction time on IONP formation 
 In an effort to reduce the mean size and size distribution of the IONPs, the duration of the 
second reaction was decreased to 4 h (IONP-B). The IONPs obtained had a larger mean size 
distribution as well as an increased standard deviation as determined by TEM in Figure 3-2: 
dTEM = 13.5 ± 2.7 nm (δ = 19.8%, n = 332). In order to determine if the reaction time, and 
hence the size distribution and dispersity of the IONPs obtained, had an influence on their 
magnetic properties, a magnetisation curve was obtained at 300 K for both samples (IONP-A 
and IONP-B). As is shown in Figure 3-3 below, the SQUID-VSM measurements demonstrated 
that both samples had similar magnetic properties with saturation magnetisation values of 
Ms = 63.5 emu/g and Ms = 58.9 emu/g for samples IONP-A and IONP-B respectively. The XRD 
diffraction patterns for both samples can be found in Figure 3-7. Using the Scherer equation 
approximation (described in chapter 2), the crystallite size for each sample was respectively 
determined to be dXRD = 10 nm and dXRD = 11 nm. Both samples had an inverse spinel 
structure although, as explained in section 2.3.4, distinguishing maghemite and magnetite 
by XRD is not a trivial issue.  
D = 13.5 ± 2.7 nm 
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Figure 3-3 Magnetisation curves of IONPs synthesised for 4h (■) or 7 h (●) at 230 °C during the second 
reaction step.   A 
 
Figure 3-2 TEM images of samples obtained at 230 °C for 4 h. (A) magnification 25 k scale bar 50 nm, (B) 
magnification 50 k scale bar 20 nm. (C) TEM size distribution was fitted with a log normal function.  
d = 13.5 ± 2.7 nm 
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3.2.1.3 Influence of the reaction temperature on IONP formation 
Another strategy to reduce the size of the IONPs and obtain a better size distribution was 
explored. It consisted in an increase of both reaction temperatures. The first reaction is 
carried out at 180 °C in order to ensure the entire dissolution of Fe(acac)3, the latter has 
been reported to take place at approximately 180 – 190 °C.77 The second reaction is further 
reduced to 2 h but the temperature is increased to 250 °C. Indeed, this was chosen to test 
the formulated hypothesis that the nucleation of the IONPs occurs at high temperatures, 
close to the boiling point of the solvent (t = 245 °C for DEG). Increasing the temperature 
aims to increase the generation of new iron species through decomposition of the 
intermediate complexes formed and the remaining Fe(acac)3 in solution.   
However, as can be seen in Figure 3-4, the IONPs obtained were polydisperse with a size 
distribution measured from TEM as: dTEM = 13. 5 ± 2.9 nm (δ = 21.9%, n = 248). The results 
obtained were compared with those of several publications reporting the use of the polyol 
method and these suggested that a one-step reaction at the boiling point of the solvent 
could improve the size distribution of IONPs. From the initial experiments, it is plausible that 
the two-step reaction led to the nucleation of NPs at two different temperatures, hence 
leading to a polydisperse sample.  
 
Figure 3-4 TEM images of IONPs obtained with 1 mmol of Fe(acac)3 heated at 250 °C for 2 h. (A) 
magnification 25 k scale bar 50 nm, (B) magnification 50 k scale bar 20 nm. TEM size distribution (C) was 
fitted with a log normal function 
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In comparison to the previous samples, these new reaction conditions affected the 
magnetic properties of the IONPs as can be seen in Figure 3-6. The sample was 
characterised by an increased saturation magnetisation of Ms = 83.4 emu/g, coercivity Hc ± 
30 Oe and remanent magnetisation Hr ± 4 emu/g. The Ms > 78 emu/g indicates the presence 
of non-oxidised magnetite within the core of the IONPs obtained. However, the sample’s 
dispersity is still above the threshold for monodispersity of 10% defined earlier. Some IONPs 
being larger than the superparamagnetic critical size, the hysteresis curve is not that of 
superparamagnetic NPs as it shows coercivity of about 40 emu/g and slight remanence. The 
magnetic properties of the obtained NPs are crucial for their potential biomedical 
applications and these will later be assessed as a function of the shape and morphology of 
the IONPs. 
 
Figure 3-5 (A) TEM image of IONPs synthesised at 240 °C for 30 min, magnification 50 K, scale bar 20 nm 
(B) TEM size distribution fitted with a log normal function and (C) hydrodynamic diameter in water 
measured by DLS. 
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Figure 3-6 Magnetisation curve measured at 300 K of IONPs obtained at 240 °C for 30 min in a single-step 
reaction (sample IONP-C). 
  
Figure 3-7 XRD pattern of iron oxide nanoparticles synthesised using the Schlenk line. Peaks have been 
indexed according to the reference pattern for magnetite (pdf ref. 01-088-0315).  Diffraction patterns have 
been offset along the y-axis for better comparison.  
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Nevertheless, all synthetic reactions allowed us to obtain iron oxide nanoparticles with 
inverse spinel structure as confirmed by their XRD diffraction patterns in Figure 3-7.  
3.2.1.4 In situ PEG functionalisation  
In order to functionalise the surface of IONPs and improve their morphology, in situ 
functionalisation with different PEG polymers was attempted as suggested in literature.74 It 
has been reported that PEG may be easily adsorbed on the surface of metal oxide colloids, 
and this phenomenon will hinder the growth of the NPs thus controlling and limiting their 
size.217, 218 In these experiments, 2 mmol of Fe(acac)3 with PEG of various molecular weight 
(200, 2000 and 6000 g/mol) was heated for 1 h at 260 °C. The XRD patterns of the three 
samples of IONPs synthesised with PEG are shown in Figure 3-9. The crystal structure of the 
IONPs obtained was unaffected by the addition of PEG as peaks present are in accordance 
with those of the reference pattern for the inverse spinel structure of magnetite (ref. 01-
088-0315). However, the peaks are broader as the molecular weight of the polymer 
increases, which is certainly due to size effect of the crystals.219, 220 This was confirmed by 
the crystallite sizes determined by the Scherer equation for all samples: 4 nm for PEG 200, 
and 5.8 nm for PEG 2000 and 6000. However there is a decrease in the intensity of the 
peaks obtained for PEG 200 which might be due to the poor growth of the nuclei when 
critical concentration of the spontaneous nucleation was reached.220, 221  
The hydrodynamic diameter of these samples could not be measured as the IONPs 
precipitated during the measurement. The TEM images of the IONPs obtained with PEG of 
various molecular weights can be found in Figure 3-8 below. The morphology of the IONPs 
obtained was not spherical, and was irregular in shape and size.  
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Furthermore, the saturation magnetisation decreased significantly with the addition of PEG 
in situ. Although not shown here, the magnetisation curve of the sample obtained with PEG 
6000 was characterised by a saturation magnetisation of Ms = 60 emu/g, coercive field of 
approximately 28 Oe and remanence of 0.25 emu/g.  
 
Figure 3-9 XRD patterns of IONPs synthesised  using 2 mmol of Fe(acac)3 in the presence of PEG 6000, 
2000 and 200. Peaks have been indexed according to the reference pattern for magnetite  (ref. 01-088-
0315). Diffraction patterns have been offset along the y-axis for better comparison. 
 
 
Figure 3-8 TEM images of IONPs synthesised with PEG of different molecular weights (A) 6000, (B) 2000 
and (C) 200 g/mol. Magnification 75 k scale bar 20 nm. 
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To determine the effect of the addition of PEG during the synthesis, all samples were 
characterised by ATR-FTIR. Figure 3-10 below shows the spectra obtained. The peak around 
3413 cm−1 is attributed to the stretching vibrations of the O-H groups. The peak around 
2885 cm−1 is attributed  to  the  alkanes of the polymer; the peak at 1467 cm−1 is due to C − 
H scissoring, the  bands  around  1106  cm−1 are  due  to  skeletal vibrations of CH2 – O – CH2 
bonds, the  band  at  1343  cm−1 is  due  to  C-H  bending  vibrations;  the  band  at 1242 cm−1 
can be attributed to C-H twisting vibrations and the peak at 963 cm-1 is due to C-O  
stretching  vibrations.222-224  These peaks are characteristic of the polymer and are present 
in all samples, however a shift in wavenumber in comparison to the spectrum of free PEG 
(found in Appendix 1) suggests hydrogen-bonding and the interaction with the surface of 
the IONPs.225  
 
Figure 3-10 ATR-FTIR representative spectra of IONPs obtained after in situ functionalisation with PEG 200 
(blue), PEG 2000 (black), and PEG 6000 (red). The 1800 - 2500 cm
-1
 range has been excluded as no significant 
information was found.  
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The use of PEG did not aid in controlling the shape and size of the IONPs. The samples 
obtained had lower saturation magnetisation values than those obtained with the polyol 
solvent. Also, when attempting to determine their hydrodynamic size in aqueous solution, 
these nanoparticles precipitated out of solution. This could potentially be due to an excess 
of polymer contributing to the overall nanoparticle mass. These initial attempts with PEG 
did not allow us to improve the morphology of the IONPs.  
3.2.1.5 Conclusion  
These initial experiments allowed us to obtain IONPs through a conventional polyol 
synthesis method using a Schlenk line while following reaction conditions from literature 
references. However, with these experimental conditions, the size distribution of the IONPs 
obtained was not monodisperse and strongly dependent on the reaction parameters. The 
standard deviation of the mean size distribution was improved when carrying out a single 
step reaction (δTEM = 14%) as opposed to a two-step heating process (δTEM = 18 - 20%). The 
improved size and shape of the IONPs contributed to increasing the saturation 
magnetisation values of the samples up to Ms = 83 emu/g. However, the IONPs were not 
superparamagnetic as some larger NPs contributed to the remanence and coercivity of the 
sample.  
To improve the dispersity of the sample, the single step reaction was maintained, but the 
solvent was changed in order to gain better control over the morphology of the IONPs. For 
this, in situ functionalisation of IONPs with PEG of different molecular weight (6000, 2000 
and 200 g/mol) was attempted. FTIR allowed us to prove the presence of PEG in all samples 
of IONPs obtained with PEG. By XRD, it was determined that the addition of the polymer did 
not affect the inverse spinel structure of the IONPs. However, their crystallite size was found 
to be dependent on the Mw of the PEG used, and their shape and size were observed to be 
irregular by TEM. Their hydrodynamic size could not be determined by DLS as the samples 
precipitated out of solution. Additional studies could be carried out in the future with PEG 
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polymer with various functional groups. For example, catechol-derived functional groups 
have been proven to present a high affinity with metal oxides and have been used 
successfully to functionalise the surface of IONPs with PEG derivatives.226-228   
To further improve the synthesis of the polyol coated nanoparticles, alternative heating 
methods were then investigated. Indeed, the shape of the NPs obtained led to the 
hypothesis that a conventional heating apparatus using a Schlenk line was not ideal as 
heating will occur through convection. So for example, a seed of nanoparticle will not be at 
the same temperature if it closer to the glass (edge of the flask) or if it is in the centre of the 
flask due to the steep thermal gradients created. Sections 3.2.2 and 3.2.3 will explain how a 
microwave reactor and high pressure and high temperature conditions can help overcome 
these limitations. 
 Microwave synthesis of polyol coated IONPs 3.2.2
The polyol reactions carried out using a Schlenk line led to IONPs with a broad size 
distribution. We hypothesise that the inhomogeneities of the nucleation and the growth 
process are caused at least partially by the thermal gradients in the reaction vessel. This is 
due to inefficient transfer of thermal energy from the heat source to the precursors in 
solution.  
Indeed, most synthetic reactions of NPs have been developed with a conventional heating 
mantle because of the need to have high-temperature conditions which initiate their 
nucleation. This is then followed by the addition of the precursor, as is the case in hot 
injection methods for example. However, the reaction vessel acts as an intermediary for the 
energy transfer from the heating mantle to the solvent and reactant molecules in solution. 
This, in turn, will lead to steep thermal gradients in solution which imply non uniform 
reaction conditions making it difficult to obtain uniform and scalable NPs.  
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Microwave (MW) chemistry is based on the ability of a specific material, in our case the 
polyol solvent, to absorb MW energy, which is in the low frequency in the range of 300 to 
300 000 MHz, and to convert it into heat. In comparison to a classic round bottom flask 
heated through an aluminium block or an electromantle controlled heating block, MW 
heating is much more homogenous as the sample itself is heated. This method takes 
advantage of the polar nature of certain solvents which are selectively heated by their 
dielectric losses. Unlike convective heating, volumetric heating will lead to the temperature 
being raised in a uniform manner throughout the whole liquid volume by direct coupling 
and absorption of the MWs by the reactants in solution. It has been established that this 
volumetric heating will lead to fewer thermal gradients and thus more uniform reaction 
temperatures.229 This should lead to a two-step process: a short burst of nucleation 
followed by a growth stage, which is the basis for the formation of homogenous NPs.  
MW radiation of a sample will lead to the alignment of the dipoles or ions with the electric 
field. The use of a MW requires less time and energy consumption in comparison to 
conventional high temperature decomposition methods and may decrease the surface 
reactivity of the NPs which could be beneficial for biomedical applications.230 However, 
since this is an electromagnetic radiation, the reaction vessel is in presence of an oscillating 
field, so the dipoles or ions will continuously attempt to realign themselves, and this in turn 
will lead to different amounts of heat being produced through molecular friction and 
dielectric loss.  
The dielectric loss tangent (tan δ) of a solvent reflects its ability to be polarised by the 
electric field and its ability to convert the MW radiation to heat. Solvents such as ethanol, 
polyols or dimethyl sulfoxide present a high tan δ and are therefore able to be heated 
efficiently by this method. For example, ethylene glycol is classified as a high absorbing 
solvent (tan δ  > 1) with a loss tangent value of 1.35.231 Selective heating which can occur in 
MW reactions will arise due to the relative difference of dielectric constants between the 
solvent and reactants in solution. Due to the strong polarity of the polyol solvent, the 
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microscopic temperature instantly increases when the MW field is applied, so the internal 
temperature near the NP seed surface is high.  
The volume of reaction was limited to 15 ml as the MW vessel mustn’t be filled to its 
maximum capacity for security purposes, in order to not exceed the vessel’s pressure limit 
The concentration of iron precursor Fe(acac)3 was varied from 33 mM to 200 mM, the 
reaction time was varied between 10 min and 1.5 h with the temperature range being 
between 240 °C and 280 °C. 
3.2.2.1 Effect of the reaction time on IONP formation 
To study the influence of the reaction time on the IONPs obtained, the reaction times were 
varied in the range of 5 min to 90 min. The IONPs were synthesised with DEG at 240 °C and 
a concentration of Fe(acac)3 of 33 mM and 100 mM. Reaction times can be significantly 
reduced from hours to minutes using MW reactors as the sample itself will be heated, in 
comparison to Schlenk line reactions which rely on convective transfer of thermal energy to 
the reactants in solution.88  
Table 3-2 reports the size (measured by XRD and TEM) and magnetic properties of the 
IONPs obtained in a MW reactor with different reaction times. By TEM, a change in the size 
of the NPs with the reaction time was observed. Up to 30 min there was an increase in the 
core size of the nanoparticles. When increasing the reaction time above 30 min there was 
initially a decrease in the size of the IONPs, before another increase in their size. This 
evolution of the size was correlated with the values of saturation magnetisation measured: 
69.5 emu/g for the 30 min reaction, then decreasing to 55.1 emu/g for a 60 min reaction, 
before increasing to 58.4 emu/g for a 90 min reaction. This trend was also confirmed with 
the crystallite sizes determined by XRD.  
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This increase in size of the IONPs with the reaction time up to 30 min before decreasing 
briefly then increasing again, was a pattern that was also noticed at other concentrations of 
iron precursor such as 100 mM as is confirmed with the data provided in Table 3-2. There is 
no linear relationship between the reaction time and the size of the IONPs obtained. 
Furthermore, the IONPs obtained are not regular with high polydispersity values determined 
by TEM between 10 and 20% on average. This could potentially be due to a non-defined 
separation between the nucleation and growth phases of the reaction, thus increasing the 
polydispersity of the samples. In the case of microwave-assisted reactions, increasing the 
reaction time does not necessarily lead to an increase in the size of the IONPs and their 
magnetic properties.2 This can be due to dissolution of the nanoparticles initially formed in 
solution under oxidative conditions for longer reaction times, as this has been previously 
demonstrated with silver nanoparticles.89 
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Table 3-2 Summary size and magnetic characterisation of the IONPs obtained in a microwave reactor with 
different reaction times and Fe(acac)3 = 33 mM. Core diameter (DTEM), standard deviations (σTEM) and 
dispersity (δTEM) were calculated from TEM images, counting at least 300 particles per sample. Crystallite 
sizes (DXRD) were obtained from the Scherer equation of room temperature XRD patterns and saturation 
magnetisation (Ms) was obtained at 300 K.  
 
Fe(acac)3 
(mM) 
reaction time 
(min) 
Ms (emu/g) DXRD (nm) 
DTEM ± σTEM 
(nm) 
δTEM (%) 
IONP-1 33 5 41 4 2.4 ± 0.5 21 
IONP-2 33 20 47.4 4.1 5 ± 2.2 44 
IONP-3 33 30 69.5 5.6 5.6 ± 0.8 14 
IONP-4 33 60 55.1 5.1 6 ± 0.7 12 
IONP-5 33 90 58.4 5.8 6 ± 0.9 15 
IONP-6 100 5 45.1 4.1 4.5 ± 0.6 13 
IONP-7 100 10 64.6 5.8 6 ± 0.8 13 
IONP-8 100 20 59.7 6 6.9 ± 0.9 13 
IONP-9 100 60 66.3 4.8 5.9 ± 0.7 12 
IONP-10 100 90 60.2 5.4 5.5 ± 0.7 13 
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3.2.2.2 Effect of the amount of iron precursor Fe(acac)3 on IONP 
formation 
An important factor in the synthesis of nanoparticles is the amount of initial metal 
precursor, in our case iron (III) acetylacetonate. The concentration of precursor was varied 
in DEG from 33 to 190 mM while keeping the reaction at 250 °C for 15 min.  
Table 3-3 Summary size and magnetic characterisation of the IONPs obtained in a microwave reactor with 
different concentrations of Fe(acac)3. Core diameter (DTEM), standard deviations (σTEM) and dispersity (δTEM) 
were calculated from TEM images, counting at least 300 particles per sample. Crystallite sizes (DXRD) were 
obtained from the Scherer equation of room temperature XRD patterns and saturation magnetisation (Ms) 
was obtained at 300 K. 
 Fe(acac)3 
(mM) 
Ms (emu/g) DXRD (nm) DTEM ± σTEM 
(nm) 
δTEM (%) 
IONP-A  33 42.7 6 5.8 ± 0.8 14 
IONP-B  47 71 10.6 13 ± 3 23 
IONP-C  132 54.9 5.6 5.7 ± 0.7 12 
IONP-D  152 75.7 6 6.8 ± 1 15 
IONP-E 190 74.2 15.4 16.9 ± 3.8 22 
It is difficult to conclude on the impact the amount of Fe(acac)3 has because the results are 
inconclusive. There is no definite linear relationship between these two parameters when 
considering Fe(acac)3 in the range of 47 to 150 mM, as can be seen in Figure 3-11 below.  
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Figure 3-11 Graphical representation of saturation magnetisation (blue) and average core diameter (green) 
for various concentrations of precursor, as well as their respective forecast linear trend line (dashed line). 
However, there is a clear difference between particles obtained with 33 mM and those 
obtained with 190 mM of Fe(acac)3. The smaller concentration of iron precursor leads to 
small IONPs with dTEM = 5.8 ± 0.8 nm (δ = 14.1%, n = 372) with Ms (300 K) = 42.7 emu/g, 
while the larger amount of iron precursor results in IONPs with a size of: dTEM = 16.9 ± 3.8 
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Figure 3-12 Magnetisation curves of IONPs obtained with Fe(acac)3 = 47 mM (●) and 190 mM (■) at 300 K. 
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nm (δ = 22.7%, n = 218) with Ms (300 K) = 74.2 emu/g.  
The most notable difference is the morphology of the IONPs obtained, especially at high 
concentrations of Fe(acac)3. As it can be seen in Figure 3-13, in comparison to IONPs 
obtained with 47 mM of precursor, the NPs obtained with 190 mM of Fe(acac)3 are 
polydisperse and of irregular shape with some being spherical and others being hexagonal 
or square shaped. The increase in Fe(acac)3 has a detrimental effect on the nanoparticle size 
distribution and morphology. When measuring the hysteresis curve of all samples at 300 K, 
these could all be characterised by the presence of a small coercive and remanent field. 
However, when Fe(acac)3 = 190 mM, some NPs are non-spherical and above the 
superparamagnetic size threshold and are therefore blocked at 300 K. At this concentration 
of precursor, with a population of larger and irregular IONPs, Hc and Hr increased to 23 Oe 
and 2.65 emu/g respectively.  
 
 
 
Figure 3-13 TEM images of samples obtained with (A) Fe(acac)3 = 47 mM and (B)  Fe(acac)3 = 190 
mM magnification 25 k scale bar 50 nm. 
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It has been hypothesised that the different shapes of IONPs reflects a difference in growth 
processes (Figure 3-14).232 In MW synthesis of nanocrystals, several reactions conditions 
have been identified as disruptive to the isotropic growth of NPs, leading to the formation 
of nanostructures with anisotropic shapes such as nanorods or ellipsoids for example.233 In 
our case, this may depend on the amount of precursor and hence the shape and size of 
seeds initially formed. To this day, the effect of reaction parameters, such as the amount of 
precursor, on the morphology of nanocrystals is not yet fully understood.234 The faceting 
process allows us to obtain spherical nanoparticles from small spherical seeds in the initial 
stages of the reaction. With lower amounts of Fe(acac)3 present in solution, the initial 
spherical seeds will fuse along well-defined crystallographic directions as a way to get rid of 
any unstable facets. This is a thermodynamically driven process which aims to minimise the 
overall surface energy. However, anisotropic growth may occur in reactions which are 
kinetically driven.235 These can occur far from the thermodynamic equilibrium state, when 
there is a steep concentration gradient of monomers in solution. With the high 
concentration of Fe(acac)3 in solution, it is plausible that the non homogenous spatial 
distribution of monomers in solution will induce instabilities which will promote the growth 
 
Figure 3-14 Proposed faceting processes leading to (a) spherical nanoparticles or (b) hexagonal 
nanoparticles. Reproduced from A. Rizzuti et al., Journal of Nanoparticle Research, 2015 with permission 
from Springer.  
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of certain crystal facets at high-energy corners and edges of these seeds, thus leading to 
hexagonal or other anisotropic shaped NPs as seen in Figure 3-14 b. Several causes for this 
may include the preferential adsorption of capping molecules on certain crystal facets, 
structural defects, anisotropic interactions of various facets with the surfactant or solvent, 
or formation of twin planes in the seed particles for example.236-243   
3.2.2.3 Effect of the reaction temperature on IONP formation 
Another critical parameter in the synthesis of IONPs is the reaction temperature. When 
using DEG (boiling point = 248 °C), the reaction temperature was varied between 240 and 
280 °C to determine if this had an impact on the properties of the IONPs synthesised. The 
concentration of Fe(acac)3 was kept constant at 100 mM with a reaction time of 10 min. In 
Table 3-4 below are summarised the size and magnetic characterisation of the IONPs 
obtained.  
Table 3-4 Summary size and magnetic characterisation of the IONPs obtained in a microwave reactor with 
different reaction temperatures. Core diameter (DTEM), standard deviations (σTEM) and dispersity (δTEM) were 
calculated from TEM images, counting at least 300 particles per sample. Crystallite sizes (DXRD) were 
obtained from the Scherer equation of room temperature XRD patterns and saturation magnetisation (Ms) 
was obtained at 300 K. 
 Reaction 
temperature (° C) 
Ms (emu/g) DXRD (nm) DTEM ± σTEM 
(nm) 
δTEM (%) 
IONP-A  240 64.6 5.8 6 ± 0.8 13 
IONP-B  250 54.1 6.4 7.1 ± 1 14 
IONP-C  260 55.6 6.4 6.3 ± 0.7 11 
IONP-D  280 87.2 10.1 8.5 ± 1.7 20 
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As can be observed from the TEM images in Figure 3-15, when the temperature is close to 
the boiling point of the solvent, there is no significant change in the morphology of the 
IONPs obtained. However, when increasing the reaction temperature to 280 °C some IONPs 
obtained are hexagonal shaped. Although the exact mechanism of formation has not been 
studied, we hypothesise that this could be due to specific microwave (MW) effects. For 
example, this could be caused by superheating of the solvent by MW.  It has been suggested 
that this phenomenon arises from the rapid dissipation of MW power which leads to the 
absence of bubble nucleation sites in the solvent which are necessary for the boiling of the 
solvent.244 MW heating is more rapid and homogenous than convective heating by uniform 
loss processes at high enough temperatures, there may however be the creation of local 
“new nucleation points”, at temperatures above 280 °C, which could contribute to the 
formation of hexagonal shaped IONPs. These can be due to local areas of higher 
temperatures in the solution due to “selective heating” within a non homogenous 
dispersion. MWs are preferentially absorbed by a material with a higher tan δ value, 
 
Figure 3-15 TEM images of IONPs obtained with different reaction temperatures (A) 240 °C, (B) 250 °C, (C) 
260 °C and (D) 280 °C. Magnification 25 k, scale bar 50 nm. 
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however if these are not well dispersed within a reaction solution, this may lead to an 
increased local temperature.245 According to Richert, “local heating can occur in cases where 
absorptivity is a spatially varying quantity”.246 The viscosity in this area will decrease, more 
collisions will occur and nuclei will aggregate locally. This mechanism has been shown to 
take place during the synthesis of ZnO nanoparticles using a MW reactor.29 Although this 
strategy has not been explored during this project, the phenomenon of selective heating in 
the context of NP synthesis may be interesting when dealing with solid/liquid interfaces, as 
the metal oxide NP strongly absorbs MW which leads to local overheating and a change in 
surface properties such as their functionalisation with ligands for example.247, 248 
However, when performing the syntheses using a MW reactor, it was challenging to 
demonstrate the reproducibility of the synthetic conditions. In an attempt to replicate 
reactions and determine the reproducibility of this method, 2 reactions were performed 
back to back on the same day in identical conditions. 2 mmol of Fe(acac)3 and 15 ml of DEG 
were heated up to 280 °C and maintained at that temperature for 10 min. The temperature 
reached was monitored and the first reaction only reached 205 °C, whereas the second 
reached 260 °C. This impacted their magnetic properties significantly as the first sample had 
a saturation magnetisation of Ms = 73.9 emu/g while the second sample had a measured 
magnetisation Ms = 56.3 emu/g. This may potentially be due to the limited MW power of 
300 W that was not always sufficient to heat DEG to its boiling point. However, as suggested 
in literature, IR detection with which was performed the temperature measurement, is not 
accurate as it is a read of the vial surface temperature, unlike a fibre optics probe. As the 
polyol strongly absorbs MW radiation, the IR sensor will tend to underestimate the reaction 
temperature, measuring the cooler outside temperature of the vial. Materials with large tan 
δ values have the most apparent discrepancies due to rapid heating of the solution while 
the vessel itself remains cooler. 
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3.2.2.4 Effect of the solvent  
Another parameter that has been shown to have a significant impact on the synthesis of 
IONPs is the solvent. To evaluate this, identical reactions were carried out using DEG and 
triethylene glycol (TREG). However, since their boiling points differ DEG was heated up to 
250 °C whereas TREG was heated up to 280 °C. As can be deduced from the results 
presented in Table 3-5, the solvent had a significant impact on the IONPs obtained. In this 
method, this is also due to the fact that the polyol will act not only as the solvent, but also 
as a surfactant and reducing agent. It has been demonstrated that when the solvent is a 
polyol, nanoparticles may be produced without any additional surfactants to stabilise them 
thanks to the polyols and their low viscosity, their role as a reducing agent and minimal 
steric hindrance.249 These experiments show that as the length of the polyol surfactant 
increases, larger nanoparticles are obtained. As this has been reported in several studies, it 
is believed that the viscosity of the polyol solvent will determine the mobility of diffusion of 
ions or NP seeds, which in turn will have a significant impact on the growth of NPs.249-251 
DEG is less viscous than TREG with a viscosity of 35.7 millipascal second (mPa) s at 25 °C in 
comparison to 49 mPa s for TREG. The lower viscosity of DEG could aid in the mobility and 
diffusion of monomers in solution, thus leading to more nucleation, and with less 
monomers in solution smaller IONPs are obtained. On the contrary, with TREG, which has a 
higher molecular weight and is more viscous, the diffusion of species on solution is limited. 
This implies a slower nucleation rate, fewer seeds are formed, more iron-TREG chelates are 
available for the subsequent growth of IONPs, thus larger NPs are obtained.   
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Table 3-5 Summary size and magnetic characterisation of the IONPs obtained in a microwave reactor with 
diethylene glycol (DEG) and triethylene glycol (TREG). Core diameter (DTEM), standard deviations (σTEM) and 
dispersity (δTEM) were calculated from TEM images, counting at least 300 particles per sample. Crystallite 
sizes (DXRD) were obtained from the Scherer equation of room temperature XRD patterns and saturation 
magnetisation (Ms) was obtained at 300 K. 
 Reaction 
solvent 
Fe(acac)3 
(mM) 
Ms (emu/g) DXRD (nm) DTEM ± σTEM 
(nm) 
δTEM (%) 
IONP-A  DEG 47 56.2 4.7 3.9 ± 0.6 15 
IONP-B  TREG  47 49.4 6.9 7 ± 0.9 13 
IONP-C  DEG  132 80 6.2 6.5 ± 0.9 14 
IONP-D  TREG  132 94.6 16.5 15.7 ± 3.2 20 
IONP-E DEG  152 77.8 4.9 5.9 ± 0.8 14 
IONP-F TREG 152 86.3 11.9 12.5 ± 2.4 19 
3.2.2.5 Conclusion  
The effect of different reaction parameters on the synthesis of IONPs by the polyol method 
in a MW reactor was studied. No direct correlation could be established between the 
reaction time and the size or properties of the IONPs obtained. Indeed, increasing the 
reaction time did not necessarily lead to larger IONPs with enhanced magnetic properties. 
An increase in the concentration of iron precursor Fe(acac)3 did lead to overall larger IONPs 
and increased saturation magnetisation, but no direct linear correlation could be observed. 
The hypothesis is that this could be merely due to insufficient mixing of the reactants in 
solution which are not properly dissolved in the polyol solvent. Furthermore, at high 
concentrations of Fe(acac)3 such as 190 mM, anisotropic growth could be observed with 
IONPs being hexagonal shaped.  
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The reaction temperature had an impact on the IONPs obtained, as the MW can provide 
sufficient energy to cause superheating of the solvent. If the reaction mixture is not 
homogenous, materials with higher tan δ values may preferentially absorb the MW energy 
which can lead to the formation of new local nucleation points at high temperatures where 
there is an increase in the local temperature. In turn, these may affect the crystalline growth 
of IONPs and their surface properties, leading to potential hexagonal shaped IONPs. To 
avoid this effect, careful attention must be provided to ensure the homogeneity of the 
reaction solution and the temperature must be carefully monitored. Finally, these 
experiments led to the conclusion that the length of the polyol had an impact on the size of 
the IONPs obtained. Due to its smaller molecular weight, DEG is less viscous than TREG, 
which in turn will allow for a more rapid diffusion of species in solution hence for more 
nucleation events to take place and thus smaller IONPs are obtained.  
 High pressure – high temperature synthesis  3.2.3
In the next phase of this work, the polyol synthesis was adapted to high pressure and high 
temperature conditions of an oven. Synthesis in these conditions offers the opportunity to 
examine their effect on the properties of IONPs obtained. Indeed, several publications link 
the high pressure conditions to NPs with improved crystallinity, as well as the possibility for 
superheating conditions which can also have an impact on the synthesis of 
nanomaterials.204 The aim of the next section was to attempt to contribute to a better 
comprehension of the polyol synthesis and to improve the properties of the IONPs by 
carrying out a systematic study of the process. For this, the conditions were finely tuned 
(reaction time, type of solvent and concentration of iron precursor) and their effects on the 
final size, morphology and magnetic properties of the obtained NPs were investigated. 
3.2.3.1 Effect of polyol solvent on IONP formation 
As discussed in section 3.2.2.4, when the polyol synthesis was carried out in a MW reactor, 
the type of polyol solvent had a significant impact on the size of the NPs, hence on their 
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magnetic properties. Section 3.2.3.1 aims to determine if this effect was also observed in 
the case of IONP synthesis in high pressure high temperature conditions. 
In a typical reaction, the following reaction conditions were used: 0.7 g Fe(acac)3 were 
dissolved in 20 ml of polyol solvent (diethylene glycol (DEG), triethylene glycol (TREG) and 
tetraethylene glycol (TEG)), then heated up to 250 °C and maintained at that temperature 
for 8 h. The characterisation of the IONPs obtained with different polyols can be found in 
Table 3-6 below.  
The TEM analysis of IONPs synthesised with different polyols, as can be seen in Figure 3-16, 
revealed that IONPs obtained with DEG and TREG were spherical and below the 
superparamagnetic critical size with an average diameter of 5.8 ± 0.8 nm (δ = 14.1%) and 9.1 
± 0.9 nm (δ = 9.8%) respectively. On the other hand, when a longer polyol ligand such as 
tetraethylene glycol (TEG) was used, larger nanoparticles of 13.9 nm ± 3.4 nm (δ = 24.5%) 
were obtained with an increase in the polydispersity of the sample. There is a correlation 
between the length of glycol and size of NPs, as the higher the length of the glycol, the 
larger the size of the synthesised NPs. The magnetic properties of these polyol coated IONPs 
Table 3-6 Summary size and magnetic characterisation of the IONPs obtained in high pressure-high 
temperature conditions with different solvents DEG, TREG and TEG. Core diameter (DTEM), standard 
deviations (σTEM) and dispersity (δTEM) were calculated from TEM images, counting at least 300 particles per 
sample. Crystallite sizes (DXRD) were obtained from the Scherer equation of room temperature XRD patterns 
and saturation magnetisation (Ms) was obtained at 300 K. 
Reaction 
solvent 
Ms 
(emu/g) 
DXRD (nm) DTEM ± σTEM 
(nm) 
δTEM (%) 
DEG  71.5 6.1 5.8 ± 0.8 14 
TREG  80.8 8.4 9.1 ± 0.9 10 
TEG  79.1 12.8 13.9 ± 3.4 25 
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were measured at 300 K, the hysteresis curves obtained can be seen in Figure 3-17. IONPs 
obtained with DEG and TREG exhibited superparamagnetic behaviour with a saturation 
magnetisation Ms = 71.5 and Ms = 80.8 emu/g respectively and negligible coercivity. On the 
other hand, when using TEG, IONPs were characterised by Ms = 79.1 emu/g but also a small 
coercive field Hc = 4.6 Oe and remanence of approximately Mr = 1 emu/g. Since the particle 
size distribution increased, it is plausible that amongst the TEG coated IONPs, a population 
of larger IONPs above the superparamagnetic threshold become blocked at 300 K.27 
 
 
 
Figure 3-16 TEM images and particle size distributions of iron oxide nanoparticles synthesised using 
different polyols A) TEG, B) TREG and C) DEG. Magnification 75 k scale bar 20 nm. Size distributions 
were fitted with a normal function (solid line), d = mean diameter, δd = standard deviation and n = 
number of particles counted. 
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Figure 3-17 Magnetisation curves of IONPs synthesised in high pressure-high temperature conditions with 
different polyol solvents (■) DEG, (●) TREG and (▲) TEG.    
Different sizes of NPs were obtained with different polyol ligands in identical high pressure 
and high temperature conditions.  
The exact nucleation and growth process for this reaction remains poorly understood to this 
day. As observed by Douglas et al., the mechanism here is not consistent with a classic 
LaMer mechanism.249 This study highlights the importance of the solvent on the final NP 
morphology, especially in the case of an unstirred system. The solvent viscosity will play a 
critical role in the diffusion of species in solution, thus having an impact on the nucleation 
and growth of NPs. As this has also been observed with various NP systems such as with 
titanium dioxide and gold NPs, it is plausible that the higher the length of the carbon chain 
of the polyol, the more effective they are as capping ligands, hence bigger NPs are obtained 
as it was shown to be the case with poly(ethylene glycol) of different molecular weight.249, 
252-254 
 139 
 
These experiments confirm that the choice of the solvent is critical in obtaining high quality 
nanoparticles with a desired size and with a narrow size distribution.249, 255, 256 From these 
results, it was determined that IONPs produced in DEG and TREG were suitable for further 
investigations as they had a narrow size distribution, were superparamagnetic, and had a 
high saturation magnetisation which are necessary for biomedical applications.257 
3.2.3.2 Effect of the reaction time on IONP formation 
To study the effect of the reaction time on the NPs obtained, in a typical synthesis 1.4 g of 
Fe(acac)3 was dispersed in 20 ml of TREG. The reaction mixture was transferred to a 45 ml 
capacity Teflon lined autoclave vessel then heated up to 250 °C and maintained at that 
temperature for 1 h, 2 h, 4 h, 8 h, 12 h and 24 h. The results obtained are summarised in 
Table 3-7.  
The increase in the reaction time from 1 h to 24 h led to an increase in the size of the NPs 
 
Figure 3-18 TEM images of IONPs synthesised with TREG in high pressure high temperature conditions 
with different reaction times A) 24 h B) 12 h C) 8 h D) 4 h E) 2 h F) 1 h. Magnification 25 k scale bar 50 
nm. 
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obtained from 7.2 nm ± 0.8 nm (δ = 11%) to 15 nm ± 1.9 nm (δ = 12.5%). This was also 
coupled with an increase in the saturation magnetisation from 61.2 emu/g to 88 emu/g. 
Longer reaction times led to particle growth with narrow size distribution, leading us to the 
hypothesis that the reaction mechanism is coalescence.258 This allows us to finely control 
the size of the nanoparticles, which is crucial for their biomedical applications.  
This trend in the evolution of the core size determined by TEM, crystallite size determined 
by XRD and the saturation magnetisation measured at 300 K as a function of the reaction 
time also occurred with DEG. A graphical representation of the evolution of core diameter 
measured by TEM and saturation magnetisation as a function of the reaction time in DEG 
and TREG can be found in Figure 3-19 below. This confirms the overall linear evolution of 
these parameters with the reaction time in high pressure high temperature conditions.  
 
Figure 3-19 Graphical representation of the core diameter measured by TEM and saturation magnetisation 
measured at 300 K of the IONPs obtained in TREG and DEG in high pressure high temperature conditions 
with different reaction times. 
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Table 3-7 Summary size and magnetic characterisation of the IONPs obtained in TREG and DEG in high 
pressure high temperature conditions with different reaction times. Core diameter (DTEM), standard 
deviations (σTEM) and dispersity (δTEM) were calculated from TEM images, counting at least 300 particles per 
sample. Crystallite sizes (DXRD) were obtained from the Scherer equation of room temperature XRD patterns 
and saturation magnetisation (Ms) was obtained at 300 K. 
Sample 
 
Solvent 
Reaction 
time (h) 
Ms(emu/g) 
DXRD 
(nm) 
DTEM ± σTEM 
(nm) 
δTEM 
(%) 
 
IONP-A TREG 1 61.2 6.2 7.2 ± 0.8 11  
IONP-B TREG 2 66.1 7.3 8.7 ± 1 11  
IONP-C TREG 4 73 7.8 8.9 ± 1 11  
IONP-D TREG 8 70.5 9.4 9.9 ± 1.1 11  
IONP-E TREG 12 81 29.2 11.7 ± 1.4 12  
IONP-F 
 
 
 
NP-F 
TREG 24 88.8 13.5 15.1 ± 1.2 8  
IONP-A DEG 0.5 65.7 4.1 4 ± 0.5 13  
IONP-B DEG 1 68.6 4.6 4.7 ± 0.8 17  
IONP-C DEG 2 71.9 5 5.4 ± 0.6 11  
IONP-D DEG 4 69.3 5.5 6.3 ± 0.7 11  
IONP-E DEG 8 63.7 5.9 6.4 ± 0.7 11  
IONP-F DEG 12 75.2 18.6 6.6 ± 0.7 11  
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3.2.3.3 Effect of the amount of Fe(acac)3 on IONP formation 
The final parameter that was studied was the effect of the amount of precursor Fe(acac)3 on 
the IONPs synthesised with TREG at 250 °C for 8 h. The amount of precursor was varied 
from 100 mM up to 500 mM and the results obtained are presented in Table 3-8.  
From the IONPs obtained, a direct linear relationship between the concentration of 
Fe(acac)3 and the crystallite size determined by XRD was observed. On the other hand, the 
core diameter measured by TEM and the saturation magnetisation measured at 300 K did 
overall increase with the amount of precursor but not in a proportional manner. Further 
thermogravimetric analysis was carried out on all samples to confirm the amount of polyol 
coating and determine its contribution to the overall NP mass. This data can be found in 
Appendix 2. This allows for a more accurate magnetic characterisation of the IONPs 
obtained. Along with the saturation magnetisation of these samples, this trend was also 
observed for the core size of the IONPs measured from TEM images which increased from 
10.3 ± 1 nm for Fe(acac)3 = 100 mM to 13.6 ± 2.4 nm for Fe(acac)3 = 500 mM. Overall, these 
experiments allowed us to observe a direct correlation between the amount of precursor 
used and the size of the NPs obtained. In turn, this was directly linked to the magnetic 
properties of the IONPs. However, the concentration of 500 mM was deemed too high as 
IONPs obtained had an estimated crystallite size of 22 nm and a core diameter measured by 
TEM of 13.6 ± 2.4 nm. These values are consistent with the small coercive field of 
approximately 15 Oe which characterises this sample (data not shown here), and which is 
not desirable when for superparamagnetic IONPs in biomedical applications.  
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Table 3-8 Summary size and magnetic characterisation of the IONPs obtained in a TREG in high pressure-high 
temperature conditions with different amounts of precursor Fe(acac)3. Core diameter (DTEM), standard 
deviations (σTEM) and dispersity (δTEM) were calculated from TEM images, counting at least 300 particles per 
sample. Crystallite sizes (DXRD) were obtained from the Scherer equation of room temperature XRD patterns 
and saturation magnetisation (Ms) was obtained at 300 K. 
3.2.3.4 Reproducibility studies  
While it was found that the IONPs obtained were consistent under the same experimental 
conditions, the reproducibility of the synthetic conditions was investigated in order to 
evaluate the reliability of this method and its potential for mass-production of IONPs. Most 
publications reporting the synthesis of nanoparticles for biomedical applications fail to study 
the reproducibility of the synthetic method which is critical before any commercialisation or 
clinical trials can be considered. Each reaction, using TREG as the polyol capping agent, was 
repeated three times and the properties of the IONPs obtained were assessed. A standard 
condition for the reaction was kept constant: 1.4 g of Fe(acac)3 and 20 ml of TREG were 
heated up to 250 °C and maintained at that temperature for 8 h before cooling down to 
room temperature over 2 h. Indeed, previous results presented in Table 3-7 indicate that 
the IONPs obtained with these conditions lead to the formation of superparamagnetic 
Sample 
Fe(acac)3 
(mM) 
Ms (emu/g) 
Ms (TGA 
corrected) 
DXRD (nm) 
DTEM ± σTEM  
(nm) 
δTEM (%) 
IONP-A 100 65.4 73.7 8.6 10.3 ± 1 10 
IONP-B 150 72.9 74.1 8.5 9.9 ± 1.2 12 
IONP-C 200 64 72.4 9.1 9.5 ± 1 11 
IONP-D 250 73.4 80.8 12 10 ± 1.2 12 
IONP-E 500 83.3 90.8 22 13.6 ± 2.4 18 
 144 
 
IONPs with interesting magnetic properties and with an appropriate size for biomedical 
applications. For simplicity, the triplicates obtained with these reaction conditions are 
named IONP-1, IONP-2 and IONP-3. The results are illustrated in Table 3-9.  
Table 3-9 Summary size and magnetic characterisation of the triplicates obtained (as described in section 
3.2.3.4). Core diameter (DTEM), standard deviations (σTEM) and dispersity (δTEM) were calculated from TEM 
images, counting at least 300 particles per sample. Crystallite sizes (DXRD) were obtained from the Scherer 
equation of room temperature XRD patterns and saturation magnetisation (Ms) was obtained at 300 K. 
These results indicate a well-controlled synthesis route with a standard deviation of the core 
size determined by TEM which is very narrow. Similarly, the crystallite size determined by 
XRD only presented a standard deviation of 0.3 nm. It was therefore possible to obtain 
IONPs in high temperature high pressure conditions by a reproducible and reliable method 
when controlling the synthesis conditions.  
To demonstrate the advantage of high pressure high temperature conditions, the same 
reaction was replicated (1.4 g Fe(acac)3 in 20 ml of TREG) using a conventional set-up 
consisting of a round bottom flask, condenser and magnetic stirring. The IONPs obtained in 
these conditions differed by their polydispersity and magnetic properties.  
 
Sample DTEM ± σTEM (nm) δTEM (%) DXRD (nm) Ms (emu/g) 
IONP-1 9.9 ± 1.1 11 9.4 70.5 
IONP-2 10.9 ± 1.1 10 8.9 77.8 
IONP-3 10.5 ± 1.1 10 9.3 81.1 
Overall average 10.2 ± 1.2 12 9.2 ± 0.3 76.5 ± 5.4 
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TGA of these samples differed significantly in terms of the percentage of organic coating 
present. Both samples had an initial 6% weight loss due to elimination of water and solvent 
evaporation (T < 200 °C). For IONPs obtained in a round bottom flask, a 16.8% weight loss of 
organic material was observed in the range of T = 200 °C to T = 400 °C. IONPs obtained in 
high pressure high temperature conditions were characterised by a 9.7% weight loss in the 
same temperature range. However, both samples present a single step of mass loss which is 
characteristic of chemisorption of the surfactant,259-261 TREG in this case.  
As can be seen in Figure 3-21, the hysteresis curves at 300 K of TREG coated IONPs obtained 
with a Schlenk line showed that they exhibited a superparamagnetic behaviour with Ms = 
81.8 emu/g. At 5 K a value of Ms = 90 emu/g was measured indicating that spins are blocked 
at that temperature. While the magnetic properties are similar to the IONPs obtained in 
 
Figure 3-20 Thermogravimetric analysis of TREG coated IONPs obtained in high pressure high 
temperature conditions (black) and TREG coated IONPs obtained with a Schlenk line (blue). 
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high pressure and high temperature conditions, the size distribution of the core diameter 
measured by TEM is significantly larger. As can be seen in Figure 3-22, IONPs obtained had a 
much broader size distribution: dTEM = 9.9 ± 1.8 nm (δ = 18%), in comparison to IONPs 
obtained in high pressure high temperature conditions: dTEM = 10.5 ± 1 nm (δ = 10%). High 
pressure conditions allowed better control of the morphology of the IONPs obtained, hence 
leading to monodisperse nanoparticles as demonstrated in the summary of the 
characterisation of these IONPs found in Table 3-10.  
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Figure 3-21 Magnetisation curves of TREG coated IONPS obtained with a conventional apparatus consisting 
of a round bottom flask, magnetic stirring and condenser at 300K  (∆) and 5K (◊), and of IONPs obtained in 
high pressure high temperature (HPHT) conditions at 300K (□) and 5K (○).  
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Table 3-10 Summary size and magnetic characterisation of the IONPs obtained in high pressure high 
temperature conditions or using a conventional set-up consisting of a round bottom flask, condenser and 
magnetic stirring. The same reaction conditions were used: 1.4 g Fe(acac)3 in 20 ml of TREG were heated up 
to 250 °C and maintained at that temperature for 8 h before cooling down to RT over 2 h. Core diameter 
(DTEM), standard deviations (σTEM) and dispersity (δTEM) were calculated from TEM images, counting at least 
300 particles per sample. Saturation magnetisation (Ms) was obtained at 300 K. 
 dTEM ± σTEM (δTEM) TGA weight loss 
(%) 
Ms 300 K 
(emu/g) 
Schlenk line 9.9 ± 1.8 nm (18%) 16.8 81.8 
High pressure high 
temperature conditions  
10.5 ± 1.1 nm (10%) 9.7 76.2 
3.2.3.5 Magnetic characterisation of polyol coated IONPs  
A sample was made in identical conditions as previously (Section 3.2.3.4) and characterised 
by SQUID-VSM at 300 K and 5 K. Briefly, 1.4 g of Fe(acac)3 and 20 ml of TREG were heated 
up to 250 °C and maintained at that temperature for 8 h before cooling down to RT over 2 h. 
Furthermore, Mössbauer spectroscopy was conducted on a sample obtained in identical 
 
Figure 3-22 TEM image of IONPs obtained with TREG (A) in a conventional apparatus consisting of a 
round bottom flask, magnetic stirring and condenser, magnification 75 K scale bar 20 nm or (B) in high 
pressure high temperature conditions, magnification 25 K scale bar 50 nm. (C) Particle size distributions 
were fitted with a log normal function for IONPs obtained using a Schlenk line (green) and in high 
pressure high temperature conditions (red).  
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conditions by Dr Lara Bogart from University College London, UK in an attempt to identify 
the phase of iron oxide obtained. SQUID-VSM was used to measure the magnetic properties 
of the IONPs at 5 K and 300 K and these are reported in Figure 3-23. 
 
 Saturation magnetisation Ms at 300 K was measured at 77.3 emu/g which is close to the 
bulk value of maghemite (78 emu/g at 300 K) and magnetite (92 emu/g at 300 K),34, 35 which 
indicates that the contribution of the polyol ligand to the mass of the nanoparticle structure 
is negligible. The decrease in the Ms in comparison to the bulk could be due to surface and 
nanoscale effects. Indeed, the spherical morphology of the IONPs is consistent, so we do not 
attribute the decrease of Ms to shape effects.
86, 249, 262
 This value is slightly smaller than the 
theoretical magnetisation value for bulk maghemite,36, 81 and this is due to a ﬁnite size 
effect: canting of surface spins which are unaligned with the spins present in the rest of the 
magnetic domain.133 This effect is more pronounced for NPs of smaller size.263 At 5 K a Ms of 
 
 Figure 3-23 Magnetisation curves of IONPs obtained with TREG in high pressure high temperature 
conditions at 300 K (■) and 5 K (▲), showing the transition from a superparamagnetic state at 300 K to a 
blocked state at 5 K. 
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86.5 emu/g was measured indicating that spins are blocked at that temperature hence a 
higher value than at 300 K.  
All curves were corrected by taking into account the organic layer’s contribution due to 
polyol. Indeed, the presence of the polyol on the surface of the NPs was confirmed by TGA 
measurements (Figure 3-24).  
The thermal decomposition of TREG coated IONPs is characterised by a two-stage weight 
loss profile. The first stage from approximately 40 to 200 °C corresponds to the removal of 
the physically adsorbed water molecules. The second step from 200 to 570 °C, which 
 
Figure 3-24 TGA curves for TREG coated IONPs obtained by heating 1.4 g Fe(acac)3 at 250 °C before cooling 
back down to RT for 2 h. Thermogravimetric (TG) curve (green) represents the mass of sample versus 
temperature. The corresponding weight loss curve (blue) is obtained by dividing the weight of the samples 
by its initial mass. The differential of the weight loss curve (red) is the first derivative of the weight loss 
curve. The differential thermal analysis (DTA) of an inert reference Al2O3 is indicated by the black curve and 
reflects the temperature difference between the sample and reference. 
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represents the most significant loss, can be attributed to the removal of TREG in the sample 
(or other polyols such as DEG or TEG) as the boiling point is in that temperature range.264, 265 
This is supported by the peaks of the first derivative curve, also known as inflection points, 
which indicate the greatest rate of change on the weight loss curve. In this sample, beyond 
the initial 1.5% weight loss due to elimination of water (T < 200 °C), an 8.5% weight loss of 
organic material was observed in the range of T = 200 °C to T = 400 °C. A residual mass of 
approximately 90 wt% of the initial sample remained at the end of the TGA experiment. This 
allowed to correct the SQUID-VSM measurements by correcting the mass of iron oxide 
sample with the organic ligand contribution determined by TGA. The corrected hysteresis 
curves are those presented in Figure 3-23. 
XRD does not allow distinction between maghemite (-Fe2O3) and magnetite (Fe3O4) phases 
(section 2.3.4). Room temperature 57Fe Mossbauer spectra were recorded by Dr Lara Bogart 
at UCL on samples obtained in the same reaction conditions as in section 3.2.3.4. Briefly, 1.4 
g of Fe(acac)3 and 20 ml of TREG were heated up to 250 °C and maintained at that 
temperature for 8 h before cooling down to RT over 2 h. After cleaning the sample with 
acetone and centrifugation as described in chapter 2, the sample was freeze-dried and a 
first Mössbauer spectrum was recorded on the day of the synthesis and over time until 18 d 
after the synthesis, when the spectrum changed. As seen in Figure 3-25, these spectra 
exhibited absorption out to ± 8 mm/s, indicative of magnetic hyperfine splitting, due to the 
dipole interaction between the nuclear spin moment and a magnetic field. However, the 
spectra were dominated by a very broad central absorption peak, as is typical of disordered 
and/or fine particle materials.266 The mean isomer shift of the spectra, relative to alpha-iron, 
was determined to be in the range delta = 0.38 to 0.42 mm/s. These values lie between 
those of pure maghemite (delta = 0.32 mm/s) and pure magnetite (delta = 0.53 mm/s), 
implying that the samples were either non-stoichiometric magnetites, or 
magnetite/maghemite composites, or some combination of the two.267 After 18 d, the 
shape of the spectrum had changed possibly suggesting the formation of clusters, but this 
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was difficult to confirm as the broadening of the main absorption peak did not allow to 
determine whether a change in the mean isometric shift had occurred. 
 
Room temperature 57Fe Mossbauer spectra could also be correlated with the instability 
demonstrated by DLS of this same sample in Figure 3-26 below. These TREG coated IONPs 
were well dispersed in water; however the hydrodynamic diameters measured were quite 
large (> 200 nm) in comparison to the core and crystallite size determined by TEM and XRD 
respectively. Furthermore, sedimentation was visible in the centrifuge tubes after several 
days. This observation along with the information obtained by Mössbauer spectroscopy 
suggested that the polyol coating was unstable, thus leading to the formation of NP clusters 
or agglomerates in solution. At this stage, it was confirmed visually by precipitation out of 
solution of these IONPs in water and salt conditions (NaCl 150 mM) in less than 30 min.  
 
Figure 3-25 Mössbauer spectrum of TREG coated IONPs obtained in high pressure-high temperature 
conditions recorded (a) on the day of their synthesis (b) 18 d after their synthesis.  
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Figure 3-26 Representative DLS measurement in water of TREG coated IONPs synthesised in high pressure 
high temperature conditions 
While the exact binding mechanism of polyols to the surface of IONPs has not been 
confirmed experimentally, recent literature suggests that the polyol, such as DEG, chelates 
iron. However, the exact structure of this chelate remains undetermined. Under high 
pressure high temperature conditions, the stainless steel vessel does not allow for direct 
observation or analysis of the reaction mixture so no mechanistic insight may be obtained 
from physical or chemical changes of the solution. The underlying mechanism may involve 
three consecutive steps as determined by Dey et al.: metal complexation reaction between 
hydrated metal precursor and the polyol which acts as a chelating agent and the solvent, 
followed by hydrolysis to transition to a metal hydroxide and finally dehydration due to heat 
treatment forming spinel structured metal ferrites.268 In recent publications, TREG coated 
IONPs synthesised by the polyol method in an autoclave or under standard conditions using 
a Schlenk line were reported to be unstable and aggregate in solution. It is suggested that 
the polyol coating is labile and is only weakly linked to the IONPs by physisorption, meaning 
there are no chemical bonds between the polyol coating and the IONP, thus leading to the 
aggregation of the nanoparticles in solution.73, 77  
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3.2.3.6 In situ functionalisation  
Nanoparticles must be stable in aqueous and salt conditions in order to be considered for 
biomedical applications. After determining that aggregation of TREG coated IONPs takes 
place, the stability of the polyol coated IONPs obtained in high pressure high temperature 
conditions must be improved. It has been reported that IONPs may be synthesised in polyols 
with structural agents such as polyvinylpyrrolidone (PVP) or polyethyleneimine (PEI) to help 
stabilise the NPs obtained as well as to control their shape and size.147, 151 In situ 
functionalisation strategies using PEG were therefore investigated. PEG of different 
molecular weight was added to the polyol synthesis. The reaction conditions were:  20 g of 
PEG 300, 2000 or 6000 was added to 2 mmol of Fe(acac)3 and heated up to 250 °C for 1 h.   
Below are the TEM images obtained with the addition of 20 g of PEG of different molecular 
weight (Figure 3-27). 
From the morphology of the IONPs obtained, only the use of PEG 300 allowed us to obtain 
spherical IONPs. Using PEG of higher molecular weight (2000 and 6000) led to polydisperse 
nanoparticles and irregularly shaped IONPs including some cubic and triangular shapes. 
Uniformity in size and shape was best observed using PEG 300, however the polydispersity 
still remained elevated as the average core diameter measured by TEM was determined: 
dTEM = 11.2 ± 2.1 nm (δ = 18.9%).  
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To determine the effect of the addition of PEG during the synthesis, all three samples were 
characterised by ATR-FTIR. Figure 3-28 below shows the FTIR spectra IONPs after in situ 
functionalisation with PEG 200 as well as the spectrum of PEG 200. The peak around 3413 
 
Figure 3-27 TEM images of TREG coated IONPs synthesised in high pressure high temperature 
conditions with A) PEG 300 B) PEG 2000 and C) PEG 6000. Magnification 25 k scale bar 50 nm. 
 
Figure 3-28 ATR-FTIR representative spectra of PEG 200 (blue) and IONPs obtained after in situ 
functionalisation with PEG 200 (black). The 1800 - 2500 cm
-1
 range has been excluded as no significant 
information was found.  
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cm−1 is attributed to the stretching vibrations of the hydroxyl groups. The peak around 2870 
cm−1 is attributed to  the  alkanes of the polymer; the peak at 1454 cm−1 is due to C − H 
scissoring, the  bands  at  1121  cm−1 and 1067  cm−1 are  due  to  skeletal vibrations of CH2 – 
O – CH2 bonds, the  band  at  1350  cm
−1 is  due  to  C-H  bending  vibrations;  the  band  at 
1248 cm−1 can be attributed to C-H twisting vibrations and the peak at 935 cm-1 is due to C-
O  stretching  vibrations. New bands are visible in the spectrum of IONPs after the reaction 
with PEG 200. These include the bands around 3413, 2882, 1352 and 1075 cm−1, however a 
shift in wavenumber in comparison to the spectrum of PEG suggests hydrogen-bonding and 
the interaction with the surface of the IONPs.225  
Figure 3-29 shows the FTIR spectra of PEG 2000 and IONPs after in situ functionalisation 
with PEG 2000. Similarly to PEG 200, characteristic peaks of the polymer can be identified 
on the spectrum of PEG 2000. The peak around 2886 cm−1 is attributed  to  the  symmetric 
stretching of CH2 groups in PEG; the peak at 1467 cm
−1 is due to C − H scissoring, the  bands  
at  962, 1101  cm−1 and 1061  cm−1 are  due  to  the C-O-C  stretching  vibrations, the  band  
at  1342  cm−1 is  due  to  C-H  bending  vibrations;  and  the  band  at 1241 cm−1 can be 
attributed to C-H twisting vibrations.222-224 After the reaction with PEG 2000, the broad peak 
observed around 3385 cm-1 due to O-H stretching vibrations confirms the presence of the 
polymer as it is due to O-H groups present in PEG 2000. Other characteristic peaks are 
observed in the spectrum of these IONPs. These include the bands around 2933, 1542, and 
1412 cm−1, however a shift in wavenumber in comparison to the spectrum of PEG suggests 
hydrogen-bonding and the interaction with the surface of the IONPs.225  
For simplification purposes, the FTIR spectrum of IONPs obtained after functionalisation 
with PEG 6000 has been included in Figure 3-29 as the wavenumber of peaks in FTIR spectra 
of PEG with various Mw does not change, only the intensity of the peaks can vary with the 
local organisation of certain structure-sensitive bands.269-271 As with PEG 200 and PEG 2000, 
after the reaction with PEG 6000, characteristic peaks of the polymer are observed in the 
spectrum of these IONPs. These are identical to those identified with PEG 200 and 2000,  
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also with a shift in wavenumber in comparison to the spectrum of the polymer, suggesting 
hydrogen-bonding and the interaction with the surface of the IONPs.225  
 DISCUSSION AND CONCLUSIONS  3.3
Results in this chapter have shown that both the experimental conditions and the reaction 
parameters have an impact on the IONPs obtained by the polyol method.  
In the initial experiments, the reaction was carried out using a Schlenk line according to 
several literature references. A two-step reaction did not allow for a separation of the 
growth and nucleation phases, hence very polydisperse samples were obtained (δTEM = 15 to 
20% ca.). A one-step reaction allowed for better control of the morphology of polyol coated 
IONPs, but these were still not monodisperse (δTEM > 10%). One possible explanation for the 
 
Figure 3-29 ATR-FTIR representative spectra PEG 2000 (blue) and IONPs obtained after in situ 
functionalisation with PEG 2000 (black) or PEG 6000 (red). The 1800 - 2600 cm
-1
 range has been excluded 
as no significant information was found. 
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lack of monodispersity is the creation of thermal gradients in solution due to convective 
transfer of thermal energy from the heating mantle to the reactants in solution.  
In order to improve the heating uniformity, the use of a microwave (MW) reactor was 
investigated. This works by direct coupling and absorption of the MWs by the reactants in 
solution, also known as volumetric heating, which will lead to the temperature being raised 
in a uniform manner throughout the whole liquid volume.272 This increases the speed and 
efficiency of chemical reactions by dipolar polarisation and ionic conduction.229 
When determining the effect of the amount of precursor on the IONPs obtained, an overall 
increase in the size of the NPs was obtained with larger concentrations of Fe(acac)3 used.  
The experiments on the effect of temperature on the synthesis of IONPs, suggested that 
MWs can provide sufficient energy to superheat the solvent. Furthermore, solvents or 
solutes with high tan δ values may preferentially absorb MWs in comparison to other 
reactants with lower tan δ values. This can lead to the formation of local new nucleation 
points and an increase in the local temperature. In terms of nanoparticle synthesis, this can 
modify the surface morphology or reactivity of the NPs obtained.230 This should be avoided 
by ensuring a more homogenous initial reaction mixture. Finally, the effect of the polyol 
solvent on the IONPs obtained was studied. Results revealed that when using a polyol with a 
larger molecular weight, larger IONPs were obtained. One possible reason for this is that the 
difference in viscosity of the solvent will impact the diffusion of species in solution which in 
turn will have an effect on the nucleation and growth of nanoparticle seeds in solution. For 
example, with DEG, the smallest polyol studied, the less viscous solution would allow for a 
more rapid diffusion of species in solution, so more nucleation events would take place, 
thus leading to the formation of smaller IONPs.  
While the microwave reactor is an ideal system through its simplicity and reduced reaction 
times, results obtained were not reproducible with batch to batch variations being 
observed. Indeed, it is plausible that the microwave power was not regular and sufficient to 
 158 
 
achieve the boiling point of some of the polyol solvents used.  In the case of polyol reactions 
using iron, the reaction temperature is critical and should reach the boiling point of the 
polyol, in order to allow oxidation to its diacetyl form, leading to the reduction of the metal. 
In the future, it could be worthwhile carrying out this reaction with a higher MW power 
(above 300 W), as well as using a more sensitive fibre optics temperature probe to avoid 
local irregular MW radiation leading to local “new nucleation points”. 
Mixing problems, supersaturation and the formation of local heating spots can be minimised 
by starting the synthesis with an already homogenous mixed solution of precursors, 
allowing for the MW to be a viable method for rapid and efficient reactions. Careful 
attention is needed when measuring the temperature using an infrared sensor as this gives 
a reading of the external glass vial temperature. One of the limitations to carry out the 
synthesis of nanomaterials with the use of a MW remains the limited temperature and 
pressure range (10 ml, 20 – 25 bar) of most instruments in research laboratories which 
could limit scaling up and nature of the reactions carried out.  
Polyol coated IONPs were successfully obtained in a reproducible and reliable manner in 
high pressure and high temperature conditions of an oven. The influence of different 
synthetic parameters such as the polyol solvent used, the reaction time and the amount of 
iron precursor Fe(acac)3 were studied.  
As in the case of the MW reactor, the type of polyol solvent used was critical to the size of 
the IONPs obtained. The shape of the NPs obtained remained spherical with all three polyols 
studied, however it was observed that the larger the size of the polyol used the larger the 
NPs were. From the results obtained, TREG coated IONPs were deemed the most suitable as 
these were characterised by superparamagnetic behaviour with a core diameter measured 
by TEM ca.  8 to 10 nm. On the other hand, IONPs obtained with DEG were too small and 
hence had smaller saturation magnetisation values, while using TEG led to larger and 
polydisperse IONPs (δTEM = 24.5%) above the superparamagnetic critic domain size which 
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could explain the remanence and coercive field of these IONPs determined at 300 K by 
SQUID-VSM.  
On the other hand, it was difficult to conclude on the effect of the amount of precursor. As 
in the case of the MW synthesis, an increase in the size of the NPs obtained was observed 
when increasing the amount of Fe(acac)3 from 100 mM to 500 mM, but no direct 
proportional effect between these two parameters could be established.  
Also, a direct correlation between the size of IONPs and the reaction time was determined. 
As it can be seen in Figure 3-30 below, this was also linked to an increase in the crystallite 
size obtained by XRD and the saturation magnetisation measured at 300 K. An odd value for 
the crystallite size determined by XRD for the 12 h reaction was obtained. It was not taken 
into consideration as the Ms, core size and crystallite size led to believe that this was an 
experimental error and did not fit the data trend.  
 
Figure 3-30 Evolution of the average core diameter determined by TEM (black), the crystallite size 
determined by XRD (green) and the saturation magnetisation measured at 300 K (blue) as a function of the 
reaction time with TREG in high pressure-high temperature conditions. 
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In addition, while the synthesis of IONPs with the classic polyol method using the Schlenk 
line has already been reported in literature,75 in comparison, the IONPs obtained during our 
project in high pressure and high temperature conditions can be obtained in a reliable and 
reproducible manner in order to finely tune their magnetic properties. 
IONPs in the range of 5 – 10 nm suitable for biological applications, as monodisperse as 
possible, with interesting magnetic properties and in a reproducible manner were obtained 
with TREG in high pressure high temperature conditions. The optimisation of the reaction in 
these conditions, the ability to finely control the morphology of the NPs obtained and the 
reproducible results may allow for potential scale up and GMP manufacturing of these types 
of NPs for biomedical applications. Unfortunately, the TREG coated IONPs obtained in high 
pressure high temperature conditions were found to be unstable, as their precipitation out 
of aqueous solution was observed rapidly after their purification and dispersion in dH2O. 
These IONPs were further characterised by DLS and Mössbauer spectroscopy. Both these 
methods confirmed the colloidal aggregation of IONPs. Future studies will include 
thermogravimetric analysis in order to determine the loss of the polyol coating over 
different time points. A recent study by Miguel Sancho et al. has speculated that the polyol 
coating is only weakly linked to the IONPs by physisorption and may therefore be 
insufficient to stabilise IONPs long term in solution. In the next chapter, different surface 
functionalisation strategies are investigated to overcome this limitation.  
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Chapter 4 FUNCTIONALISATION OF IRON OXIDE NANOPARTICLES 
 BACKGROUND AND OBJECTIVES  4.1
The stabilisation of IONPs is essential for their biomedical applications as they possess an 
isoelectric point close to physiological pH of 7.4 meaning that they will aggregate at this 
pH.218 Furthermore, nanoparticle-cell interactions will rely heavily on their ability to be 
stable in a variety of pH environments such as the endosome or lysosome (pH 4-5)216 or a 
tumour (pH 7 approximately).213 It is therefore essential to ensure their stability across a 
range of pH conditions.  
Polyethylene glycol is commonly used to render IONPs stealth for biomedical applications as 
it provides steric hindrance and reduces protein adsorption.94 PEG may also provide free 
functional groups which can be used for further functionalisation with biomolecules such as 
peptides or antibodies.95, 96 Coating the NPs with an inert silica shell is also another way of 
minimising interactions with biological environments while also adding functional groups on 
the surface for functionalisation with biomolecules. 
It has been shown that carboxylic ligands are able to bind covalently to IONPs and act as 
surface ligands. This strategy was investigated with the goal of displacing the polyol TREG 
coating of IONPs synthesised in high pressure high temperature conditions, and replacing it 
with different ligands in order to confer better stability to these IONPs. These will include 
carboxylic acid ligands, polymers, silica coating or phosphonic acid ligands.  
The functional groups with the most affinity towards the iron oxide NPs include: carboxylic 
acids, phosphonate or catechol-based ligands.45-47, 91 Adsorption of carboxylic acids at the 
surface of metal oxide NPs occurs through coordination of the carboxylate group to the 
metal atoms at the surface of the NP. The carboxylate will act as a ligand for vacant 
coordination sites of surface Fe3+ ions.273 Deacon and Philips studied the carboxylate-metal 
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coordination modes,274 and these can be categorised as either monodentate or bidentate. In 
the case of a bidentate coordination, chelating or bridging modes can be observed.  
To choose different surface ligands, the fact that these IONPs are developed for potential 
biomedical applications, such as cell tracking by MRI for example, was taken into 
consideration. This means several requirements need to be met by the IONPs:  
- Water-soluble ligands only were chosen to avoid any phase transfer step 
- Ideally, their size was limited so as to not increase significantly the hydrodynamic 
diameter 
- They contained at least two functional groups: one which would interact with IONPs 
and the other to provide surface functional groups for further potential 
biofunctionalisation.  
Within this chapter, different ligands were tested which all had the above characteristics as 
potential stabilisers for the TREG coated IONPs, and their impact on the properties of the 
IONPs was studied. The aims of the work carried out in this chapter were: 
 - To determine an efficient method of ligand exchange to replace the TREG coating 
 - To obtain a stable suspension of IONPs in aqueous solution in the short term and long 
term  
 - To ensure these stable and functionalised nanoparticles have good relaxivity properties 
which allow them to be considered as potential MRI contrast agents  
 - To determine if, and how the ligand exchange method can influence these relaxivity 
properties.  
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 RESULTS AND DISCUSSION 4.2
 Ligand exchange with IONP powder and magnetic separation  4.2.1
In our initial attempts, was used the standard ligand exchange (section 2.2.4) with a variety 
of ligands: meso-2,3-dimercaptosuccinic acid (DMSA), tartaric acid, trisodium citrate, citric 
acid, L-cysteine, folic acid, 2-mercaptopropionic acid (2-MPA). These ligands have 
extensively been reported in literature as surface ligands of IONPs with which they have a 
strong affinity, and they fulfil our requirements listed above (section 4.1).  
4.2.1.1 Meso-2,3-dimercaptosuccinic acid (DMSA) 
DMSA has been recently reported as a ligand to successfully displace the polyol surfactant in 
order to stabilise IONPs.77 Furthermore, it has been a surface ligand of choice for IONPs as it 
has strong affinity with these NPs and provides functional groups for further surface 
functionalisation.91 ATR-FTIR was used to obtain information regarding changes in the 
functional groups before and after the ligand exchange process. In this sample, the peak at 
1064 cm-1 corresponding to the C-O stretching absorption of the primary alcohol group in 
CH2-OH is present for IONPs before and after ligand exchange with DMSA. This is also the 
case of the broad band centred at about 3400 cm–1 due to the O–H stretching vibrations 
attributed to water and TREG molecules adsorbed to the IONP surface.65 The carboxylic 
group of DMSA is identified through different peaks: at 1394 cm-1 due  to the C-O stretch, 
and at 1710 cm-1 due to the stretching vibration of the C=O bond. These are present in the 
sample after ligand exchange but not with polyol coated IONPs. These indicate the presence 
of COOH groups due to DMSA. 
However, there is no confirmation that DMSA had been linked to the surface of IONPs as 
there is no shift in the peaks of the COOH which would occur after chemisorption to IONPs. 
The peak due to C=O vibration (asymmetric stretching) of the carboxylic group at 1696 cm-1 
in the spectrum of the free ligand (blue curve) is still present in the spectrum of the IONPS 
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after ligand exchange at 1710 cm-1, suggesting the presence of unbound COOH groups in the 
sample.  Furthermore, the sample was not stable and its precipitation was observed rapidly. 
 
 
 
 
 
  
 
Figure 4-1 ATR-FTIR representative spectra of DMSA (blue), TREG coated IONPs before (black) and after 
(red) ligand exchange with DMSA. The 1800 - 2700 cm
-1
 range has been excluded as no significant 
information was found. 
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4.2.1.2 2-mercaptopropionic acid (2-MPA) and 3-mercaptopropionic 
acid (3-MPA) 
This method of ligand exchange was also investigated with 2-mercaptopropionic acid (2-
MPA) and 3-mercaptopropionic acid (3-MPA). There ligands were chosen as it has been 
confirmed in the literature that a covalent bond can be established between the thiol group 
and the iron metal of IONPs.217, 228  
In the spectrum of TREG coated IONPs, the following characteristic peaks can be observed: a  
broad peak at 3371 cm-1 due to O-H stretching vibrations in the alcohol groups that are intra 
molecularly bonded (polyols), as well as a sharper peak at 1230 cm-1 due to C-O stretching 
vibrations in the same hydroxyl groups. When using 2-MPA as a ligand, distinctive peaks 
within the spectrum of the functionalised IONPs were noted (blue curve in Figure 4-2):  
 
Figure 4-2 ATR-FTIR representative spectra of 2-MPA (blue), TREG coated IONPs before (black) and after 
(red) ligand exchange with 2-MPA. The 1850 - 2500 cm
-1
 range has been excluded as no significant 
information was found. The FTIR spectrum of 2-MPA was obtained from the infrared spectrum database 
of the National Institute of Standards and Technology.
1
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- Sharp peaks at 2930 and 2975 cm-1: C-H stretching vibrations in the –CH3 methyl group 
- 1411 cm-1: bending vibrations due to CH3 deformation 
- The weak broad band at 2592 cm-1 attributed to the vibrations of the S-H group.  
- The strong peaks at 1595 cm-1 and 1454 cm-1 attributed to a shift in the peak of C=O 
vibration (asymmetric stretching) of the carboxylic group from 1778 cm-1 in the 
spectrum of the free ligand (blue curve).  This could potentially indicate the binding of a 
2-MPA to the IONPs by chemisorption of the COOH groups. Indeed, carboxylate groups 
can form complexes with Fe atoms on the surface, rendering partial single bond 
character to the C=O bond, resulting in a weaker bond, which in turn leads to a shift in 
the stretching frequency to a lower wavenumber value.48, 202, 275 
As illustrated by the FTIR spectrum in Figure 4-3, when using 3-MPA, in the TREG coated 
IONPs spectrum, the same characteristic peaks can be observed: a broad peak at 3371 cm-1 
due to O-H stretching vibrations in the alcohol groups that are intra molecularly bonded 
(polyols), as well as a sharper peak at 1242 cm-1 due to C-O stretching vibrations in the 
same hydroxyl groups. When using 3-MPA as a ligand the following distinctive peaks were 
noted:  
- 1698 cm-1: C=O stretching vibrations of COOH groups. This strong peak can be due to a 
shift in the peak of C=O vibration (asymmetric stretching) of the COOH group from 1782 
cm-1 in the spectrum of the free ligand (black curve).  As with 2-MPA, this could indicate 
the binding of a 3-MPA to the surface of the IONPs by chemisorption of COOH. 
- Two peaks at 1536 cm-1 and 1436 cm-1 which can be attributed to C=O vibration 
(asymmetric and stretching respectively) of the COOH group from 3-MPA immobilised 
on the IONP surface.276 The wavenumber separation (∆ν0) between the asymmetric and 
symmetric IR peaks can be used to identify the type of interaction between the 
carboxylate group and the metal atom.274 In this case, ∆ν0 = 100 cm
-1, which indicates a 
bidentate mode in which two oxygen atoms of COO- are coordinated to the iron 
atom.277   
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- 1402 cm-1: alkene bending vibrations due to CH2 deformation. 
- 1378 cm-1: C-H bending of the CH2 group.  
- No weak broad band at 2550 - 2600 cm-1 attributed to the vibrations of the S-H group is 
observed.  
- Figure 4-3 demonstrates that 3-MPA is present and can be linked to the surface of the 
IONPs by the carboxylate group and/or the thiol group.  
The magnetic properties of the IONPs functionalised with 2-MPA and 3-MPA were measured 
at 300 K. As observed in Figure 4-4, these samples were characterised by a value of 
saturation magnetisation of Ms = 73.5 emu/g for the TREG coated IONPs, Ms = 45.3 emu/g 
for the 2-MPA coated IONPs and Ms = 66.4 emu/g for the 3-MPA coated IONPs. These 
values of Ms are smaller than those of bulk maghemite and magnetite (respectively 78 
emu/g and 92 emu/g at 300 K),36, 81 For all samples, Hc and Mr were close to zero with values 
 
Figure 4-3 ATR-FTIR representative spectra of 3-MPA (blue), TREG coated IONPs before (black) and after 
(red) ligand exchange with 3-MPA. The 1850 - 2500 cm
-1
 range has been excluded as no significant 
information was found. The FTIR spectrum of 3-MPA was obtained from the infrared spectrum database 
of the National Institute of Standards and Technology.
1
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of 5 Oe and 0.3 emu/g respectively, which indicates quasi superparamagnetic behaviour. 
The decrease in magnetisation can be attributed to the removal of surface cations, which 
takes place during ligand exchange, particle dissolution, oxidation of the particles, higher 
surface magnetic disorder or an excess of organic ligand which contributes to the larger 
overall NP mass.78,278 
This, along with the precipitation of these nanoparticles after several days, suggests that the 
removal of the excess ligand by magnetic separation is not sufficient and should be 
improved.   
4.2.1.3 Other ligands tested 
Citric acid has been used extensively as a surface ligand of IONPs in various biomedical 
applications. Indeed, the carboxylic groups present are advantageous as they provide 
electrostatic stability and surface functional groups for further biofunctionalisation. As 
explained previously, the carboxylate groups can form complexes with Fe atoms on the 
 
Figure 4-4 Magnetisation curves of TREG coated IONPs before (●) and after the ligand exchange reaction 
with 2-MPA (▲) and 3-MPA (■) using Method 1. The hysteresis curves were measured at 300 K, and the 
inset shows a zoom into the low magnetic field region. 
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surface thereby binding to the surface of IONPs by chemisorption. It has also been shown to 
enhance the uptake of IONPs by MSCs,7 and this was also confirmed by some preliminary 
data studying the uptake of IONPs made by a colleague, Dr. Blanco-Andujar, with bone 
marrow derived hMSCs (data not shown here). This enhanced uptake may be due to an 
altered endocytotic mechanism because of the high negative surface charge this ligand 
provides. The high surface charge allows for electrostatic interactions with phospholipids of 
the cellular membrane, and the increased cell-nanoparticle interactions lead to enhanced 
cellular uptake.79, 85    
Citric acid was tested as a ligand, but as it can be seen in Figure 4-5, no difference in the FTIR 
spectrum was observed between before and after the ligand exchange process. In 
particular, no shift in the symmetric and antisymmetric stretching frequencies of the COOH 
group (peaks at 1740 and 1388 cm-1 respectively) were observed which would be the case 
had the ligand been linked to the IONPs.  
 
Figure 4-5 ATR-FTIR representative spectra of citric acid (blue), TREG coated IONPs before (black) and 
after (red) ligand exchange with citric acid. The 1800 - 2500 cm
-1
 range has been excluded as no 
significant information was found.  
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As shown in Figure 4-6, this was also the same result obtained when L-tartaric acid (TA) was 
used: no difference in the FTIR spectrum was observed in the samples obtained before and 
after the ligand exchange reaction. These samples were therefore not additionally 
characterised. Due to the observed precipitation of samples obtained with DMSA, 2-MPA 
and 3-MPA as well as the decrease in the saturation magnetisation demonstrated in Figure 
4-4, this method was proven to be inefficient in the stabilisation and functionalisation of the 
polyol coated IONPs. In order to improve the method, it was hypothesised that the excess of 
organic ligand which could contribute to the decrease in saturation magnetisation with 2-
MPA and 3-MPA functionalised IONPs, could be eliminated by an additional purification 
step: dialysis.  
 Ligand exchange with IONP powder and dialysis  4.2.2
In an attempt to obtain a stable dispersion of functionalised nanoparticles, the ligand 
 
Figure 4-6 ATR-FTIR representative spectra of tartaric acid (blue), TREG coated IONPs before (black) 
and after (red) ligand exchange with tartaric acid. The 1800 - 2500 cm
-1
 range has been excluded as no 
significant information was found.  
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exchange and magnetic separation were followed by additional purification step of dialysis. 
A variety of ligands were tested using this second method, including tartaric acid, COOH-
PEG-SH, L-cysteine, or folic acid for example. However, the samples obtained were not 
characterised additionally as the FTIR spectra did not vary before or after the ligand 
exchange process: no significant peaks belonging to the ligand in question could be 
observed, the spectra remained identical to those of TREG coated IONPs. In the next section 
are presented the results obtained with ligands which could potentially allow efficient 
stabilisation and functionalisation of the polyol coated IONPs.   
4.2.2.1 DMSA   
In Figure 4-7, the peak at 1063 cm-1 corresponding to the C-O stretching absorption of the 
primary alcohol group of polyols is present for IONPs before and after ligand exchange with 
DMSA. This is also the case of the broad band centred at about 3300 cm–1 due to the O–H 
stretching vibrations attributed to water and TREG molecules adsorbed to the IONP 
 
Figure 4-7 ATR-FTIR representative spectra of DMSA (blue) and TREG coated IONPs before (black) and 
after (red) ligand exchange with DMSA. The inset shows a zoom into the range 700 - 575 cm
-1
. 
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surface.65 The COOH group of the ligand DMSA is identified through different peaks: at 1292 
cm-1 due  to the C-O stretch, and at 1696 cm-1 due to the stretching vibration of the C=O 
bond. However, these peaks are not observed after ligand exchange, proving that DMSA has 
not been linked to the surface of IONPs. 
When using DMSA during the ligand exchange, flocculation of the solution was observed 
and the magnetic properties were significantly altered in comparison to the TREG coated 
IONPs. The hysteresis curves measured at 300 K are found in Figure 4-8 and allow for 
comparison of the polyol coated IONPs (blue curve) with those obtained after ligand 
exchange with DMSA without dialysis (green curve) and with an additional dialysis step (red 
curve). Quasi superparamagnetic behaviour can be attributed to all samples, as they present 
coercive field and remanence values close to zero: 5 Oe and 0.3 emu/g for IONP-TREG, and 
10 Oe and 0.5 emu/g for IONP-DMSA. TREG coated IONPs presented a saturation 
magnetisation of 73.5 emu/g. Once the ligand exchange reaction with DMSA took place, this 
value decreased to 45.1 emu/g for samples purified solely by magnetic separation and 51.3 
emu/g for IONPs purified with an additional dialysis step. These values of saturation 
magnetisation are noticeably different from the bulk value of maghemite or magnetite (78 
emu/g and 91 emu/g respectively at 300 K).36, 81 The decrease in saturation magnetisation 
could be due to the removal of surface cations which can occur during ligand exchange, 
particle dissolution, oxidation of the particles, higher surface magnetic disorder or an excess 
of organic ligand which contributes to the larger overall NP mass.78,278 However, the 
increase in Ms obtained after the dialysis step suggests that this method of purification does 
help eliminate any additional unbound ligands which contribute to the overall NP mass.  
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In Figure 4-7, IONPs before and after reaction with DMSA are characterised by Fe-O bands at 
579 and 585 cm-1. Since the Fe-O peak of magnetite is found around 570 cm−1, and 
maghemite will have several peaks between 400 to 800 cm-1, this leads to the conclusion 
that the decrease in magnetisation cannot be due to the oxidation of the IONPs but rather 
to higher surface magnetic disorder or an excess of DMSA which contributes to the larger 
overall NP mass. 
4.2.2.2 2-mercaptosuccinic acid (2-MPA) 
As seen in Figure 4-9, the FTIR spectrum obtained was identical to the one observed with 
the first method (Figure 4-2), which seems to indicate the conjugation of 2-MPA to the 
IONPs through the carboxylate group or the thiol group.  
 
Figure 4-8 Magnetisation curves of TREG coated IONPs before (▲) and after the ligand exchange reaction 
with DMSA. The IONPs with DMSA have been purified by magnetic separation solely (●) or magnetic 
separation and dialysis against distilled water for 24 h (■). The curves were measured at 300 K, and the 
inset shows a zoom into the low magnetic field region.  
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In the TREG coated IONPs spectrum, the characteristic peaks can be observed: a  broad peak 
at 3280 cm-1 due to O-H stretching vibrations in the alcohol groups that are intra molecularly 
bonded (polyols). Characteristic peaks within the spectrum of the functionalised 
nanoparticles were noted (blue curve in Figure 4-9):  
- Sharp peaks at 2936 and 2975 cm-1: C-H stretching vibrations in the –CH3 group 
- 1411 cm-1: bending vibrations due to CH3 deformation 
- The strong peaks at 1606 cm-1 and 1456 cm-1 can be attributed to a shift in the peak of 
C=O vibration (asymmetric and symmetric stretching) of the carboxylic group from 1779 
cm-1 in the spectrum of the free ligand (blue curve).  This could potentially indicate the 
binding of a 2-MPA to the IONPs by chemisorption of the COOH groups.  
 
Figure 4-9 ATR-FTIR representative spectra of 2-MPA (blue), TREG coated IONPs before (black) and after 
(red) ligand exchange with 2-MPA. The 1850 - 2500 cm
-1
 range has been excluded as no significant 
information was found. The FTIR spectrum of 2-MPA was obtained from the infrared spectrum database of 
the National Institute of Standards and Technology.
1
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On the other hand, as can be seen in Figure 4-11, the magnetic properties of the IONPs 
obtained were significantly different. The saturation magnetisation measured at 300 K after 
the ligand exchange reaction with 2-MPA was 23.3 emu/g, which could be caused by 
oxidation of the IONPs, the removal of cations during the ligand exchange or by an excess of 
2-MPA contributing to the overall NP mass. Additional characterisation by TGA shown in 
Figure 4-10 below provides the percentage of organic ligand present in the sample. This 
Figure also shows that 2-MPA is eliminated at temperatures ranging between 100 and 
170 °C which are consistent with its boiling point of 120 °C. The sample had an initial 8% 
weight loss due to elimination of water, solvent evaporation and 2-MPA (T < 200 °C). This 
was followed by a 38% weight loss of organic material in the range of T = 200 °C to T = 
400 °C which is due to the elimination TREG linked by chemisorption to the IONPs.259-261 This 
TGA analysis validates our previous hypothesis that the decrease in the saturation 
magnetisation of the IONPs after ligand exchange is, at least partially, due to a significant 
contribution by the organic layer coating the NPs.  
 
Figure 4-10 Thermogravimetric analysis of 2-MPA (black) and IONPs after ligand exchange with 2-MPA 
and purification by magnetic separation followed by dialysis (blue).  
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4.2.2.3 L-cysteine 
L-cysteine was chosen as a ligand for the stabilisation of TREG-coated IONPs as it fulfils all 
the criteria listed in section 4.1, and is a naturally occurring essential amino acid, which 
could contribute to better biocompatibility of the obtained IONPs. The FTIR spectra of IONPs 
after ligand exchange with L-cysteine followed by magnetic separation with or without 
additional dialysis are found in Figure 4-12. After the additional purification step by dialysis, 
only the intensity of the peaks has changed in comparison to the sample cleaned by 
magnetic separation only.  
The alkanes of L-Cysteine were identified through the following peaks: stretching vibrations 
with 2 strong peaks centred at 2980 cm-1, CH2 rocking (bending vibrations) at 724 cm
-1, and 
CH2 deformation (bending vibrations) at 1348 cm
-1. The primary amine group of L-Cysteine 
was identified by: C-N stretching vibrations at 1065 cm-1, primary amine NH2 scissoring 
 
Figure 4-11 Magnetisation curves of TREG coated IONPs before (■) and after (●) the ligand exchange 
reaction with 2-MPA. The IONPs with 2-MPA have been purified by magnetic separation and dialysis 
against distilled water for 24 h. The curves were measured at 300 K, and the inset shows a zoom into the 
low magnetic field region. 
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(bending vibrations) at 1580 cm-1, and NH and NH2 wagging (shifts on H-bonding) at 847 and 
777 cm-1.  
The carboxylic acid group of L-cysteine was identified with: broad O-H stretching vibrations 
at 3140 and 2554 cm-1, C-O stretching vibrations at 1256, 1268 and 1298 cm-1, and C-O-H 
bending vibrations at 1397 cm-1.  
Also, a weak broad band centred at 2554 cm-1 and attributed to the vibrations of the S-H 
group is observed for all samples. Collectively, this data suggests that there is no difference 
between the spectrum of L-Cysteine and the IONPs after the ligand exchange process, 
proving that this ligand has not bound to the IONPs through any of its functional groups. 
More importantly, rapid precipitation of the IONPs in solution a few hours after the dialysis 
step was observed, demonstrating the lack of stability of these samples.  
 
Figure 4-12 ATR-FTIR representative spectra of L-Cysteine (blue) and TREG coated IONPs before (black) 
and after ligand exchange with L-Cysteine. IONPs were purified by magnetic separation only (red) or by 
magnetic separation followed by dialysis against distilled water for 24 h (green).The inset shows a zoom 
into the range 1800 - 1000 cm
-1
. 
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4.2.2.4 Folic acid  
The presence of the ligand, folic acid is confirmed by FTIR through its different functional 
groups (Figure 4-13). In the TREG coated IONPs spectrum, the following characteristic peaks 
are observed: a broad peak at 3262 cm-1 due to O-H stretching vibrations in the alcohol 
groups that are intra molecularly bonded (polyols), as well as a sharper peak at 1248 cm-1 
due to C-O stretching vibrations in the same hydroxyl groups.  
In the spectrum of the free ligand, the carboxylic acids were identified by:  O-H stretching 
vibrations at 3106 cm-1, C-O stretching vibrations at 1290 and 1300 cm-1, C-O-H bending 
vibrations at 1408 cm-1. The primary amine was identified through the C-N stretching 
vibration at 1000 – 1250 cm-1 which overlaps with peaks of aliphatic primary amine groups, 
N-H stretch of primary amines at 3418 and 3324 cm-1, primary amine scissoring in bending 
mode at 1605 cm-1, NH2 and NH wagging (shifts on H-bond) which could be attributed to 
peaks at 765, 818 or 840 cm-1. The phenol group also presented characteristic peaks at 1193 
cm-1 with the strong C-O bending mode and at 3542 cm-1 due to hydrogen bonded O-H 
stretch.  
The aromatic rings and alkanes are distinguishable through the peaks at 2926 and 2963 cm-1 
due to CH3, CH2 and CH stretching vibrations, at 3106 cm
-1 due to =C-H and =CH2 stretching 
vibrations, peaks at 1414, 1450 and 1484 cm-1 due to C-C stretches and asymmetric 
stretching of C-C=C in aromatic rings, as well as a peak at 765 cm-1 which could be due to 
aromatic C-H “oop” bending.  
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No difference in the FTIR spectrum was observed between before and after the ligand 
exchange process. In particular, no shift in the symmetric and asymmetric stretching 
frequencies of the COOH group (peaks at 1638 and 1519 cm-1 respectively) was observed 
which indicates the absence of coordination of the COOH groups to the surface of the 
IONPs.  Also, the peak at 1695 cm-1 can be attributed to the asymmetric stretching of C=O in 
the carboxyl group, and this is consistent with free carboxylic acids rather than the 
conjugated version.279 FTIR confirms that conjugation of folic acid to the nanoparticles did 
not take place.  
The magnetic properties of the sample were measured at 300 K (Figure 4-14). The 
saturation magnetisation measured at 300 K after the ligand exchange step was 30.7 emu/g. 
The decrease in saturation magnetisation can be due to the removal of surface cations 
which takes place during ligand exchange, particle dissolution, oxidation of the particles, 
 
 Figure 4-13 ATR-FTIR representative spectra of folic acid (blue), TREG coated IONPs before (black) and 
after (red) ligand exchange with folic acid. IONPs were purified by magnetic separation followed by 
dialysis against distilled water for 24 h. The 1800 - 2500 cm
-1
 range has been excluded as no significant 
information was found.  
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higher surface magnetic disorder or an excess of organic ligand which contributes to the 
larger overall NP mass.78,278 FTIR did not demonstrate any binding to the IONPs, but the 
decrease in saturation magnetisation suggests that a significant amount of free ligand 
remained in solution. Indeed, in Figure 4-13, IONPs before and after reaction with folic acid 
are characterised by Fe-O bands at 579 and 585 cm-1. Since the Fe-O peak of magnetite is 
found around 570 cm−1, and maghemite will have several peaks between 400 and 800 cm-1, 
this suggests the decrease in saturation magnetisation is due to higher surface magnetic 
disorder or an excess of free ligand which contributes to the larger overall NP mass.  
 
 
Figure 4-14 Magnetisation curves of TREG coated IONPs before (■) and after (●) the ligand exchange 
reaction with folic acid. The IONPs with folic acid have been purified by magnetic separation and 
dialysis against distilled water for 24 h. The curves were measured at 300 K, and the inset shows a zoom 
into the low magnetic field region. 
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4.2.2.5 Oxamic acid 
In Figure 4-15, several characteristic peaks of the ligand are identified in the sample after 
the ligand exchange process including a broad peak from 2500 to 3300 cm-1 due to O-H 
stretching vibrations of the carboxylic group. The latter is also characterised by the C-O-H 
bending vibration at 1406 cm-1 and a strong peak at 1238 cm-1 (in the free ligand) or 1300 
cm-1 (IONP-oxamic acid) due to the C-O stretching vibrations. This overlaps with a broad 
peak at 3425 cm-1 which can be due to the primary amine N-H stretching vibration. The 
amine also is characterised by the C-N stretching vibration at 1068 cm-1 and NH2 scissoring 
(bending vibrations) at 1598 cm-1. The sharpest peak at 1698 cm-1 can be attributed to the 
asymmetric stretching of C=O in the carboxyl group, and this wavenumber is consistent with 
free carboxylic acids rather than the conjugated version.279  This leads to the conclusion that 
oxamic acid did not bind to the surface of IONPs.  
 
Figure 4-15 ATR-FTIR representative spectra of oxamic acid (blue) TREG coated IONPs before (black) and 
after (blue) ligand exchange with oxamic acid (red). IONPs were purified by magnetic separation 
followed by dialysis against distilled water for 24 h.  
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4.2.2.6 Succinic acid 
In the spectrum of IONPs obtained after the ligand exchange (red), the broad band centred 
around 3375 cm-1 may correspond to the stretching vibrations of unbound O-H groups from 
succinic acid. As it is also present in the spectrum of TREG-IONPs (black), it may also be due 
to hydrogen bonded water molecules on the IONP surface, valence vibration of the 
constitutional water,184, 280 or O-H stretching vibrations in the alcohol groups that are intra 
molecularly bonded (polyols), and which are also characterised by a sharper peak at 1242 
cm-1 due to C-O stretching vibrations.  
Peaks at 2932 and 2860 cm-1 are attributed to the asymmetric and symmetric CH2 stretching 
respectively.281  These are found in all three spectra, but this may be due to the succinic acid 
 
 Figure 4-16 ATR-FTIR representative spectra of succinic acid (blue), TREG coated IONPs before (black) 
and after (red) ligand exchange with succinic acid. IONPs were purified by magnetic separation 
followed by dialysis against distilled water for 24 h. The 1800 - 2500 cm
-1
 range and relative lower 
transmittance range have been excluded as no significant information was found. 
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or the TREG present in the samples.  
Several peaks characterise the free ligand (blue): the carboxylic group is identified through 
C-O stretching vibrations at 1200 cm-1, C-O-H in-plane bending vibrations at 1417 cm-1 and 
C=O stretching at 1682 cm-1.  
The peaks at 1438, 1392 and 1376 cm-1 in the spectrum of the IONPs after the ligand 
exchange also confirm the presence of CH2 groups through their bending vibrations due to 
deformation. As these are present before and after the ligand exchange, they are certainly 
due to the CH2 groups present in TREG.  The peaks at 1115 cm
-1 (C-O-C asymmetric stretch) 
and 1066 cm-1 (C-O-C symmetric stretch) appear in the spectra before and after the ligand 
exchange, indicating TREG is still present after the reaction.  
However, the spectra obtained after ligand exchange shows two peaks at 1538 cm-1 and 
1438 cm-1 which can be attributed to C=O vibration (asymmetric and stretching respectively) 
of the COOH group from succinic acid immobilised on the IONP surface.276 Indeed, COOH 
groups can form complexes with Fe atoms on the surface, resulting in a weaker bond, which 
in turn leads to a shift in the stretching frequency to a lower value.48, 202, 275 The 
wavenumber separation (∆ν0) between the asymmetric and symmetric IR peaks can be used 
to identify the type of interaction between the carboxylate group and the metal atom.274 In 
this case, ∆ν0 = 100 cm
-1, which indicates a bidentate mode in which two oxygen atoms of 
COO- are coordinated to the iron atom.277   
While FTIR demonstrated the successful functionalisation of IONPs with succinic acid, this 
reaction did not allow us to obtain stable IONPs as these aggregated and precipitated in 
solution.   
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4.2.2.7 Tiopronin 
Tiopronin was chosen as it is a pharmaceutical drug known as Thiola® used in the treatment 
of cystinuria by preventing the formation of kidney stones.282, 283  
As seen in Figure 4-17, the free ligand is characterised by S-H stretching vibration peaks 
(2534 cm-1). In the same spectrum, the CH3 function was identified through: stretching 
vibrations with peaks at 2942, 2980 and 3090 cm-1, as well as CH3 deformation (bending 
vibrations) at 1378 cm-1. The amine group was identified by: C-N stretching vibrations at 
1030 cm-1, secondary amine N-H stretching vibrations at 3310 cm-1, and NH wagging at 861 
cm-1. These peaks are absent from the spectrum after ligand exchange with IONPs. In the 
spectrum of tiopronin, COOH was identified by C-O stretching vibrations at 1199 and 1267 
cm-1, C-O-H bending vibrations at 1400 cm-1, C=O stretching at 1617 cm-1 and 1744 cm-1. In 
 
 Figure 4-17 ATR-FTIR representative spectra of TREG coated IONPs before (black) and after (red) ligand 
exchange with tiopronin (blue). IONPs were purified by magnetic separation followed by dialysis against 
distilled water for 24 h. The 1800 - 2500 cm
-1
 and relative lower transmittance range have been excluded 
as no significant information was found. 
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the spectrum of IONPs obtained after the ligand exchange, the broad band centred around 
3300 – 3400 cm-1 may correspond to the stretching vibrations of unbound O-H groups. As it 
is also present in the spectrum of TREG coated IONPs, it is most certainly due to hydrogen 
bonded water molecules on the IONP surface, more precisely the valence vibration of the 
constitutional water therefore it cannot be used for definitive characterisation.184, 280 The 
peaks at 1595 cm-1 and 1454 cm-1 can be attributed to a shift in the peak of C=O vibration 
(asymmetric stretching) of the carboxylic group from 1744 cm-1 in the spectrum of the free 
ligand (blue curve). This could potentially indicate the binding of tiopronin to the IONPs by 
chemisorption of the COOH groups.  
 
 
Figure 4-18 Magnetisation curves of TREG coated IONPs before (■) and after (●) the ligand exchange 
reaction with Tiopronin. The IONPs with Tiopronin have been purified by magnetic separation and dialysis 
against distilled water for 24 h. The curves were measured at 300 K, and the inset shows a zoom into the 
low magnetic field region. 
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On the other hand, as can be seen in Figure 4-18, the magnetic properties of the IONPs were 
similar before and after the ligand exchange reaction. The saturation magnetisation 
measured at 300 K after the ligand exchange reaction with tiopronin was 73.3 emu/g, in 
comparison to 76 emu/g for TREG coated IONPs. The slight decrease in saturation 
magnetisation may be caused by oxidation of the IONPs, the removal of cations during the 
ligand exchange or by an excess of ligand contributing to the overall NP mass.  
However, their precipitation in solution was observed, and it was hypothesised that the 
strong ionic interchange between the TREG molecules and Tiopronin may have resulted in 
an strong aggregation of the IONPs.  
4.2.2.8 PEG diacid 600 
The broad band centred around 3422 cm-1 may be due to O-H stretching vibrations of 
unbound O-H functions of the carboxylic group from PEG diacid. Since it is present in the 
 
Figure 4-19 ATR-FTIR representative spectra of TREG coated IONPs before (black) and after (red) ligand 
exchange with PEG diacid 600 (blue). IONPs were purified by magnetic separation followed by dialysis 
against distilled water for 24 h. The 1800 - 2500 cm
-1
 range and the relative lower transmittance range 
have been excluded as no significant information was found. 
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spectrum of TREG coated IONPs, it is more likely due to hydrogen bonded water molecules 
on the IONP surface, more precisely it corresponds to the valence vibration of the 
constitutional water therefore it cannot be used for definitive characterisation of the ligand 
exchange reaction.184, 280 This may also be due to O-H stretching vibrations in the alcohol 
groups that are intra molecularly bonded (polyols), which are also characterised by a 
sharper peak at 1248 cm-1 due to C-O stretching vibrations.  
The peaks at 1412 and 1376 cm-1 in the spectrum of the IONPs after the ligand exchange 
also confirm the presence of CH2 groups through their bending vibrations due to 
deformation. The peak around 2878 cm−1 is attributed to the alkyl chain of PEG diacid 600. 
The bands at 1350 and 1105 cm−1 are due to C-H bending and C-O stretching vibrations 
respectively; and the band at 1245 cm−1 is due to C-H twisting vibrations.222-224 
The characteristic C=O band at 1742 cm-1 for the free COOH groups in PEG diacid 600 shifts 
to a lower wavenumber of 1622 cm-1 after the ligand exchange reaction. This indicates the 
binding of PEG diacid to surface of the IONPs by chemisorption of carboxylate ions. 
Carboxylate groups of PEG diacid form complexes with Fe atoms on the surface of the 
IONPs representing partial single bond character to the C = O bond. However, flocculation of 
the IONPs in solution after a couple of hours was observed. This is most likely due to an 
insufficient dialysis time of 24 h, after which an excess of polymer remains in solution and 
causes the precipitation of the IONPs.   
From all these previous ligand exchange experiments, few were successful with PEG diacid 
600, tiopronin, succinic acid and 2MPA. From their visual observation, nanoparticles were 
difficult to redisperse after the reaction. For example, an excess of 2MPA was shown to 
remain in solution by TGA and this led to a decrease in the magnetic properties of the 
IONPs. Before the ligand exchange reaction, IONPs which had been freeze dried were 
redispersed in water. However, as confirmed by several publications, freeze drying may 
have an effect on the colloidal dispersion of NPs and cause their aggregation.284-286 In the 
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next method, NPs were therefore maintained in solution after their synthesis and added to 
dissolved ligands also in solution, before purification by dialysis. 
 Ligand exchange with IONP solution and dialysis  4.2.3
This method was investigated with a variety of ligands including glutamic acid, tiopronin, 
azelaic acid, terephtalic acid, oxalic acid, succinic acid, PEG diacid and folic acid. The ligands 
were always added in a ratio 2:1 to the IONP mass in solution, stirred for 48 h before 
undergoing dialysis with a 10 000 MWCO membrane against distilled water. This ratio of 
ligand to IONP is generally considered in the literature as a reference in order to ensure 
sufficient coverage of IONPs by the ligand.287, 288 However, the DLS data summarised below 
demonstrates that aggregation took place in aqueous solution with these ligands. Therefore, 
these samples were not characterised additionally by FTIR. In this chapter, we will focus on 
the samples which did not aggregate in solution immediately after the ligand exchange 
reaction.  
Ligand Hydrodynamic diameter measured in water (nm) 
L-glutamic acid 381.3 ± 7.2 
PEG diacid 507.6 ± 26.9 
oxalic acid 589.6 ± 28.3 
Folic acid 1310 ± 225.7 
Succinic acid 2662 ± 591 
tiopronin 3183 ± 199.5 
terephtalic acid 16670 ± 4391.3 
azelaic acid 17580 ± 5261.6 
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Most of the ligands which led to the aggregation of the IONPs, were ideally small in size and 
did possess a carboxylic function through which they should be able to bind to the IONPs by 
chemisorption; but these ligands were composed of a hydrophobic part made of alkanes or 
benzene rings which could possibly lead to their incompatibility with IONPs in water. In 
order to overcome this, similarly small ligands which were more hydrophilic were evaluated: 
citric acid, tartaric acid and 3,4-dihydroxyhydrocinnamic acid (DHCA). 
 
4.2.3.1 Citric acid  
60 mg of citric acid was added to 120 mg of TREG-coated IONPs in solution. The ligand is put 
in excess (6.17 million ligands per NP equivalent to 30.6 x 103 ligands/nm2) in order to 
ensure sufficient surface coverage of the IONPs by citric acid. The detailed calculations of 
the IONP to ligand ratio can be found in Appendix 3. The mixture was stirred for 48 h at RT 
at 300 rpm before being purified by dialysis over 7 d. The hydrodynamic diameter was then 
determined by DLS in aqueous solution and saline solution (PBS) immediately after dialysis 
and 1 week later.  
 
Figure 4-20 Schematic molecular structures of A) citric acid monohydrate, B) L-tartaric acid and 
C) 3,4-dihydroxyhydrocinnamic acid. 
A B C 
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Immediately after the ligand exchange reaction, the hydrodynamic diameter measured was: 
DH = 87.9 ± 0.9 nm in water and DH = 76.5 ± 2.1 nm in PBS (Figure 4-21). These 
hydrodynamic diameters were deemed suitable in terms of biocompatibility, size and short 
term stability, so to the sample was further characterised by SQUID-VSM. The magnetic 
properties of these IONPs were measured at 300 K and 5 K (Figure 4-22), and this data 
showed that the IONPs exhibited a superparamagnetic behaviour with a saturation 
magnetisation Ms = 75.8 emu/g at 300 K which is close to the bulk value of maghemite or 
magnetite (78 emu/g and 91 emu/g respectively at 300 K)34, 35 which indicates that the 
contribution of the ligand to the mass of the nanoparticle is negligible and that the ligand 
exchange reaction did not significantly alter the IONPs. At 5 K a value of Ms = 83.2 emu/g 
was measured indicating that spins are blocked at that temperature. Furthermore, at 5 K a 
relatively high coercive field of Hc ± 444 Oe and remanence of Hr ± 17.6 emu/g were 
measured.  
 
Figure 4-21 Hydrodynamic diameters of IONP-citric acid in (A) water and in (B) PBS immediately after 
the dialysis purification step and 1 week later. 
A B 
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Finally, the ligand exchange reaction was characterised by FTIR to evaluate changes in the 
functional groups of the IONPs before and after the ligand exchange process. The ATR-FTIR 
spectra are reported in Figure 4-23.  
The broad band centred around 3500 cm-1 may correspond to several functional groups: 
unbound OH groups from citric acid, hydrogen bonded water molecules on the IONP surface 
(the valence vibration of the constitutional water), or O-H stretching vibrations in the 
alcohol groups that are intra molecularly bonded (polyols). Therefore this band cannot be 
used for definitive characterisation of one specific functional group.184, 280 A sharper peak at 
1242 cm-1 is due to C-O stretching vibrations in the hydroxyl groups. In the spectrum of 
IONPs obtained after ligand exchange with citric acid, the carboxylic group is identified 
through different peaks: O-H bending vibrations at 1066 cm-1, C-O symmetric stretching 
vibrations at 1250 cm-1, C-O-H symmetric bending vibrations at 1395 cm-1.289 The smaller 
peak at 2880 cm-1 is attributed to the CH2 deformation. Most significantly, the 1755 
cm−1 peak of citric acid usually attributed to the C = O vibration from the carboxylic group 
 
Figure 4-22 Magnetisation curves measured at 300 K (●) and at 5 K (■) after the ligand exchange reaction 
with citric acid. The inset shows a zoom into the low magnetic field region. 
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shifts to 1620 cm−1 for IONP-citric acid. This indicates binding of the ligand to the surface of 
the IONPs by chemisorption of carboxylate ions. Carboxylate groups of citric acid form 
complexes with Fe atoms on the surface of the IONPs leading to partial single bond 
character of the C = O bond which is shifted towards lower wavenumber values.  
 
 
Figure 4-23 ATR-FTIR representative spectra of IONPs before (black) and after (red) ligand exchange with 
citric acid (blue). IONPs were purified by dialysis against distilled water for 48 h. The 1800 - 2500 cm
-1
 
range and the relative lower transmittance range have been excluded as no significant information was 
found. 
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Additional characterisation by TGA shown in Figure 4-24 provides the percentage of organic 
ligand present in the sample. This Figure also shows that citric acid is eliminated at 
temperatures ranging between 200 and 250 °C, because although its boiling point is 310 °C 
it will decompose before boiling at atmospheric pressure.290 The sample had an initial 8.5% 
weight loss due to elimination of water, solvent evaporation and citric acid (T < 500 °C). The 
offset of temperatures between citric acid and the IONPs indicates the adsorption of citric 
acid to the surface of the NPs. An additional 1.5% weight loss of organic material is observed 
in the range of T = 500 °C to T = 600 °C which is due to the phase transformation of Fe3O4 to 
Fe2O3.
291 This TGA analysis is in accordance with the ATR-FTIR data confirming the 
adsorption of citric acid to IONPs. However, as can be seen in Figure 4-26 below, the zeta 
potential of the citric acid coated IONPs could not be measured as aggregation took place in 
saline conditions and under the application of an electric field. Although not shown here, 
this precipitation took place over a range of pH from pH 3 to 10. This suggests that further 
optimisation of the ligand exchange reaction should be studied including the pH and the 
 
Figure 4-24 Thermogravimetric analysis of citric acid (blue) and IONPs after ligand exchange with citric 
acid and purification by magnetic separation followed by dialysis (black). 
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ratio between the ligand and NP for example.  
 
4.2.3.2 Tartaric acid (TA) 
 
 
Figure 4-25 (left) Precipitation of citrate coated IONPs in the zeta potential measurement cuvette and (right) 
precipitation of IONPs in water and NaCl 0.1M.   
 
Figure 4-26 (A) Hydrodynamic diameters measured by DLS of IONPs before ligand exchange (IONP-TREG) 
in water and of IONPs after ligand exchange and dialysis with tartaric acid (IONP-TA) in water and PBS 
(B) Zeta potential measurements of IONP-TA from pH = 3 to pH = 9 in NaCl 0.1 M 
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The second ligand studied using this method was L-tartaric acid. Initially, 50 mg of tartaric 
acid was added to the equivalent of 25 mg of IONPs in solution and stirred for 48 h at RT at 
300 rpm. Then, the sample was cleaned by dialysis against distilled water for 72 h, the water 
once was changed once. The ligand is put in excess (7.9 million ligands per NP equivalent to 
39.3 x 103 ligands/nm2) in order to ensure sufficient surface coverage of the IONPs by TA. 
The detailed calculations of the IONP to ligand ratio can be found in Appendix 3. As 
illustrated in Figure 4-25, the obtained IONPs have a hydrodynamic diameter DH = 192.7 ± 
9.6 nm (δ = 5%) in water and 243 ± 72 nm (δ = 29%) in PBS. The zeta potential seemed to 
confirm the exchange of the ligand was successful with a strong negative value measured 
from pH 3 to pH 9 in NaCl 100 mM. This reflects the negative surface charge of the IONPs in 
solution, probably due to the carboxylic groups of the ligand. Also, the zeta potential being 
in the range -25 to -50 mV indicates electrostatic stability of the IONPs. However, the 
stability of these IONPs was found to be limited in time. As seen in Figure 4-27 below, the 
hydrodynamic diameter was measured 72 d later by DLS, and very slight aggregation had 
occurred with an increased diameter of DH = 199 ± 13 nm (δ = 6.5%). Also, slight 
precipitation of these IONPs in solution was visually observed.  
B 
 
Figure 4-27 Hydrodynamic diameter of IONP-TA measured by DLS in water immediately post synthesis 
(red) and 72 d later (blue) 
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Furthermore, the magnetic properties of the sample were determined by SQUID-VSM 
(Figure 4-29). The IONPs obtained displayed a superparamagnetic behaviour with a 
saturation magnetisation Ms = 48.1 emu/g at 300 K. Before the exchange with TA, the TREG 
coated IONPs exhibited a higher magnetisation of Ms = 79.6 emu/g. The decrease in 
saturation magnetisation could be due to the removal of surface cations which can occur 
during ligand exchange, particle dissolution, oxidation of the particles, higher surface 
magnetic disorder or an excess of organic ligand which contributes to the larger overall NP 
mass.78,278
 
 
Figure 4-28 Magnetisation curves measured at 300 K before (■) after (●) the ligand exchange reaction 
with tartaric acid. The inset shows a zoom into the low magnetic field region. 
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Additional characterisation by TGA shown in Figure 4-28 provides the percentage of organic 
ligand present in the sample. The sample had an initial 3% weight loss due to elimination of 
adsorbed water and solvent evaporation (T < 180 °C). This was followed by a 20% weight 
loss of organic material in the range of T = 180 °C to T = 600 °C which is due to the 
elimination TREG linked by chemisorption to the IONPs and the decomposition of the 
supporting tartaric acid.259-261, 292 This TGA analysis validates our previous hypothesis that 
the decrease in the saturation magnetisation of the IONPs after ligand exchange is, at least 
partially, due to a significant contribution by the organic layer coating the NPs.  
Finally, to confirm whether tartaric acid was successfully linked to the surface of the IONPs, 
their FTIR spectrum was obtained (Figure 4-30). In the spectrum of IONPs before and after 
ligand exchange, the broad band centred around 3300 cm−1 is due to hydrogen bonded O-H 
stretching vibration from surface hydroxyl groups on IONPs and adsorbed TREG and water, 
therefore it cannot be attributed specifically to the hydroxyl groups of tartaric acid.293 
Tartaric acid functionalised NPs exhibited specific peaks including a sharp peak at 1732 cm-1 
 
Figure 4-29 Thermogravimetric analysis of IONPs after ligand exchange with tartaric acid and 
purification by dialysis (blue). 
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due to C=O stretching vibrations in protonated carboxyl groups.294 At 1635 cm-1 and 1378 
cm-1 were identified sharp peaks corresponding to the asymmetric and symmetric stretching 
of carbon–oxygen bonds of carboxylate groups, respectively.276, 295 These are shifted 
towards lower wavenumber as it is bound to the surface of the NPs.202, 275 The band 
observed at 1089 cm-1 is due to the C-O stretch in hydroxyl groups. The wavenumber 
separation (∆ν0) between the asymmetric and symmetric IR peaks can be used to identify 
the type of interaction between the carboxylate group and the metal atom.274 In this case, 
∆ν0 = 257 cm
-1, which indicates an unidentate mode in which a monotartrate species is 
bound to the IONP surface via the deprotonated carboxylate group.277, 292, 296, 297 ATR-FTIR 
has therefore confirmed the effective binding of tartaric acid to the surface of the IONPs 
through the monodentate interaction of the carboxylate group with iron. 
 
 
Figure 4-30 ATR-FTIR representative spectra of IONPs before (black) and after (red) ligand exchange with 
tartaric acid (blue). IONPs were purified by dialysis against distilled water for 5 d. The 1800 - 2500 cm
-1
 
range and the relative lower transmittance range have been excluded as no significant information was 
found. 
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In order to optimise the hydrodynamic diameter of IONPs obtained after ligand exchange 
with tartaric acid, the influence of different parameters during the ligand exchange process 
was studied, such as the ratio IONPs: ligand or the dialysis time for example. 
4.2.3.2.1 Effect of dialysis time on functionalisation of IONPs  
The reaction was scaled up while maintaining a constant ratio of IONPs to TA, using 200 mg 
of TREG-coated IONPs in solution with 500 mg of TA. The solution was stirred at RT for 48 h 
before being dialysed against distilled water for 5 d. The scale up was successful and, as 
seen in Figure 4-31, the extended dialysis time produced IONPs with a smaller 
hydrodynamic diameter of DH = 168.4 ± 5.7 nm (δ = 3.4%).  
This improvement in the size distribution IONPs was confirmed with the magnetic 
properties of the IONPs obtained (Figure 4-33). The IONPs obtained were characterised by 
quasi superparamagnetic behaviour at 300 K with a saturation magnetisation Ms = 76.5 
emu/g. This value is close to that of bulk maghemite and magnetite (respectively 78 emu/g 
and 92 emu/g at 300 K),34-36, 81 and in particular maghemite. The small difference between 
the bulk value of ɣ-Fe2O3 and of the IONP-TA sample indicates that the contribution of the 
 
Figure 4-31 Hydrodynamic diameter of IONP-TA measured by DLS in water. A ratio IONP to ligand of 
1:2,5 was used and the solution was dialysed against distilled water for 5 d. 
DH = 168.4 ± 5.7 nm 
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ligand is negligible on the overall nanoparticle mass and that the longer dialysis time of 5 d 
was beneficial in eliminating any remaining excess ligand in solution.  
In Figure 4-32, IONPs before and after reaction with tartaric acid are characterised by FTIR in 
the range of 400 to 800 cm-1 in order to obtain information regarding the crystal structure of 
the IONPs obtained. In both samples of IONPs are absent Fe-O bands around 570 - 580 cm−1, 
which supports the lack of magnetite phase in these NPs.88 IONPs after ligand exchange with 
tartaric acid are characterised by peaks at 537, 620 and 734 cm-1 attributed to maghemite as 
this iron oxide phase will have several peaks between 400 and 800 cm-1. 
 
4.2.3.2.1 Effect of ratio IONP: ligand on functionalisation of IONPs  
Finally, another parameter which was studied was the ratio IONP to ligand. 10 mg of TREG-
coated IONPs was mixed with either 10 mg (ratio 1:1), 100 mg (ratio 1:10) or 500 mg (ratio 
1:50) of tartaric acid to see whether this had an influence on the IONPs. As can be seen in 
 
Figure 4-32 ATR-FTIR representative spectra of IONPs before (black) and after (red) ligand exchange 
with tartaric acid. IONPs were purified by dialysis against distilled water for 5 d. The 800 - 4000 cm
-1
 
range has been excluded as it is not relevant to the Fe-O bands of iron oxides.   
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Appendix 3, this corresponds to a large excess of ligand to IONP from approximately 4 up to 
200 million ligands per IONP, equivalent to 19.9 up to 994.5 x 103 ligands/nm2. The dialysis 
time was kept relatively long at 7 d, as this seems necessary to ensure sufficient purification 
of free ligands remaining in solution. The summary of the hydrodynamic diameters 
measured by DLS for each sample is presented below (Figure 4-34). Overall, the data 
presented in sections 4.2.3.2.1 and 4.2.3.2.1 ascertains that suitable IONPs for biomedical 
applications could be obtained after ligand exchange with tartaric acid in a ratio 1:1 or 1:2 
and with a dialysis time of 5 to 7 d. Indeed, as demonstrated by Figure 4-34, shorter dialysis 
times or an increased ratio of ligand to IONP led to larger hydrodynamic diameters and 
lower saturation magnetisation. 
 
 
Figure 4-33 Magnetisation curve measured at 300 K after the ligand exchange reaction with tartaric 
acid and dialysis for 5 d. The inset shows a zoom into the low magnetic field region. 
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4.2.3.2.2 Relaxivity of nanoparticles in solution at 1.47 T 
Finally, to determine whether these IONPs could potentially be used for stem cell labelling 
and imaging by MRI, their relaxivity was measured at 1.47 T. The r1 and r2 values were 
 
Figure 4-34 Hydrodynamic diameters of IONPs measured by DLS in aqueous solution, obtained after ligand 
exchange with different ratios of tartaric acid. 
DH = 715.8 ± 47 nm 
DH = 2488 ± 120.9 nm 
DH = 143.7 ± 0.8 nm 
 
Figure 4-35 Relaxation rates 1/T1 (■) and 1/T2 (♦) over Fe2O3 concentration of the IONP-TA 
nanoparticles. The slope indicates the specific relaxivity (r1 or r2). 
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measured according to the linear relationship of longitudinal and transverse relaxation rates 
versus the magnetic metal concentrations of Fe (Figure 4-35). The obtained values were: r1 = 
8.63 mM-1 s-1 and r2 = 149.68 mM
-1 s-1. The relatively high r2/r1 ratio of 17.3 suggests these 
nanoparticles are suitable as T2 weighted contrast agents. Indeed, to be considered as 
effective T2 MRI contrast agents, these must possess a high r2 and high r2/r1 ratio.
298 As 
demonstrated in Table 4-1, in water and at 37 °C, these tartaric acid functionalized IONPs 
possess a higher r2/r1 ratio than FDA-approved contrast agents Resovist® and Endorem®.
299 
4.2.3.3 3,4-dihydroxyhydrocinnamic acid 
Finally, the third ligand using this ligand exchange method was 3,4-dihydroxyhydrocinnamic 
acid (DHCA). After attempting ligand exchange with dopamine, it not ideal as a surface 
ligand for these IONPs as it led to their precipitation (data not reported here); however a 
new hypothesis was developed to determine whether a ligand with similar structure, such 
as DHCA, would be more efficient as it does also possess a catechol group, and in particular 
the two hydroxyl groups, which could be linked to IONPs in a similar manner to dopamine.16, 
158, 300 Indeed, dopamine derived ligands present a high affinity for metal oxide surfaces 
through their catechol groups. This arises from the ability of two adjacent hydroxyl groups 
of the enediol group to chelate surface metal ions.227, 301 However, dopamine is no longer a 
ligand of choice when it comes to the functionalisation of IONPs as it was previously 
reported to react with Fe3+ according to a radical mechanism to produce 
leucodopaminochrome.302 Furthermore, in the presence of IONPs the decomposition of 
dopamine was also observed303 and this led to a significant decrease in the core size of 
MNPs after ligand exchange from 7.6 nm to 6.6 nm.304   
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Initially, 50 mg of DHCA was added to the equivalent of 25 mg of IONPs in solution and 
stirred for 48 h at RT at 300 rpm. Then, the sample was cleaned by dialysis against distilled 
water for 7 d. After the ligand exchange step, the hydrodynamic size of the IONPs measured 
was DH = 154 ± 4.5 nm (δ = 2.8%) in water. In PBS, the hydrodynamic diameter of IONP-
DHCA decreased to DH = 140 nm ± 4.5 nm (δ = 2.8%), and no aggregation was observed. The 
zeta potential seemed to confirm the exchange of the ligand was successful with a strong 
negative value measured from pH 3 to pH 9 in NaCl 100 mM. This reflects the negative 
surface charge of the IONPs in solution probably due to the carboxylic groups on the ligand. 
Also, the zeta potential being in the range -25 to -50 mV indicates electrostatic stability of 
the IONPs in solution. This is contrary to TREG coated IONPs which were unstable and 
aggregated on the electrodes of the cuvette.  
 
Figure 4-36 (A) Hydrodynamic diameters measured by DLS of IONPs after ligand exchange and dialysis 
with 3,4-dihydroxyhydrocinnamic acid (IONP-DHCA) in water and PBS (B) Zeta potential measurements 
of IONP-DHCA from pH = 3 to pH = 9 in NaCl 0.1 M 
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In a similar manner to IONP-TA, the hydrodynamic diameter was measured 72 d later to see 
whether any aggregation could be determined. The hydrodynamic diameter had not 
significantly changed and slightly decreased to DH = 137.7 ± 1.6 nm (δ = 1.1%), thus 
indicating that the IONPs were stable in aqueous solution in the long term (Figure 4-37). The 
ligand exchange of IONP-TREG with DHCA was further confirmed by ATR-FTIR 
measurements. The FTIR spectra obtained are found in Figure 4-38. For polyol coated NPs, 
the broad band centred around 3365 cm−1 is due to hydrogen bonded O-H stretching 
vibration from surface hydroxyl groups on nanoparticles and adsorbed TREG and water.293 
Bands at 1115 and 1066 cm−1 are characteristic of C–O stretching in TREG molecules. In the 
case of DHCA functionalised IONPs, the broad band at approximately 1403 cm-1 and peaks at 
1247 cm-1  are attributed to catechol groups binding covalently to various metal oxides as 
catechol anions.305 They can be attributed to the benzene ring vibration and a C–O stretch, 
respectively. The band at 1403 cm-1 can also be assigned to symmetric vibrations of 
carboxylate groups. This suggests the ligand bound to the IONPs through the catechol 
groups, whereas the carboxylic groups remain free on the surface of the IONPs.  
FTIR in the range of 400 to 800 cm-1 provides information regarding the crystal structure of 
the IONPs obtained.306, 307 In both samples of IONPs Fe-O bands around 570 - 580 cm−1 can 
 
Figure 4-37 Hydrodynamic diameter of IONP-DHCA measured by DLS in water 72 d post synthesis  
D
H
 = 137.7 ± 1.6 nm 
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be found, which supports the presence of magnetite phase in these NPs.88 Furthermore, 
IONPs after ligand exchange with DHCA are characterised by peaks at 554, 620 and 680 cm-1 
attributed to maghemite as this iron oxide phase will have several peaks between 400 and 
800 cm-1. This can be attributed to different events which take place during ligand exchange 
including the removal of surface cations, particle dissolution, or oxidation of the particles. 
78,278 Similarly to tartaric acid, the ligand exchange reaction was optimised through the study 
of the influence of different parameters on the IONPs obtained. 
 
4.2.3.3.1 Effect of dialysis time on functionalisation of IONPs 
Keeping the same experimental conditions as mentioned previously, TREG coated IONPs 
were put in presence of the ligand, before purification by dialysis for 4 d, 6 d or 10 d.  
 
Figure 4-38 ATR-FTIR representative spectra of IONPs before (black) and after (red) ligand exchange with 
DHCA (blue). IONPs were purified by dialysis against distilled water. The 1800 - 2500 cm
-1
 range and the 
relative lower transmittance range have been excluded as no significant information was found. 
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In Figure 4-39 below are presented the DLS measurements of the hydrodynamic diameters 
of the obtained IONPs after 4 d, 6 d or 10 d dialysis in water.  
After 4 d of dialysis, the IONPs obtained had a hydrodynamic diameter of DH = 214 ± 3.6 nm. 
The hydrodynamic diameter decreases to DH = 195.6 ± 1.5 nm after 6 d and DH = 178.7 ± 0.8 
nm after 10 d. This suggests that the extended dialysis time up to 10 d allowed the 
elimination of excess ligand still present in solution and thus decrease the hydrodynamic 
diameter of the IONPs in solution. 
However, as mentioned in chapter 1, IONPs considered for potential biomedical applications 
should have limited hydrodynamic diameters (DH < 100 nm) in solution to maximise their 
biocompatibility and dispersion in biological conditions. In order to further decrease the 
hydrodynamic diameter of the IONPs obtained, both the ligand exchange reaction time and 
dialysis time were increased. In this next set of experiments, the ligand exchange reaction 
time was extended to 6 d. Furthermore, the effect of various dialysis times (5 d, 10 d and 15 
d) on the IONPs obtained was studied. As seen in Figure 4-40, after 5 d of dialysis the IONPs 
had a hydrodynamic diameter in water of DH = 203.2 ± 2.2 nm, which then decreased to DH = 
198.1 ± 1.5 nm after 10 d and DH = 145.5 ± 1.3 nm after 15 d. This seems to indicate that the 
  
Figure 4-39 Hydrodynamic diameters of IONPs measured by DLS in aqueous solution, obtained 
after ligand exchange with DHCA for 48 h and dialysis against distilled water for 4 d, 6 d, and 10 d. 
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excess ligand is progressively removed as the dialysis time is extended. 
The magnetic properties of IONPs obtained after 5 d and 15 d of dialysis were then 
compared as shown in Figure 4-41. As observed in Figure 4-41, IONPs were characterised by 
a superparamagnetic behaviour at 300 K with a saturation magnetisation Ms = 73.6 emu/g 
after 5 d of dialysis and Ms = 73.1 emu/g after 15 d dialysis. This value is close to that of bulk 
 
Figure 4-40 Hydrodynamic diameters of IONPs measured by DLS in aqueous solution, obtained after ligand 
exchange with DHCA for 6 d and dialysis against distilled water for 5 d, 10 d, and 15 d. 
 
Figure 4-41 Magnetisation curve measured at 300 K after the ligand exchange reaction with DHCA and 
dialysis for 5 d (black) or 15 d (red). The inset shows a zoom into the low magnetic field region. 
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maghemite and magnetite (respectively 78 emu/g and 92 emu/g at 300 K).34-36, 81 This is 
consistent with the FTIR data of Figure 4-38 which suggests that oxidation of IONPs may 
take place during the ligand exchange reaction, thus leading to a decrease in the saturation 
magnetisation in comparison to TREG coated IONPs (Ms = 80 emu/g, data not shown here). 
Additional characterisation by TGA shown in Figure 4-42 below provides the percentage of 
organic ligand present in the sample. This figure also shows that DHCA is mostly eliminated 
at temperatures ranging between 200 and 300 °C. The sample had an initial 5% weight loss 
due to elimination of water and solvent evaporation (T < 200 °C). This was followed by a 
19% weight loss of organic material in the range of T = 200 °C to T = 600 °C which is due to 
the elimination TREG linked by chemisorption to the IONPs and DHCA.259-261 TGA reveals 
that DHCA is bound to the IONP as the free ligand volatilises at lower temperatures than in 
presence of IONPs after ligand exchange. This TGA analysis also suggests that the decrease 
in the saturation magnetisation of the IONPs after ligand exchange is, at least partially, due 
to a significant contribution by the organic layer coating the NPs. 
 
 
Figure 4-42 Thermogravimetric analysis of DHCA (black) and IONPs after ligand exchange with DHCA 
and purification by dialysis (blue). 
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4.2.3.3.2 Effect of ratio IONP:ligand on the functionalisation of IONPs  
Finally, another parameter which was studied was the ratio IONP to ligand. DHCA (300 mg) 
was added to either 300 mg of IONPs (ratio 1:1) or 150 mg of IONPs (ratio 2:1) to determine 
if this had an impact on the IONPs obtained after ligand exchange, which took place for 48 
h. The dialysis time was kept relatively long at 10 d, as section 4.2.3.3.1 indicates that this 
seems to improve the quality of the IONPs obtained.  
In a ratio 1:1, the IONPs obtained had a DH = 213.8 ± 5.3 nm (δ = 2.5%), whereas in a ratio 
2:1 this decreased to DH = 178.7 ± 0.8 nm (δ = 0.45%). While the change in hydrodynamic 
diameter was not considerable, this did affect the relaxivity properties of the IONPs.  
4.2.3.3.3 Relaxivity of IONP-DHCA in solution 
Once the stability of the IONPs obtained after ligand exchange with 3,4-
dihydroxyhydrocinnamic acid was confirmed in water and PBS by DLS, their potential as MRI 
contrast agents was determined by measurement of their relaxivity. Their relaxivity 
properties were measured at 1.47 T within the facility of our collaborators Professor Begin-
Colin and Dr Mertz from the University of Strasbourg, and at 7 T by our collaborators 
Professor Srinivas and Dr Gharagouzloo from Northeastern University.  
Nanoparticles obtained in section 4.2.3.3.2 were initially tested. The r1 and r2 values were 
measured according to the linear relationship of longitudinal and transverse relaxation rates 
versus the magnetic metal concentrations of Fe. The obtained values at 1.47 T were: r1 = 
7.95 mM-1 s-1 and r2 = 185.58 mM
-1 s-1. The relatively high r2/r1 ratio of 23.3 confirms that 
these IONPs are suitable as T2 weighted contrast agents. As reported in Table 4-1, at the 
same frequency, in comparison to FDA-approved nanoparticles for MRI Resovist® and 
Endorem®, the NPs obtained had an improved r2/r1 ratio by a factor of more than 3.
299 
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To determine the relaxivity value of the IONP-DHCA solution at 7 T, longitudinal (T1) and 
transverse proton relaxation times (T2) were measured as a function of iron concentration, 
at 37 °C. The different concentrations of IONPs for relaxivity characterisation were obtained 
by dilution with deionised water. 
The IONPs exhibit r1 and r2 values of 0.78 and 142.2 mM
−1 s−1 respectively. The r2/r1 value of 
182.3 confirms that the IONP-DHCA has a significant advantage as a negative MRI contrast 
agent. Indeed, IONP-DHCA possess improved relaxivity properties in comparison to the 
relaxivity properties of FDA approved IONPs at 7 T:  Ferumoxides® (r1 = 1.8 mM
−1 s−1, r2 = 132 
 
Figure 4-43 Relaxation rates 1/T1 (■) and 1/T2 (♦) over Fe2O3 concentration of the IONP-DHCA 
nanoparticles. The slope indicates the specific relaxivity (r1 or r2). 
Table 4-1 Relaxivities for IONPs functionalised with 3,4-dihydroxyhydrocinnamic acid (DHCA) or tartaric 
acid (TA), and FDA approved contrast agents Endorem
®
and Resovist
®
measured at 1.47 T, at 37 °C in 
water. 
 r2 (mM
-1
 s
-1
) r1 (mM
-1
 s
-1
) r2/r1 
IONP-DHCA  185.58 7.95 23.3 
IONP-TA  149.68 8.63 17.3 
Endorem
®
 41 4.7 8.72 
Resovist
®
 61 8.7 7 
 212 
 
mM−1 s−1, r2/r1 = 73.3) and Ferucarbotran® (r1 = 1.6 mM
−1 s−1, r2 = 205mM
−1 s−1, r2/r1 = 
128.1).308 
Finally, the effects of experimental parameters of the ligand exchange reaction were 
studied. These include the dialysis time or the mass ratio between DHCA and IONPs. For 
example, when the ratio of ligand to IONP was increased from 1:1 to 2:1, this did not have a 
significant impact on the hydrodynamic diameter of the IONPs obtained (section 4.2.3.3.2), 
but this did lead to an increase in relaxivity values as can be seen in the following Table 4-2. 
Also, for the sample obtained with a ratio 2:1 in Table 4-2, after only 4 d of dialysis the 
relaxivity properties of these IONPs in solution were: r1 = 2.08 mM
-1 s-1, r2 = 8.3 mM
-1 s-1 and 
r2/r1 = 3.98. This leads to the conclusion that increasing the dialysis time allowed us to 
eliminate any excess surface ligand which may hinder the interaction of the nanoparticles 
with surrounding water molecules as this has been observed with PEGylated Gd2O3 
nanoparticles.309  
Table 4-2 Relaxivity properties at 1.4 T of IONP-DHCA obtained with different ligand to IONP ratio 
after 48 h of ligand exchange and 10 d dialysis 
Ratio ligand to IONP 1 : 1 2 : 1 
r1 (mM
-1
 s
-1
)  7.63 6.23 
r2 (mM
-1
 s
-1
) 50.77 72.46 
ratio r2/r1 6.66 11.63 
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 CONCLUSIONS 4.3
The aim of this chapter was to establish a ligand exchange method to remove the TREG 
coating of IONPs and find a suitable ligand to confer stability and biocompatibility to the 
IONPs. Several methods were tested, and one was found to be successful with a ligand 
exchange method using IONPs in solution which were added to a ligand, stirred for 48 h and 
purified by dialysis against distilled water. While a number of ligands led to the immediate 
precipitation of the IONPs as determined by DLS, three other ligands provided stable 
dispersions of NPs and these were further characterised: citric acid, L-tartaric acid and 3,4-
dihydroxyhydrocinnamic acid (DHCA). Table 4-3 provides a summary of the characterisation 
of the IONPs obtained after these 3 ligand exchange reactions.  
ATR-FTIR demonstrated that citric acid could bind to the IONPs through its carboxylic 
functions. Immediately after the ligand exchange reaction, their hydrodynamic diameter in 
water was: DH = 87.9 ± 0.9 nm and in PBS: DH =76.5 ± 2.1 nm. These citric acid coated IONPs 
exhibited superparamagnetic behaviour with Ms = 75.8 emu/g at 300 K. However, the IONPs 
were found to aggregate in saline conditions and under the application of an electric field. 
Further optimisation of the ligand exchange reaction conditions should be carried out 
including the pH and the ratio between the ligand and NP. 
With L-tartaric acid, the bond of the ligand to the surface of the IONP was confirmed by 
ATR-FTIR through its carboxylic group. The IONPs obtained were characterised by 
superparamagnetic behaviour with Ms = 76.5 emu/g at 300 K. Their hydrodynamic diameter 
was measured: DH = 192.7 ± 9.6 nm (δ = 5%) in water and 243 ± 72 nm (δ = 29%) in PBS, 
however slight aggregation was observed after several weeks. The effect of experimental 
parameters on IONPs obtained such as the mass ratio of the ligand to IONP, and the dialysis 
time were studied. Increasing the ratio of L-tartaric acid to IONP led to IONPs with an 
increased hydrodynamic diameter. However, a longer dialysis time of up to 7 d decreased 
the diameter to DH = 168.4 ± 5.7 nm (δ = 3.4%). Finally, their relaxivity values were 
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measured at 1.4 T: r1 = 8.63 mM
-1 s-1 and r2 = 149.68 mM
-1 s-1. The relatively high r2/r1 ratio 
of 17.3 confirms their potential as MRI T2 weighted contrast agents. However, as their 
aggregation could not be resolved, these IONPs are not suitable for potential biomedical 
applications and will not be further studied in vitro. Finally with DHCA, ATR-FTIR showed 
that this ligand had reacted to the surface of the IONP through its catechol group. Their 
hydrodynamic diameter was DH = 154 ± 4.5 nm (δ = 2.9%) in water and 140 nm ± 4.5 nm (δ = 
3.2%) in PBS, and no aggregation was observed. The effect of experimental parameters on 
IONPs obtained such as the mass ratio of the ligand to IONP, and the dialysis time was 
studied. Increasing the ratio of ligand to IONP did not have a significant effect on the 
diameter of the IONPs obtained. On the other hand, a longer dialysis time of up to 15 d led 
to a decrease in their hydrodynamic diameter from DH = 203.2 ± 2.2 nm (δ = 1.1%) after 5 d 
to DH = 145.5 ± 1.3 nm (δ = 0.9%) after 15 d. The IONPs obtained displayed 
superparamagnetic behaviour with Ms = 73.6 emu/g after 5 d of dialysis and Ms = 73.1 
emu/g after 15 d dialysis. Their potential as MRI contrast agents was confirmed at 1.4 T and 
7 T. The relaxivity of the IONPs was at 1.47 T: r1 = 7.95 mM
-1 s-1 and r2 = 185.58 mM
-1 s-1, and 
at 7 T: r1 = 0.78 mM
-1 s-1 and r2 = 142.2 mM
-1 s-1. The r2/r1 value of 23.3 at 1.4 T and 182.3 at 
7 T confirms these nanoparticles are suitable as T2 weighted contrast agents and can be 
tested in vitro and in vivo to determine their biocompatibility as potential MRI contrast 
agents.  
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Table 4-3 Summary characterisation of the IONPs obtained after ligand exchange with different citric acid, 
L-tartaric acid and 3,4-dihydroxyhydrocinnamic acid (DHCA). The nature of their bond to IONPs was 
obtained from ATR-FTIR data. Hydrodynamic diameters (DH) were measured in water and PBS 
immediately after synthesis. Saturation magnetisation (Ms) was obtained at 300 K. The total organic 
coating was determined by thermogravimetric analysis between 28 °C and 600 °C. The relaxivity values 
were measured in water at 37 °C and at 1.47 T. 
Ligand Citric acid L-tartaric acid DHCA 
ATR-FTIR Bind to Fe via COOH 
groups 
Bind to Fe via COOH groups Bind to Fe via catechol 
groups 
DH (nm) 87.9 ± 0.9 nm in water 
76.5 ± 2.1 nm in PBS 
192.7 ± 9.6 nm in water  
243 ± 72 nm in PBS 
154 ± 4.5 nm  in water  
140 nm ± 4.5 nm  in PBS 
Ms (300 K) 75.8 76.5 73.6 emu/g after 5 d 
dialysis 
73.1 emu/g after 15 d 
dialysis 
Total organic 
coating (%) 
10 23 24 
Relaxivity (1.47 
T) 
N/A r1 = 8.63 mM
-1
 s
-1
 
r2 = 149.68 mM
-1
 s
-1
  
r2/r1 = 17.3 
r1 = 7.95 mM
-1
 s
-1
 
r2 = 185.58 mM
-1
 s
-1
  
r2/r1 = 23.3 
Stable and 
biocompatible 
IONPs 
obtained?  
no no yes 
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Chapter 5 INTERACTION OF FUNCTIONALISED NPS WITH hMSCS 
 INTRODUCTION AND OBJECTIVES 5.1
In the previous chapters, the synthesis of IONPs within high pressure and high temperature 
conditions was achieved, followed by the optimisation of their stability through surface 
functionalisation with 3,4-dihydroxyhydrocinnamic acid (DHCA) were studied. Furthermore, 
their ability as negative contrast agents for MRI in solution was demonstrated at 1.47 T and 
7 T. The relaxivity of the IONPs were at 1.47 T: r1 = 7.95 mM
-1 s-1 and r2 = 185.58 mM
-1 s-1, 
and at 7 T: r1 = 0.78 mM
-1 s-1 and r2 = 142.2 mM
-1 s-1. The r2/r1 value of 23.3 at 1.47 T and 
182.3 at 7 T confirms these IONPs are suitable as T2 weighted contrast agents and they have 
the potential to be used for cell labelling and cell tracking applications for stem cell therapy 
for example. Indeed, there is an urgent need for stem cell tracking in cellular therapy and 
regenerative medicine, superparamagnetic IONPs could be used as contrast agents in MRI to 
allow visualisation of the implanted cells ensuring they reach the desired sites in vivo. 
In this chapter, the work presented aims to assess the suitability of these IONP-DHCA for 
biological applications, in particular for the labelling and tracking of bone marrow-derived 
primary human mesenchymal stem cells (hMSCs) by MRI.  
In order to ensure their potential as contrast agents for cell labelling, their uptake in cells 
must first be assessed. This was carried out by TEM and iron-specific Prussian Blue staining. 
In order to quantify their cellular uptake, the amount of iron was determined using a 
colourimetric method. Finally, several methods were necessary to assess the effect of cell-
nanoparticle interactions. Indeed, it was determined that information obtained from 
conventional methods such as flow cytometry or colourimetric viability assays (for example 
MTT assay) are not always suitable for IONPs and have certain limitations that must be 
addressed. However, a multi parametric method such as high-content analysis was suitable 
to evaluate the effect these IONPs had on cell morphology, cell viability, mitochondrial 
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health and the production of reactive oxygen species. High-content analysis describes a set 
of analytical methods using automated high-resolution microscopy, multi-parameter image 
processing, and molecular tools of cell biology tools to extract quantitative data from large 
cell populations. Finally, the potential of IONP-DHCA as a negative contrast agent was 
investigated in vitro with hMSCs and preliminary data was obtained in vivo using a Swiss 
female mice model. 
 RESULTS  5.2
In recent years, research on the development of SC therapy has intensified. The potential to 
use SCs in tissue engineering and regenerative medicine is promising, as their use has 
already been implemented in a few human clinical trials.310-313 However, a number of 
questions remain regarding the function of the transplanted SCs as well as their localisation 
and movement. To answer these, certain characteristics of IONPs can be used with a 
potential of gaining a better understanding of the role of SCs and validating clinical 
transplantations.5, 6, 314-316 Indeed, IONPs may be used to monitor the fate of SCs in a non-
invasive manner using MRI. As mentioned in chapter 1, to date, IONPs, which were FDA-
approved as MRI contrast agents for the liver, have been taken off the market. As reported 
in the previous chapters, IONPs were successfully synthesised through a high pressure high 
temperature method using the polyol route, before functionalising the surface with 
DHCA.262 For the work described in this chapter, the IONPs obtained were spherical and 
with an average diameter of dTEM = 16.8 ± 1.9 nm (δ = 11.1%, n = 324) as determined by TEM 
(Figure 5-1). The hydrodynamic diameter of these IONPs was measured in aqueous solution 
by DLS and was determined to be dH = 88.2 ± 2.4 nm (δ = 2.7%). The zeta potential 
determined from at least three measurements in water was: ζ = - 23.5 ± 1.8 mV, at pH = 6.8 
and electrical conductance = 0.173 µS. XRD was used to confirm that these IONPs were 
indeed iron oxide and have an inverse spinel structure, either magnetite Fe3O4 or 
maghemite γ-Fe2O3, although these phases cannot be distinguished by XRD due to their 
similar diffraction pattern and peak broadening effects. The IONPs may contain either or 
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both of these iron oxide phases. The crystallite diameter of dXRD = 7.8 nm determined 
approximately by the Scherer equation was coherent with that of the core size measured by 
TEM. The IONPs displayed a superparamagnetic behaviour at RT as determined by SQUID-
VSM between -7 and 7 T at 300 K, with Ms = 90 emu/g. This value is consistent with 
superparamagnetic IONPs of similar size and obtained by the polyol method.86, 249, 262 This 
value is slightly smaller than the theoretical magnetisation value for bulk magnetite (92–100 
emu/g),36, 81 and this is due to a ﬁnite size effect: canting of surface spins which are 
unaligned with the spins present in the rest of the magnetic domain.133 This effect is more 
pronounced for nanoparticles of smaller size.263  
 Prussian Blue staining of hMSCs with IONP-DHCA 5.2.1
hMSCs were incubated with IONP-DHCA for 24 h at various concentrations ranging from 0 to 
150 μg Fe per ml, then the cells were fixed and stained with Prussian blue, and the extent of 
IONP uptake was confirmed by optical microscopy. 
 
 
Figure 5-1 TEM images and particle size distributions of iron oxide nanoparticles synthesised. 
Magnification 25 k scale bar 20 nm. Size distributions were fitted with a log normal function (solid line), d= 
mean diameter, δd = standard deviation and n = number of particles counted. 
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The iron-specific Prussian Blue staining (Figure 5-2) allowed visual confirmation of the 
association of IONP-DHCA and hMSCs. The labelling efficiency seemed to increase in a dose 
dependent manner with the incubation concentration. However, these results lead to the 
hypothesis that the uptake is not necessarily higher at 50 µg Fe per ml, but instead that 
aggregates of IONPs were formed, which may have attached to the bottom of the well or to 
the extracellular surface. In the future, this may be optimised by modifying the IONP surface 
ligand or the incubation conditions. Overall, it is essential to note that hMSCs incubated 
with IONP-DHCA remained adherent and maintained their usual fibroblast-like shape 
similarly to the control. 
 Cell uptake visualised by TEM 5.2.2
Cell uptake and intracellular IONP distribution in MSCs were visually confirmed by TEM. 
Images were obtained at different incubation times of 1 h, 4 h and 24 h and at a 
concentration of 50 μg Fe per ml, as this concentration is deemed non-toxic and safe where 
the IONPs did not have any effect on cell morphology, viability, mitochondrial health and did 
not lead to the production of any reactive oxygen species (section 5.2.6).  
 
 
 
Figure 5-2 Prussian Blue staining images of cells labelled for 24 h with A) 0 and B) 50µg Fe per ml of 
IONP-DHCA. Scale bar 10 µm. 
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From these images can be confirmed the successful uptake of IONPs by hMSCs; however 
this process is relatively slow as few IONPs are observed after incubation times of 1 h and 4 
h. It is only after 24 h that significant amounts of IONPs can be visualised within the cells 
and at their surface as seen in Figure 5-3. As it has been reported extensively in 
literature,317-320 these IONPs also seem to undergo endocytosis and are therefore located in 
endosomes. The IONPs which are internalised within the cell vacuoles could mainly be found 
as aggregates. Furthermore, IONPs were not observed near the nucleus, as it seems these 
aggregates would be physically unable to breach the nuclear membrane pores with sizes in 
the range of 10 – 20 nm. Membrane deformation was also observed, confirming the 
internalisation of IONPs by endocytosis.  
 Quantification of cell uptake by a colorimetric method 5.2.3
To quantify the amount of IONPs taken up by hMSCs, a colorimetric method based on the 
chelation of Fe3+ by Tiron was used. The quantity of IONPs taken up by cells is an important 
factor to consider as this will determine how efficient the nanoparticles are as MRI contrast 
 
Figure 5-3 TEM images of hMSCs incubated with IONPs at 50 μg Fe/ml for 1 h (A, D), 4 h (B, E) and 24 h 
(C,F). A-C images scale bar = 2 μm and D-F scale bar = 0.2 μm. 
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agents, as well as the impact they will have on the cell viability and proliferation. Below, 
Table 5-1 sums up the amount of iron taken up by hMSCs and the uptake efficiency after 24 
h of incubation. The uptake percentage was determined as the ratio between the final 
amount of iron measured with 20 000 cells/well, and the initial incubation amount of iron.   
These results confirm that, for all concentrations studied, the uptake of these IONPs by 
hMSCs is significant; this can be supported by the TEM images obtained in vitro (Figure 5-3). 
The significant uptake in IONPs of hMSCs may be correlated to their strong negative surface 
charge and is dose dependent. These results tend to confirm that some of the IONPs 
accounted for may not be internalised, but remain on the surface of the cells. It is a well-
established fact that the uptake of IONPs depends on the size of the cells, more precisely 
their surface area.321  
The surface ligand may contribute to this phenomenon, and may cause IONPs to stick to the 
bottom of the wells and the surface membrane of cells thus overestimating the amount of 
iron taken up by cells. For high incubation concentrations, it was noticed that as the 
nanoparticles are in excess in the culture medium, aggregates can be observed (Figure 5-3 
F). A more accurate method of quantifying the cellular uptake is by measurement of 
relaxivities in each well, but this required a large number of cells (500 000 cells/well). It is 
quite difficult to obtain high enough number of hMSCs for this analysis, due to their limited 
proliferation capacity which is dependent on the age of the donor from which they are 
sourced and the culture conditions (media composition, temperature, CO2 and humidity) 
which are used for their expansion. The uptake efficiency is within the range of values 
reported in the literature with, for example, an efficiency of 26% for 5 nm NPs.322 However, 
this parameter is strongly dependent on the NP size, shape and type as well as the cell line 
considered, with values as high as 80 to 90% measured with gold NPs in presence of liver 
cells.323  
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Single-cell magnetophoresis is a method, which would allow us to obtain accurate and single 
cell information about the amount of iron taken up by cells. When cells are moving towards 
a magnet, any IONPs bound to their surface and which have not been internalised will be 
visualised as small chains of aggregates transported by the cell. This technique also 
previously revealed that colorimetric assays can lead to overestimation of the quantity of 
iron taken up by a factor of three in the case of agglomerated IONPs.324 Also, flow cytometry 
is another method used to determine if the nanoparticles are internalised within the cells or 
not. Nanoparticles must be labelled with a fluorescent dye such as FITC. Trypan blue is a 
stain routinely used to determine cell viability because it is excluded by viable cells. This 
characteristic, in addition to the fact that it can quench the fluorescence of FITC,325, 326 has 
been used to differentiate between nanoparticles extracellularly associated and those 
internalised by viable cells.327 Indeed, their uptake in cells is assessed by flow cytometry 
with Trypan Blue staining before the measurement. This stain will quench the fluorescence 
of nanoparticles bound to the cellular surface, whereas the fluorescence of internalised 
nanoparticles will not be affected.328  
Table 5-1 Quantification of cellular uptake of IONPs by hMSCs determined by the colorimetric method 
Incubation concentration (µg 
Fe/ml) 
Iron uptake per cell determined 
by colourimetric method (pg) / 
Uptake percentage (%) 
10 72 / 29 
100 819 / 33 
150 1108 / 30 
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 Colorimetric viability assays (MTT and MTS) 5.2.4
TEM and Prussian Blue staining have demonstrated that the synthesised IONPs were 
successfully taken up by endocytosis in hMSCs after 24 h. However, in order to be 
considered for stem cell labelling applications, it must be ensured that these IONPs are 
biocompatible and not toxic to hMSCs when exposed to increasing concentrations of IONPs. 
For this, conventional colourimetric assays, MTT and MTS assays, were carried out, which 
determine the cytotoxic effects of IONPs on cell metabolic activity or cell viability.  
 
Figure 5-4 In vitro cell viability studies on human mesenchymal stem cells after 24 h incubation with 
IONP-DHCA at concentrations ranging from 0 to 1000 μg Fe per ml. A) MTT assay and B) MTS assay. C) 
Absorbance of IONP-DHCA only at different Fe concentrations, measured at 492 nm in the same 
conditions as MTT and MTS assays performed on hMSCs.  Each graph shows the mean ± SD (standard 
deviation) of three independent experiments. The degree of significance is indicated when appropriate 
*P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 (one-way ANOVA, Dunnett post-hoc test). 
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These cytotoxicity assays rely on the same principle and only differ by the nature of the 
product obtained: the MTS assay does not require solubilisation of the formazan   
compound formed. Initial assays were conducted with hMSCs incubated during 24 h with 
IONP-DHCA concentrations ranging from 0 – 1 mg Fe/ml. The results obtained are presented 
in Figure 5-4. 
At lower concentrations of Fe, up to 100 μg Fe/ml, no significant toxic effects were observed 
by either assay: a cell viability of about 80% was measured at 100 μg Fe/ml. However, it can 
be observed that the cell viability increases significantly for elevated concentrations of 
IONPs (500 and 1000 μg Fe/ml). Figure 5-4 C demonstrates that this method is not suitable 
to assess the cytotoxic effects of IONPs at high concentrations (above 100 µg Fe/ml) as the 
values measured (Abs > 1) are no longer within the linear absorbance range. As a 
consequence, the percentage of viable cells is abnormally high for these concentrations. 
This increase in cell viability measured with both assays is therefore due to interference of 
the IONPs present in solution with the MTT and MTS dye (Figure 5-4). This finding is in line 
with literature data, where interference of IONPs with the MTT assay has been reported,329, 
330 and demonstrates that colorimetric assays are not technically suitable for high 
concentrations of IONPs. In most of today’s published research, these assays remain 
routinely used to confirm the biocompatibility of nanoparticles synthesised with various cell 
lines.331, 332 While the interference of IONPs may be subtracted from the absorbance values 
measured, it is not possible to conclude with certainty the effect of the internalised 
nanoparticles in vitro. Furthermore, these assays only give us information on the bulk of the 
cell populations present, without being able to directly observe and determine the impact of 
the nanoparticles on the cells. 
 In vitro analysis of cell viability by flow cytometry  5.2.5
To assess the effect of IONP-DHCA, and the mode of death they may induce on hMSCs, flow 
cytometry was tested as it is suitable to determine which cells are viable, apoptotic or 
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necrotic. Annexin V-phycoerythrin (PE) and 7-aminactinomycin D (7-AAD) double staining 
was used to detect cell membrane changes as this is routinely used to investigate the effect 
of nanoparticles on various cell populations. 
Annexin V binds to phosphatidylserine (PS), which is normally located in the inner cell 
membrane in healthy cell populations. However, when a cell undergoes apoptosis, 
phosphatidylserine is flipped and can be found on the external cellular membrane, and can 
thus bind Annexin V. 
 
Figure 5-5 Representative flow cytometry dot-plots obtained of a control sample consisting of only 
hMSCs. A) Before and B) after staining cells with Annexin V- phycoerythrin (x-axis) and 7- 
Aminactinomycin D (y-axis); C) Before and D) after staining cells with DRAQ7 (y-axis) 
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7-AAD will bind to DNA, and thus is a marker of necrotic cell death. Unlike propidium iodide 
(PI), another DNA marker which is more frequently used than 7-AAD in flow cytometry, the 
fluorescence emitted by 7-AAD has been shown to be more stable and it does not leach 
from cells.333 Indeed, late apoptosis is also characterised by the formation of pores appear 
on the membrane making it permeable to PI, which gives the cells double staining (Annexin-
PI). In case of necrosis, the cell membrane also becomes permeable leading to PI staining. 
While externalisation of PS during necrosis does not always occur, when it does, the porous 
membrane can lead to the possible internalisation of Annexin V. In this case, it is not 
possible to differentiate the process of apoptosis from necrosis.334, 335 
However, as we can see from the results in Figure 5-5, there are still some difficulties using 
this method. As it can be seen with the unstained cell population (A), 95% of the cell 
population is deemed viable (apoptosis negative, necrosis negative), which is expected of a 
control sample consisting of cells having undergone cell culture, and which is consistent 
with the Trypan Blue staining conducted (not shown here). When treating cells with Annexin 
V and 7-AAD, within the same population, only 31% of the cells are viable (apoptosis -, 
necrosis -), 2% are dead (apoptosis +, necrosis +) and 67% are undergoing apoptosis 
(apoptosis +, necrosis -). From these experiments, it was hypothesised that the abnormally 
high percentage of cells which are Annexin V positive are false positives. This is probably 
due to the detachment of the hMSCs from tissue culture flasks by trypsinisation which may 
lead to temporary membrane damage, thus leading to an Annexin V positive signal.336, 337 
Indeed, the binding of Annexin V to PS can be affected in adherent cells, which are detached 
from tissue culture flasks by an enzymatic or mechanical method. The latter may disrupt the 
cellular membrane and lead to false positives as during cell detachment (with Trypsin or 
other methods), PS residues in the membrane may translocate and give false positive 
results. The method of detachment of cells is cell-line dependent and its effect on the 
integrity of the cellular membrane cannot be predicted. It is therefore crucial to evaluate 
the cell detachment method and analytical method to ensure the results obtained are 
conclusive.338 While some studies still use Annexin V staining for flow cytometry, MSCs are  
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often limited to low concentrations of IONPs (< 100 µg/ml). Recent publications 
investigating the impact of IONPs on MSCs have determined the viability of cell populations 
exposed to NPs through more simple yet reliable optically-based methods such as  Trypan 
Blue staining,339 or the neutral comet assay which is based on single cell micro-
electrophoresis of DNA content.340, 341  
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Incubation concentration 
(ug Fe/ml) 
% viable cells 
Control 83.4 ± 3.6 
100 74 ± 2.6 
500 73 ± 4.9 
1000 68.7 ± 6.3 
Figure 5-6 Representative flow cytometry dot-plots obtained for hMSCs after staining with DRAQ7 and 
incubation during 24 h with A) no IONP-DHCA, B)100 µg Fe/ml of IONP-DHCA, C) 500 µg Fe/ml of IONP-
DHCA and D) 1000 µg Fe/ml of IONP-DHCA. E) Quantification of percentage of viable cells determined by 
DRAQ7 flow cytometry with each conditions being done in triplicates. 
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The flow cytometry analysis was repeated with another stain: DRAQ7, which emits in the 
far-red region and stains dead cells by binding to the DNA of cells with compromised plasma 
membranes.  
This stain did not lead to an abnormally high percentage of dead cells: approximately 85% of 
non labelled cells were deemed viable which is coherent with Trypan Blue staining and 83% 
of viable cells in the unstained control. The results obtained with IONP-DHCA are illustrated 
in Figure 5-6.  
After 24 h of incubation with 100 μg Fe/ml of IONP-DHCA, the percentage of viable is 74%, 
and the corresponding value for 1000 μg Fe/ml is 68.7% (Figure 5-6), indicating that the cell 
death induced in hMSCs by IONP-DHCA is dose-dependent. These results demonstrate that 
this method is suitable, and DRAQ7 is an adequate stain to determine the percentage of 
viable cells after exposure to IONPs. 
 High content analysis of cell – nanoparticle interactions  5.2.6
The MTT assay or other colorimetric assays mentioned previously can be classified as bulk-
cell assays because the measurement corresponds to a response from a large cell 
population.49 The behaviour of individual cells is not considered as the measurement is the 
overall absorbance collected from a cell lysate. One major disadvantage of these methods is 
that it is difficult to distinguish whether the results observed are homogenously obtained 
from all cells or whether they are due to a large response from a small subpopulation of 
cells. These colorimetric methods are in fact averaged for the entire cell population 
analysed and may therefore be misleading. Furthermore, these assays do not provide any 
information about the mechanism for cell death, such as the enzymatic pathway involved or 
the gradual changes in cell morphology and activity, as only the end result ie. percentage of 
viable cells, is obtained. As observed in section 5.2.4, it has been demonstrated that 
interactions of dyes with IONPs are possible and this leads to false positive results.342 
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Furthermore, these colorimetric assays solely report information on a single parameter and 
on a macroscopic level.  
The concentration of IONPs and their incubation time with cells are parameters known to 
impact their interactions with cells and the cytotoxicity induced. In most literature, it is 
suggested that a wide range of IONP concentrations are tested with exposure times of at 
least 4 h. Short incubation times will only provide information on immediate cytotoxic 
effects due to exposure to the IONPs but long-term effects may remain unknown.  
Therefore, to circumvent these issues, for this work high-content imaging analysis was used 
as it provides multiparametric, image based information on a large number of cells.343 The 
large population of cells imaged in an automated manner renders this method quantitative 
with high statistical power. High content imaging furthermore enables one to measure 
many parameters at the same time, is able to provide visual confirmation of the results 
obtained and gives an idea on the variability of any parameter evaluated within the sample 
tested rather than providing a single unit.344 This technique allows us to generate large 
datasets studying various cytotoxicity parameters while experimental conditions are kept 
consistent for all cellular – IONP interactions. A robust and reliable comparison of potential 
toxic responses across different conditions can be obtained by this methodology. 
Furthermore, in comparison to conventional in vitro proliferation assays, visualising and 
quantifying the nuclear stain intensity and morphology by high content imaging provides 
essential information regarding the potential toxic mechanisms of nanomaterials which may 
affect the cell cycle and cell survival.345  
In high content imaging, several parameters are studied simultaneously and we can directly 
observe the effect on the IONPs on the cells. In this case was studied the cell viability, 
oxidative stress, mitochondrial health and the change in the morphology of the cells.  
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The high-content (HC) imaging based methodology used here has been demonstrated in 
various publications to be an effective means for determining interactions between cells 
and NPs.346, 347 This technique allows the generation of large datasets comprising of 
thousands of cells per sample per replicate. Coupled with a sophisticated automated image 
analysis software, multiple parameters can be studied in a population of cells or at a single 
cell level.  
High content imaging was used in order to determine cell viability and changes to cellular 
morphology. 1000 hMSCs per well in a 96-well plate were incubated with IONP-DHCA for 24 
h at concentrations ranging from 0 to 250 µg Fe/ml and stained the nucleus with Hoechst, 
while actin was stained with Acti-Stain 488 (see section 2.2.16 ) (Figure 5-7). 
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Figure 5-7 Representative images of high-content imaging setup of hMSCs stained for nucleus (blue) and actin (green), scale bar 100 µm. 
Control 50 µg Fe/ml 150 µg Fe/ml 250 µg Fe/ml 
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It has previously been demonstrated that nanoparticles may result in actin cytoskeleton 
deformation, leading to disruption in actin-mediated cell signalling, and which may in turn 
disrupt the cell proliferation ability.348 The exact mechanism of actin cytoskeleton 
deformation has yet to be established. This phenomenon may be accompanied by a normal 
actin protein expression level which suggests an indirect effect of NPs on the cytoskeleton 
through physical deformation by clusters of NP degradation products near the nucleus,349 
and modification of Ca2+ cell signalling pathways through degradation of metal-based 
NPs.350  
As seen in Figure 5-8, high-content imaging analysis determined that the cell area was not 
affected following exposure to low concentrations of IONPs and that it is only above 100 µg 
Fe/ml that the cell area starts to decrease. However, the IONPs seemed to have a more 
significant impact on the cell aspect ratio with the cell skewness increasing above 50 µg 
Fe/ml. The latter indicates that the cell length decreases as the cells changes from its usual 
fibroblast-type shape to a slightly more spherical shape. In order to investigate whether this 
had an impact on the cellular activity, we then used high-content imaging to determine the 
effect of the IONPs on cell viability, mitochondrial activity and reactive oxygen species 
formation.
Figure 5-8 From the images captured by high content analysis, the spreading of the cell was calculated 
(a), as well as the cell skewness (width of the cell over the length of the cell) as seen in (b). Data are 
represented relative to untreated control cells as mean ± SD for minimum 500 cells per condition, 3 
replicates per condition. The degree of significance is indicated when appropriate *P < 0.05, **P < 0.01, 
***P < 0.001 and ****P<0.0001 (one-way ANOVA, Dunnett post-hoc test). 
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Figure 5-9 Representative images of high-content imaging setup of hMSCs stained for nucleus (blue), cell viability (yellow), oxidative stress (green) and mitochondrial health 
(red),  scale bar 100 µm. 
Control 50 µg Fe/ml 150 µg Fe/ml 250 µg Fe/ml 
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Figure 5-10 Oxidative stress and cell viability of hMSCs labelled with IONPs at various concentrations and 
determined by high-content imaging reveals significant induction of reactive oxygen species (ROS; green 
colour) at 10 and 50 µg Fe/ml. Additionally, these particles display reduction in A) mitochondrial viability 
(red colour) for a high concentration of 250 µg Fe/ml. B) Relative production of ROS determined by high-
content imaging. Data are represented relative to untreated control cells as mean ± SD for minimum 500 
cells per condition, scale bar 100 µm. The degree of significance is indicated when appropriate *P < 0.05, **P 
< 0.01 and ***P < 0.001 (one-way ANOVA, Dunnett post-hoc test). 
The IONPs did not have a significant effect on the viability of the cells (DRAQ7 in yellow) or 
on the mitochondrial area (Figure 5-10 and Table 5-2). However, an increase in ROS 
production was noticeable at 10 and 50 µg Fe per ml, but this did not have a direct impact 
on the mitochondrial health and was not induced at other concentrations (Table 5-2). 
Elevated ROS production often does not cause any significant toxicity, as all cells possess 
intrinsic antioxidant properties that protect them against oxidative stress.351 Oxidative stress 
induced by IONPs is due to the intrinsic properties of the NPs such as particle surface, size, 
composition, and presence of metals. Further studies on the physicochemical properties of 
IONP-DHCA at 10 and 50 µg Fe per ml will need to be carried out to investigate the possible 
phenomena which may occur at these concentrations and which are responsible for the 
slightly elevated levels of ROS.  
 
 
  
Control 50 µg Fe/ml 150 µg Fe/ml 250 µg Fe/ml 
A 
A 
A B 
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 In vitro MR image acquisition  5.2.7
In order to determine the suitability of IONP-DHCA as MRI contrast agents, it is essential to 
determine their physicochemical properties in vitro when they interact with the cells. This 
will allow us to determine whether any change in relaxation effects occurs once they have 
been internalised by hMSCs. The raw data illustrating the evolution of mean values of T1, T2 
and T2
* from in vitro MR acquisition can be found in Appendix 4. 
Figure 5-11 clearly demonstrates an overall dose dependent decrease of the mean values of 
T1, T2 and T2* as a function of the concentration of Fe. This effect has been observed with 
several types of nanoparticles and has been attributed to their endosomal internalization in 
cells which causes a clustering and hence an increase in relaxivity.352-354 Most relevant is the 
fact that Figure 5-11 demonstrates that the IONP-DHCA may be used in MRI to provide 
contrast enhancement.  
Table 5-2 From the images captured by high content analysis, mitochondrial area and mitochondrial 
activity were calculated. Data are represented relative to untreated control cells as mean ± SD for 
minimum 500 cells per condition. The degree of significance is indicated when appropriate *P < 0.05, **P < 
0.01 and ***P < 0.001 (one-way ANOVA, Dunnett post-hoc test). 
Fe concentration (µg/ml) Relative mitochondrial area 
(%) 
Relative mitochondrial activity 
(%) 
0 100 ± 7.6 100 ± 19 
5 89 ± 19.9 88.9 ± 8 
10 91 ± 18.9 84.6 ± 1.6 
50 75.7 ± 14.9 91.3 ± 8.2 
100 85.8 ± 20.9 83.6 ± 5.4 
150 88.1 ± 5.9 83.2 ± 6.4 
200 86.6 ± 4.9 80.4 ± 3.7 
250 75 ± 18.7 77.1 ± 2 * 
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* 
**** 
**** 
 
Fe concentration (µg/ml) T1  mean T2  mean 
0 2388 ± 19 54.5 ± 0.9 
1 2515 ± 27 101.0 ± 29.9 
2 2565 ± 61 127.2 ± 69.0 
5 2071 ± 60 80.9 ± 7.5 
10 1788 ± 92 70.8 ± 10.8 
Figure 5-11 Evolution of mean values of T1, T2 and T2
*
 determined from in vitro MR acquisition with the 
Fe concentration. The degree of significance is indicated when appropriate *P < 0.05, **P < 0.01 and 
***P < 0.001 (one-way ANOVA, Dunnett post-hoc test). 
 238 
 
 In vivo MR imaging of IONP-DHCA 5.2.1
Iron oxide nanoparticles as T2 contrast agents have been extensively used in liver MRI. 
Before the animal study, the cytotoxicity of IONP-DHCA was first determined using hMSCs 
as a model. The high-content imaging method was shown to be a suitable technique and 
proved that IONP-DHCA have no appreciable cytotoxicity for 24 h even at concentrations up 
to 250 μg Fe per ml, suggesting the high biocompatibility of these nanoparticles. 
Furthermore, in our previous work,262 their potential as potential MRI contrast agents was 
confirmed with their high relaxivity values measured at 1.4 T in solution(results in chapter 
4). Results regarding the safety and properties of NPs may differ between in vitro and in vivo 
experiments. To verify their ability as contrast agents in vivo, T2-weigthed MRI of liver was 
conducted using 6 female Swiss mice as a model. The images of the MRI scans included in 
Figure 5-12 are all from the same slice number, the main organs have been labelled in the 
control for identification purposes.  
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Figure 5-12 In vivo T2* weighted MR imaging showed axial views of mice liver area up to 2 weeks after 
injection, with an area of hypointensity due to the IONP indicated by the arrow. Selected MRI images are 
representative of three mice that received IONP-DHCA nanoparticles or just PBS (control). 
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After intravenous injection of IONP-DHCA at a dose of 300 µg Fe per ml, was immediately 
observed significant signal attenuation in the liver region for IONP-DHCA (Figure 5-12). This 
concentration was deemed safe as no cytotoxic effects of IONP-DHCA were visible up to 250 
µg Fe/ml. More importantly, the administered dose in vivo (42.3 µmol Fe/kg) is within the 
mid-range of clinical dose of IONPs typically used: between 15 µmol – 75 µmol Fe/kg.79, 355   
To quantify the contrast, the liver was identified as the region of interest and the 
normalized T2 weighted signal intensity was calculated for each animal over a period of 2 
weeks. These results are found in Figure 5-13. As can be expected, the accumulation of 
IONP-DHCA in the liver was observed, thus leading to a hypointense signal. This was 
quantified with the measured T2 signal in the liver, with a significant decrease in its value 
immediately post injection and 1 week later. On the other hand, the control remained 
relatively constant over the 2 week period. The MRI signal in the region recovered gradually 
2 weeks after the injection of the IONP- DHCA nanoparticles, thus indicting that the IONP-
DHCA are efficiently cleared from the liver, which is an important condition for the safe use 
of these NPs in clinical settings as prolonged retention of IONPs in the liver that are slowly 
converted to ferroproteins are a serious safety concern.356  
 
Figure 5-13 Quantification of the signal intensity of the specific region of interest defined as the liver, as 
evaluated from the MR images in mice administered PBS (control) and mice administered 300 µg Fe per ml 
of IONP-DHCA. The signal was normalised against muscle tissue around the vertebra column. The analysis 
was conducted in replicates of three mice per condition over 2 wk. The degree of significance is measured 
using GraphPad Prism software and is indicated when appropriate *P < 0.05, **P < 0.01 and ***P < 0.001 
(one-way ANOVA, Dunnett post-hoc test). 
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 CONCLUSIONS 5.3
The aim of the work presented in this chapter was to determine the suitability of IONP-
DHCA synthesised as potential MRI contrast agents. A comprehensive overview of methods 
assessing the biocompatibility of IONP-DHCA with hMSCs was presented. As supported by 
the data obtained in sections 5.2.4 and 5.2.5 there remains a lack of standardisation in the 
methods used to determine the impact of IONPs on cells, and these techniques assessing 
the effect of IONPs on cells must be considered carefully in order to obtain accurate data. As 
highlighted by Paul Weiss et al. in ACS Nano editorial in November 2016,184 the lack of 
standardisation when it comes to the study of NPs remains an obstacle to their potential 
biomedical applications.  
The uptake of IONP-DHCA by hMSCs was confirmed within 24 h by TEM and iron-specific 
Prussian blue staining. This is essential to ensure that the amount of IONPs internalised is 
sufficient contrast by MRI. IONP-DHCA were shown to be taken up in large amounts by 
hMSCs by a colourimetric method, although the data measured may include aggregates of 
IONP-DHCA internalised by hMSCs or bound to their surface. This is also supported by the 
Prussian Blue staining images obtained. Indeed, different parameters will influence the 
uptake of the IONPs within cultured cells. For example, it was demonstrated that the uptake 
process varied with the incubation temperature with cell internalisation being disrupted at 
4°C, whereas cell-associated IONPs can be seen when at 37 °C.157, 357 Experimental 
conditions must therefore be tightly controlled and reproducible for results to be 
considered and significant.  
Also, an important aspect considered is their toxic effects on the cells. Standard 
colourimetric MTT and MTS assays were initially used but these are not suitable for all IONP 
concentrations as we observed interference from the IONPs and the data obtained was no 
longer in the linear absorbance range for the highest concentrations of IONPs (500 and 1000 
µg Fe/ml). To overcome this, multiparametric high-content imaging was used to determine 
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the impact of the IONPs on several factors such as cell viability, mitochondrial activity and 
cell morphology. No considerable toxic effects were noticed, although a slight elongation of 
the cells could be observed. Furthermore, at 10 and 50 µg Fe/ml, an increase in ROS 
production was observed but could not be correlated to impaired mitochondria and was 
limited to these two IONP concentrations.  
Finally, IONP-DHCA was tested in vivo in Swiss female mice and confirmed as potential 
negative contrast agents, as they could be observed in the liver region for up to 2 weeks 
post injection. This is a longer clearance rate than FDA approved Resovist which has been 
shown to have a fast liver accumulation and a half-life of 13 min.358 Additional studies on 
Ferumoxides or Endorem, both in human and animal models, consistently demonstrate a 
clearance rate at the time scale of minutes or hours, this of course being dependent on the 
dose, model or NP considered.79 Also, IONP-DHCA are safely eliminated by renal clearance 
and provide sufficient T2 contrast which can be further optimised by their cell uptake, the 
latter being dose, incubation concentration or size dependent for example. The 
administered dose in vivo (42.3 µmol Fe/kg) is within the range of clinical dose of IONPs 
typically used: between 15 µmol – 75 µmol Fe/kg.79, 355 This highlights the potential clinical 
relevance of these IONPs as MRI contrast agents. However, additional experiments at higher 
doses would provide more information regarding the tolerance and biocompatibility of 
IONPs at these doses. In turn, this could provide additional guidelines for biodistribution 
studies and also give insight into the possible mechanism of toxicity. Collectively, the work 
carried out provides new insights into determining biological nanostructures as 
biocompatible and efficient MRI contrast agents to label and track stem cells in vivo. 
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Chapter 6 DISCUSSION, CONCLUSIONS, AND FUTURE DIRECTIONS  
The aim of this thesis was to synthesise superparamagnetic iron oxide nanoparticles as 
potential MRI contrast agents. This chapter provides an overall discussion of the main 
findings presented of this thesis and directions for future research.  
CONCUSION AND DISCUSSION 
In recent years, stem cells (SC) in tissue engineering and regenerative medicine have shown 
to be promising therapeutic tools as their use has already been implemented in human 
clinical trials. However, questions remain regarding the function and fate of transplanted 
SCs. To answer these, certain characteristics of IONPs can be used with a potential of 
gaining a better understanding of the role of SCs and validating clinical transplantations.5, 6, 
314-316 The work in this thesis has been designed and executed to obtain IONPs which may be 
potentially used to monitor the fate of SCs in a non-invasive manner using MRI. IONPs offer 
the possibility of multimodality, surface biofunctionalisation, and better MRI sensitivity than 
conventional molecular-based contrast agents as long as their magnetic properties are 
adequate and that they are administered in a sufficient but safe dose.  
There exists a wide range of synthesis methods of IONPs, amongst which the polyol 
synthesis which has the advantage of being a simple low temperature one pot method 
which leads to the formation of water-dispersible nanoparticles. While the polyol synthesis 
of IONPs can be found in literature, to our knowledge, no studies comparing different 
experimental conditions and investigating the reproducibility and reliability of this method 
have been reported. The work in chapter 1 investigated different experimental conditions: 
(1) a conventional Schlenk line apparatus with inert atmosphere, (2) a microwave reactor 
and (3) high pressure high temperature conditions in an oven. The data presented in 
chapter 1 demonstrates that a one-step reaction was optimal to obtain IONPs using a 
Schlenk line, however IONPs were not monodisperse: dTEM = 14.8 ± 2.1 nm (δ = 14.4%, n = 
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272). In order to improve the size distribution of the IONPs, reactions were investigated 
using a microwave reactor as this has been shown to reduce reaction times, improve size 
distribution of NPs through volumetric heating and modify the surface reactivity of NPs. The 
data obtained suggests that this method was not reproducible and that longer reaction 
times could lead to the re-dissolution of the formed NP seeds in solution. Finally, to 
overcome these limitations a high pressure high temperature protocol was implemented in 
an oven. This process yielded IONPs with a narrow particle size distribution in a simple, 
reproducible and cost effective manner without the need for an inert atmosphere. For 
example, IONPs with a diameter of ca. 8 nm could be obtained in a reproducible manner 
and with good crystallinity as evidenced by XRD and high magnetic properties with Ms = 84.5 
emu/g. Nevertheless, IONPs obtained were found to be unstable and precipitated in 
solution.    
In order to overcome the lack of stability, various ligand exchange protocols were tested in 
chapter 4. It was determined that storage conditions of IONPs and purification methods are 
critical in maintaining stable suspensions of IONPs and avoiding their aggregation. This is 
essential to prolong the shelf life of IONPs developed as potential biomedical products. The 
use of IONPs in solution and their purification by dialysis were necessary to avoid their 
immediate aggregation.  This method was successful with citric acid, L-tartaric acid and 3,4-
dihydrohydrocinnamic acid (DHCA). Although binding of the ligands citric acid and L-tartaric 
acid to the surface of IONPs was demonstrated by FTIR, the IONPs were found to be not 
stable in the long term. DHCA proved to be an efficient ligand which provided stability for up 
to 72d through anchoring of its catechol groups to the surface of the IONPs. Further 
optimisation of the ligand exchange could be carried out using a conductivity meter. A wider 
range of ligands could be tested, including those derived from PEG in order to improve the 
long term stability of the IONPs while maintaining their biocompatibility. Recent literature 
has highlighted the lack of characterisation techniques to probe the surface chemistry of 
NPs. More extensive studies and regulation will be needed for researchers in this field to 
define IONPs synthesised for biomedical applications in terms of the nature and amount of 
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ligands present. To address this problem, in 2014, Davis and colleagues used radiolabeled 
oleic acid to assess the ligand exchange of IONPs by PEG with various terminal groups.59 This 
study confirmed hierarchal binding of functional groups but showed that even with high 
affinity ligands, such as catechol derived groups, oleic acid still remained on the surface of 
the NPs after ligand exchange.  
Following their functionalisation with DHCA which provided stability and biocompatibility, 
the potential of the IONP-DHCA as MRI T2 weighted contrast agents was confirmed in 
solution at 1.4 T and 7 T, with an improved r2/r1 ratio by a factor of more than 3 in 
comparison to FDA-approved IONPs for MRI, Resovist® and Endorem®. At 1.47 T, r2/r1 = 23.3 
for IONP-DHCA in comparison to a value of 8.7 for Endorem and 7 for Resovist measured in 
the same conditions.  
The biocompatibility of IONP-DHCA was studied in vitro with hMSCs. Their cellular uptake 
was confirmed by TEM and iron specific Prussian blue staining. The uptake was quantified 
using a colourimetric method. The data obtained suggested that IONP-DHCA may have 
bound to the extracellular membrane and/or the well in the cell culture flask. Further 
studies using single cell magnetophoresis would allow quantitative and qualitative 
confirmation of this hypothesis. As demonstrated by Fayol et al. this technique also 
previously revealed that colourimetric assays can lead to overestimation of the quantity of 
iron taken up by a factor of three in the case of agglomerated IONPs.324 As noted in several 
recent studies, the use of conventional colourimetric MTT and MTS assays to determine cell 
viability after exposure to IONP-DHCA was inadequate as interference from the IONPs was 
observed and values outside of the linear absorbance range were obtained with 500 and 
1000 μg Fe/ml of IONP-DHCA. Flow cytometry proved ineffective with Annexin V as this dye 
led to a large number of false positives following temporary membrane damage caused by 
trypsinisation. This was overcome with the use of DRAQ7, a far infrared dye, which showed 
that after 24 h of incubation with 1000 μg Fe/ml of IONP-DHCA, the percentage of viable 
was 68.7%. Multiparametric high content imaging was shown to be an adequate method to 
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obtain information on cell-nanoparticle interactions at a microscopic level. This method has 
been used recently to investigate the potential cytotoxic effects of IONPs in only a couple of 
studies. No considerable toxic effects were noticed, although a slight elongating of the cells 
could be observed. Furthermore, at 10 and 50 µg Fe/ml, an increase in ROS production was 
observed but could not be correlated to impaired mitochondria and was limited to these 
two concentrations. Finally, IONP-DHCA were tested in vivo in Swiss female mice and were 
confirmed as potential negative contrast agents for MRI, as they could be observed in the 
liver region for up to 2 weeks post injection. Collectively, our study provides new insights 
into determining biological nanostructures as biocompatible and efficient MRI contrast 
agents to label and track stem cells in vivo. Whole body imaging has been carried out, and 
the contrast was only observed in the liver. These IONPs can therefore be used to pre-label 
hMSCs in order to visualise this cell population by MRI in vivo. hMSCs pre-labelled with 
IONPs could also be used to detect inflammatory processes as reported in the literature.8, 
339, 359
 
FUTURE WORK  
In the future, these particles could be potentially used for additional functional studies on 
the SCs transplanted. The aim of these IONPs would be to actively target stem cells at 
various differentiation stages using well designed antibody fragments to recognise specific 
surface markers present at these differentiation phases. The initial stages of this research 
proposal would include the identification of the cluster of differentiation molecules present 
at the stages of differentiation of hMSCs. Immunocytochemistry would be the most suitable 
technique to identify the expression of a panel of surface markers. Cluster of 
differentiation (CD) antigens are surface molecules characterised by the monoclonal 
antibodies to which they bind. The International Society of Cellular Therapy (ISCT) has 
recommended three minimal criteria for defining multipotent mesenchymal stromal cells 
including the expression of CD105, CD90 and CD73 as well as the absence of specific 
haematological markers.360 In the case of bone marrow derived hMSCs, we have 
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determined that CD90 is expressed by more than 95% of the cell population and have 
therefore chosen to focus on this potential surface marker.  
The use of antibodies to actively target IONPs has been essentially used for the active 
targeting of theranostic nanoparticles towards cancer cells.114, 227, 361-363 More recently, the 
strategy to target CD molecules has been investigated in the case of cancer stem cells which 
may be characterised by the overexpression of certain CD antigens such as CD44 or CD133 
for example.364-366 These cancer stem cells constitute only a small (<5%) fraction of the cells 
found in tumours, however they possess a high proliferation ability and are resistant to 
chemotherapy and radiotherapy.    
This innovative strategy requires the biofunctionalisation of these IONPs towards CD 
antigens expressed by the hMSCs targeted. Since we are dealing with biomolecules in the 
micrometre range, careful attention must be to avoid an increase in the hydrodynamic 
diameter after the conjugation step as this may lead to some instability and incompatibility 
with in vivo applications. In the case of an antibody, using a Fab fragment may be a strategy 
to consider as it has recently been shown to lead an enhanced internalisation in comparison 
with identical nanoparticles functionalised with an entire monoclonal antibody.367 It is 
hypothesised that this phenomenon could be due to the reduction in size of the conjugate, 
which leads to better stability in physiological conditions.  
Different strategies can be used to functionalise nanoparticles depending on the surface 
functional groups involved. This is an essential part to consider as this may influence the 
efficiency of the nanoparticles in certain biomedical applications.368 For example, when 
linking a drug to a nanoparticle, it is worthwhile noting that an amide bond may not be 
cleaved inside the cell whereas an ester or hydrazine bond may be cleaved according to the 
pH conditions.56, 368, 369 
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The most routinely used strategy is the carbodiimide method, which allows linking of a 
carboxylic function to an amine group through the formation of an amide bond. There is no 
linker involved and so the increase in the hydrodynamic diameter is limited. While this 
method is straightforward and easy to implement, it is not always suitable for biomedical 
application of NPs due to the hydrolysis of the reagents in water, and it may also lead to 
cross-linking of NPs in a non-specific manner. When comparing the carbodiimide reaction 
versus the “click” alkyne-azide chemistry, recent studies have proven that the latter strategy 
can lead to a 2 to 5 fold increase in the grafting yield of a polymer on the surface of an 
IONP.370, 371 Most importantly, this was shown consistently to be specific to the chemical 
reaction itself independent of the choice of ligand, and in turn this will lead to an increase in 
binding of IONPs to targeted cells by the ability to graft more targeting peptides on the 
surface of the NPs. Several excellent reviews report and compare the functionalisation of 
IONPs with antibodies or antibody-derived fragments,370, 372-374 and as such will not be 
treated here. However, in order to choose an appropriate functionalisation methodology, 
the latter will need to ensure that the properties of both the magnetic IONP and the 
antibody and maintained. This will mean characterisation of the antibody-nanoparticle (Ab-
NP) construct will include for example: determining the hydrodynamic diameter of the Ab-
NP, ensuring the biological activity of the antibody is preserved by ELISA assays, and 
confirming the uptake of the Ab-NP by cells through Prussian Blue staining.  
The use of antibody functionalised SPIONs to visualise SCs is a novel concept. It was recently 
shown in vivo that antibody-linked SPIONs can be used to recruit additional stem cells to a 
spinal cord injury lesion site by magnetic targeting using a clinical grade MRI scanner.177 In 
this 2014 study by Cheng et al., IONPs were developed to target exogenous bone marrow-
derived SCs (expressing CD45) or endogenous CD34-positive cells to injured cardiomyocytes 
expressing myosin light chain (MLC). NPs were conjugated with two types of antibodies (one 
against antigens on therapeutic cells and the other directed at injured cells) in order to link 
the therapeutic cells to the injured cells and therefore improve the therapeutic efficiency of 
SCs in the treatment of myocardial infarction. This may also be accompanied by additional 
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therapeutic and/or diagnostic applications that IONPs offer such as magnetic targeting, MRI 
or drug delivery just to a name a few.  
In the future, our objective is to develop nanoparticle-antibody conjugates that will interact 
with hMSCs in vitro within tissue-engineered scaffolds in order to develop our 
understanding of the interaction of hMSCs with the scaffolds and other cell populations 
present, as well as to gain insight into the differentiation of hMSCs and the changes in 
surface markers it induces. Furthermore, this work may be more interesting when adding 
further functionalities to the IONPs. Indeed, new nanoparticulate imaging probes, 
activatable or “smart” probes, which may be switched from the “off” to “on” state upon 
interaction with a target enzyme, are particularly attractive due to their improved sensitivity 
and specificity375. This principle can also be considered for other biological models where 
the expression of specific proteins or molecules is triggered in specific conditions. The use of 
“smart” NPs may reveal important information regarding stem cells used for regenerative 
medicine purposes. For example, SC apoptosis in a matrix-associated SC implant was 
detected in a non-invasive manner by MRI using a caspase-3-sensitive nanoaggregation MRI 
probe (C-SNAM).376 This could be a potentially useful tool for in vivo monitoring of the 
viability of transplanted SCs and facilitating the development of successful cartilage 
regeneration techniques or various SC therapies. This platform could represent an 
innovative tool in the diagnosis of SC failure at an early stage, thus minimizing any health 
consequences on patients. This approach has also been investigated with IONPs developed 
to undergo intracellular covalent aggregation in apoptotic cells and tumors which in turn 
would allow for enhanced T2 MRI.
377 These IONPs were functionalised with a small peptide 
[(Ac-Asp-Glu-Val-Asp-Cys(StBu)-Lys-cyanobenzothiazole (CBT)], which could undergo 
Casp3/7-controlled condensation. Briefly, these IONPs were designed so that after 
internalisation by Casp3/7-activated cells, the disulfide bonds from cysteine were reduced 
by intracellular glutathione (GSH), and the peptides were cleaved by the enzymes thus 
exposing reactive 1,2-aminothiol groups.377 Then, the condensation reaction between the 
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free 1,2-aminothiol groups and the cyano groups of the CBT motifs led to cross-linked 
Fe3O4 NPs aggregates, which resulted in enhanced T2 MR signal.
377  
It is proposed that the IONP-DHCA developed during this thesis could be used as a platform in 
the future to gain a better understanding of SC therapies. This strategy could be achieved 
through their active targeting towards CD molecules expressed by hMSCs in specific 
differentiation stages and/or their targeting towards biological molecules expressed only in 
certain cellular states such as apoptosis and/or their use in magnetic targeting of hMSCs towards 
specific sites in tissue-engineered models.  
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Figure 14 ATR-FTIR representative spectra of PEG 200 (red), PEG 2000 (blue), and PEG 6000 (black).  
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Figure 15 Thermogravimetric analysis of TREG coated IONPs obtained in high pressure high temperature 
conditions with 100 mM of precursor Fe(acac)3 
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Figure 16 Thermogravimetric analysis of TREG coated IONPs obtained in high pressure high temperature 
conditions with 150 mM of precursor Fe(acac)3 
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Figure 17 Thermogravimetric analysis of TREG coated IONPs obtained in high pressure high temperature 
conditions with 200 mM of precursor Fe(acac)3 
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Figure 18 Thermogravimetric analysis of TREG coated IONPs obtained in high pressure high temperature 
conditions with 250 mM of precursor Fe(acac)3 
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Figure 19 Thermogravimetric analysis of TREG coated IONPs obtained in high pressure high temperature 
conditions with 500 mM of precursor Fe(acac)3 
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APPENDIX 3 
1. Surface coverage of 120 mg citric acid with 60 mg IONPs  
Average diameter of IONP determined by TEM in chapter 3: d = 8 nm so radius r = 4nm 
Considering V = 4/3 π r3 = 268.1 nm3 
The nanoparticle surface is then determined as S = 4 π r2 = 201.1 nm2 
Considering the density of maghemite ɣFe2O3 is  ρ(Fe2O3) = 4.9 g/cm
3 then the theoretical 
mass of one nanoparticle can be calculated as: mNP = ρ(Fe2O3) x V = 98.54 x 10
-17 g  
So in 60 mg of nanoparticle powder, the theoretical amount of nanoparticles is:  
n = msample / mNP = 60 x 10
-3 g / 98.54 x 10-17 g = 60.9 x 1012 particles. This divided by 
Avogadro’s number = molarity of nanoparticles in the sample and as such: n = 60.9 x 1012 
particles / 6.02 x 1023 = 10-10 mol 
Considering MCA = 192.124 g/mol, then in 120 mg there are n = 6.25 x 10
-4 mol of ligand. In 
terms of number of molecules this is equivalent to: N = n x NA = 6.25 x 10
-4 x 6.02 x 1023 = 
3.76 x 1020 molecules, thus corresponding to a ratio of IONP to CA: 3.76 x 1020 molecules / 
60.9 x 1012 particles = 6.17 million ligands per NP.   
2. Surface coverage of 100 mg 3,4-dihydroxyhydrocinnamic acid with 50 mg IONPs  
Average diameter of IONP determined by TEM in chapter 3: d = 8 nm so radius r = 4nm 
Considering V = 4/3 π r3 = 268.1 nm3 
The nanoparticle surface is then determined as S = 4 π r2 = 201.1 nm2 
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Considering the density of maghemite ɣFe2O3 is  ρ(Fe2O3) = 4.9 g/cm
3 then the theoretical 
mass of one nanoparticle can be calculated as: mNP = ρ(Fe2O3) x V = 98.54 x 10
-17 g  
So in 50 mg of nanoparticle powder, the theoretical amount of nanoparticles is:  
n = msample / mNP = 50 x 10
-3 g / 98.54 x 10-17 g = 50.74 x 1012 particles. This divided by 
Avogadro’s number = molarity of nanoparticles in the sample and as such: n = 50.74 x 1012 
particles / 6.02 x 1023 = 8.43 x 10-11 mol 
Considering MDHCA = 182.17 g/mol, then in 100 mg there are n = 5.49 x 10
-4 mol of ligand. In 
terms of number of molecules this is equivalent to: N = n x NA = 5.49 x 10
-4 x 6.02 x 1023 = 3.3 
x 1020 molecules, thus corresponding to a ratio of IONP to DHCA: 3.3 x 1020 molecules / 
50.74 x 1012 particles = 6.5 million ligands per NP.   
3. Surface coverage of 50 mg tartaric acid with 25 mg IONPs  
Average diameter of IONP determined by TEM in chapter 3: d = 8 nm so radius r = 4nm 
Considering V = 4/3 π r3 = 268.1 nm3 
The nanoparticle surface is then determined as S = 4 π r2 = 201.1 nm2 
Considering the density of maghemite ɣFe2O3 is  ρ(Fe2O3) = 4.9 g/cm
3 then the theoretical 
mass of one nanoparticle can be calculated as: mNP = ρ(Fe2O3) x V = 98.54 x 10
-17 g  
So in 25 mg of nanoparticle powder, the theoretical amount of nanoparticles is:  
n = msample / mNP = 25 x 10
-3 g / 98.54 x 10-17 g = 25.37 x 1012 particles. This divided by 
Avogadro’s number = molarity of nanoparticles in the sample and as such: n = 25.37 x 1012 
particles / 6.02 x 1023 = 4.21 x 10-11 mol 
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Considering MTA = 150.087 g/mol, then in 50 mg there are n = 3.33 x 10
-4 mol of ligand. In 
terms of number of molecules this is equivalent to: N = n x NA = 3.33 x 10
-4 x 6.02 x 1023 = 2 x 
1020 molecules, thus corresponding to a ratio of IONP to TA: 2 x 1020 molecules / 25.37 x 
1012 particles = 7.9 million ligands per NP.   
4. Surface coverage of 10 mg IONPs with 10 mg, 100 mg and 500 mg tartaric acid  
Average diameter of IONP determined by TEM in chapter 3: d = 8 nm so radius r = 4nm 
Considering V = 4/3 π r3 = 268.1 nm3 
The nanoparticle surface is then determined as S = 4 π r2 = 201.1 nm2 
Considering the density of maghemite ɣFe2O3 is  ρ(Fe2O3) = 4.9 g/cm
3 then the theoretical 
mass of one nanoparticle can be calculated as: mNP = ρ(Fe2O3) x V = 98.54 x 10
-17 g  
So in 10 mg of nanoparticle powder, the theoretical amount of nanoparticles is:  
n = msample / mNP = 10 x 10
-3 g / 98.54 x 10-17 g = 10.15 x 1012 particles. This divided by 
Avogadro’s number = molarity of nanoparticles in the sample and as such: n = 10.15 x 1012 
particles / 6.02 x 1023 = 1.69 x 10-11 mol 
Considering MTA = 150.087 g/mol, then in 10 mg there are n = 0.66 x 10
-4 mol of ligand. In 
terms of number of molecules this is equivalent to: N = n x NA = 0.66 x 10
-4 x 6.02 x 1023 = 4 x 
1019 molecules, thus corresponding to a ratio of IONP to TA: 4 x 1019 molecules / 10.15 x 
1012 particles = 3.95 million ligands per NP.   
With 100 mg the ratio of IONP to TA will be increased to: 39.5 million ligands per NP. 
With 500 mg the ratio of IONP to TA will be increased to: 197.5 million ligands per NP. 
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APPENDIX 4 
In vitro MR image acquisition  
 
 
 
 
 
 
 
 
 
 
 
control  
1 µg Fe/ml 
control 
5 µg Fe/ml 
10 µg Fe/ml 
1 µg Fe/ml 5 µg Fe/ml 10 µg Fe/ml 
Figure 111 Phantom homogeneity and positioning was assessed using FLASH 3D sequence (TE/TR: 15/200ms, 
matrix: 512x512x128, FOV: 60x60x30 mm, resolution: 0,117x0,117x0,234 mm). A: axial view of the phantom with 
samples containing 0, 1, 5 and 10 µg Fe/ml. Distance from the bottom of the phantom for each sample being 
respectively 21, 23, and 20 and 21 mm.  
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T1 measurements 
 
 
 
 
 
Figure 21 Data were extracted from slices 2, 2, 1 and 3 for samples containing 0, 1, 5 and 10 µg Fe/ml 
respectively. Spin echo sequence with inversion preparation (TR: 10000 ms, TE: 5.67 ms, T I: array of 12 Tis 
starting from 50 ms with regular increment of 500ms, FOV: 60 x 60 mm, matrix: 256 x 256, 5 slices of 1 mm 
thickness and 1 mm gap). Data were fitted to a mono-exponential recovery function and T1 extracted 
(processing performed in PV5,1 using image sequence analysis tool. 
 
 
 
 
Fe concentration (µg/mL) T1  mean (ms) 
0 2388 ± 19 
1 2515 ± 27 
5 2071 ± 60 
10 1788 ± 92 
control  
1 µg Fe/ml 
5 µg Fe/ml 
10 µg Fe/ml 
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T2 measurements  
 
Fe concentration (µg/mL) T2  mean (ms) 
0 54.5 ± 0.9 
1 101 ± 29.9 
5 80.9 ± 7.5 
10 70.8 ± 10.8 
Figure 22 Data were extracted from slices 2, 2, 1 and 3 for samples containing 0, 1, 5 and 10 µg Fe/ml 
respectively. Multi Spin Echo sequence (TR: 5000 ms, TE: 20 TEs equally spaced by 11.35 ms, FOV: 60 x 60 
mm, matrix: 512 x 512, 5 slices of 1 mm thickness and 1 mm gap). Data were fitted to a mono-exponential 
and T2 extracted (processing performed in ImageJ using the MRI processor plugin. T2 maps were generated 
for pixels for which the R2 of the fit was higher than 0.9 and capped at 1000 ms). 
 
 
 
 
 
control  
1 µg Fe/ml 
5 µg Fe/ml 
10 µg Fe/ml 
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T2* measurements  
 
Fe concentration (µg/mL) T2* mean (ms) 
0 35.2 ± 1.6 
1 71.4 ± 17.4 
5 64.5 ± 9.1 
10 59.5 ± 10.7 
Figure 23 Data were extracted from slices 2, 2, 1 and 3 for samples containing 0, 1, 5 and 10 µg Fe/ml 
respectively. Multi gradient echo sequence (TR: 5000 ms, TE: 14 Tes starting from 2.5ms with regular spacing 
of 4 ms, FOV: 60 x 60 mm, matrix: 256 x 256, 5 slices of 1 mm thickness and 1 mm gap). Data were fitted to a 
mono-exponential and T2* extracted. Processing performed in ImageJ using the MRI processor plugin. T2* 
maps were generated for pixels for which the R2 of the fit was higher than 0.9 and capped at 200 ms). 
 
 
 
 
control  
1 µg Fe/ml 
5 µg Fe/ml 
10 µg Fe/ml 
